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ABSTRACT 
	   More than 30 years has passed since the discovery of Human Immunodeficiency 
Virus (HIV) yet it remains one of the most important current threats to global public 
health. HIV is a T-lymphotrophic retrovirus that is the causative agent of Acquired 
Immune Deficiency Syndrome, and despite decades of research, there remains no cure. 
Vaccines are most effective when they are able to induce broadly neutralizing antibodies 
at concentrations capable of blocking viral infection. Notwithstanding all of the effort, a 
successful vaccine that is capable of inducing complete protection from the immune 
system has yet to be found. In this thesis, the first chapter provides a history of the 
discovery of HIV, the origins of the virus, description of the HIV genome, focusing 
primarily on the envelope glycoprotein, a trimeric spike on the surface of the HIV virion 
necessary for viral fusion and the sole epitope for broadly neutralizing antibodies. Lastly, 
the first chapter reviews an overview of the antiviral immune response specifically the 
role of humoral immune branch and broadly neutralizing antibodies, as well as their 
limitations in protection against HIV. Antibodies developed during HIV-1 infection lose 
efficacy as the viral spike mutates. In addition to structural features of HIV’s envelope 
spike that facilitate antibody evasion, we proposed that the low-density and limited lateral 
mobility of HIV spikes impedes bivalent binding by antibodies. The resulting 
predominantly monovalent binding minimizes avidity and thereby high affinity binding 
and potent neutralization, thus expanding the range of HIV mutations permitting antibody 
evasion. The work described in subsequent chapters attempts to overcome HIV’s evasion 
strategy of low spike density through the design of novel antibody architectures.  
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 We postulated that anti-HIV-1 spike antibodies primarily bind monovalently 
because HIV’s low spike density impedes bivalent binding through inter-spike 
crosslinking, and the spike trimer structure prohibits bivalent binding through intra-spike 
crosslinking. Monovalent binding reduces avidity and neutralization potency, thus 
expanding the range of mutations permitting antibody evasion. To test this idea, we 
engineered antibody-based molecules capable of bivalent binding through intra-spike 
crosslinking. We used DNA as a “molecular ruler” to measure intra-epitope distances on 
virion-bound spikes and to construct intra-spike crosslinking molecules. Optimal bivalent 
reagents exhibited up to 2.5 orders of magnitude of increased potency (>100-fold average 
increases across a virus panel) and identified conformational states of virion-bound 
spikes. The demonstration that intra-spike crosslinking lowers the concentration of 
antibodies required for neutralization supports the hypothesis that low spike densities 
facilitate antibody evasion and the use of molecules capable of intra-spike crosslinking 
for therapy or passive protection. These results shed light on dynamic spike 
conformations and are relevant to therapeutic interventions. 
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Chapter One: Introduction 
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Introduction 
 
The Discovery of HIV 
The year was 1981: doctors in Los Angeles, San Francisco, and New York are left 
baffled at cases of pneumonia and a rare yet aggressive cancer that seems to be spreading 
among seemingly healthy young men (Gottlieb et al., 1981). The cause of the outbreak is 
unknown but the only common thread is that the men are homosexual. By the end of the 
year there will be 41 reported cases and 8 victims dead within 24 months after their initial 
diagnosis (Altman, 1981). This sudden form of the rare cancer, called Kaposi’s Sarcoma, 
originally described by Moritz Kaposi in 1872, presented with pigmented epidermal 
lesions, and led doctors and soon the media into a frenzy trying to find the cause. One of 
the earliest doctors to arrive on the scene was Dr. Michael Gottlieb, of UCLA, who first 
postulated that these patients must be suffering from a potentially sexually transmissible 
immune deficiency (Gottlieb et al., 1981).  During this time, two independent labs were 
about to discover how right Dr. Gottlieb and colleagues were.   
We will all soon know this condition as AIDS, or Acquired Immune Deficiency 
Syndrome, and despite it being over 35 years since the emergence of the AIDS epidemic 
there remains no cure. The cause of AIDS, HIV– or human immunodeficiency virus– 
would eventually be discovered two years later, in the labs of Robert Gallo, Luc 
Montagnier, and Franciose Barre-Sinoussi. Montagnier and Barre-Sinoussi would later 
receive the Nobel Prize in Physiology and Medicine for their heroic efforts. The cause: a 
retrovirus, similar to that of HTLV-1 first discovered in 1980 (Gallo and Montagnier, 
2003; Gallo, 2005) which was shown to be linked to adult T-cell leukemia.  Retroviruses 
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are a family of viruses which obtained their name when the discovery of reverse 
transcriptase by David Baltimore and Howard Temin showed that some viruses had RNA 
genomes which were copied to DNA (Gallo and Montagnier, 2003). Unlike HTLV, HIV 
proved to be of the lentivirus genus, which is best classified by the slow progression to 
disease, and the clinical latency phase can last over 20 years which made it exceedingly 
difficult in the early 80s to pinpoint (Levy, 1993; Moir et al., 2011) .   
Within 15 years, huge progress was made first with repurposing of the nucleoside 
analog, zidovudine (AZT) (Fischl et al., 1987). Previously synthesized as a potential 
cancer therapeutic, AZT failed in mouse trials and was forgotten until after the discovery 
of its use as an inhibitor to the Friend Virus, a known retrovirus that causes murine 
Friend Leukemia Virus (FLV) (Ostertag et al., 1974).  By 1985, pharmaceutical 
companies were itching to find a treatment for the ever growing population of people 
being infected and dying of AIDS. During those six years since the emergence, an 
estimated one million Americans were infected with the virus and 15,000 had already 
succumbed to the disease (Boffey, 1986).  When the Borroughs Welcome Company 
dusted AZT off the shelf and sent it to the National Institute of Health and the National 
Cancer Institute to test against HIV-infected cells, it was there that they found that the 
zidovudine could successfully inhibit the virus without harming the cells. It was not long 
after that AZT went into animals and the FDA approved it for clinical trials (“A Failure 
led to drug against AIDS”,1986).  
Unfortunately, the AZT craze was short sided, and the effects were only temporary; 
with the harsh side effects and only modest improvement on life span there was still no 
effective treatment (Fischl et al., 1987). It wasn’t until 1996, that the development of 
	  	  
4	  
highly active antiretroviral therapy (HAART) was credited with the effective decrease in 
AIDS related mortality and morbidity in the United States and other industrialized 
countries (Palella et al., 1998). However, the cost associated with HAART and lack of a 
strong health care foundation has limited its use in developing countries (UNAIDS, 
2015). Since the onset of the virus, nearly 39 million people have died from the 
HIV/AIDS related illnesses, with currently 37 million people living with HIV. Despite 
this, only 15 million people living with HIV even have access to anti-retroviral therapy 
(UNAIDS and Sabin, 2015). Looking at a regional picture, the numbers become even 
more devastating, with more than two thirds of all people currently living with HIV 
residing in Sub-Saharan Africa alone. Strikingly, within Sub-Saharan Africa resides 88% 
of the worlds HIV+ children (UNAIDS and Sabin, 2015).  
 In 1984, during an unsubstantiated moment of hubris, the U.S. Secretary of Health 
and Human Services, Margaret Heckler, announced that through the discovery of the 
virus that causes AIDS “they” believed that a vaccine would soon follow: “We hope to 
have such a vaccine ready for testing in approximately two years” (Watkins, 2008). 
Unfortunately, despite nearly 35 years since the emergence of the HIV/AIDS epidemic 
and massive efforts there remains no cure or vaccine in sight. In order to understand the 
difficulty in obtaining a feasible vaccine, one must appreciate the virus’ inherent diversity 
and ability to mutate and change over time.  
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The HIV genome 
 HIV is a roughly spherical enveloped lentivirus that contains two copies of a 
positive sense RNA genome (Levy, 1993). Encasing the RNA is a cone-shaped capsid 
with a layer known as matrix dividing it from envelope (Figure 1).  Similar to other 
lentiviruses, such as Simian immunodeficiency syndrome (SIV) and Equine infectious 
anemia virus (EIAV), HIV is known for its immunosuppressive properties, as referenced 
in its name. HIV has an intricate genome that spans 9.8 kilobases (kb), and contains both 
regulatory and accessory genes necessary to encode all of the viral proteins, that are 
defined by three regions of the genome (Figure 1): gag, pol and env (Flint et al., 2008).  
 Gag, or group-specific antigen gene produces p55, or the Gag precursor protein, a 
55 kilodalton (kDa) protein expressed from the unspliced viral RNA. Following 
translation, p55 is myristoylated at its N-terminus, which enables p55 to interact with the 
cytoplasmic region of the cell membrane. Once it is associated with the cell membrane, 
p55  then recruits other viral and cellular proteins and viral genomic RNA to induce 
budding of the virus particle from the infected cell (Flint et al., 2008; Hutchinson, 2001). 
Post budding, viral maturation occurs and p55 is then cleaved by a virally encoded 
protease into matrix, capsid, nucleocapsid, and p6 (Cook et al., 2014). Matrix is derived 
from the N’-terminus of p55 and is responsible for stabilizing the viral particle by 
attaching to the virion envelope via the insertion of the myristoyl group into a 
phosphoinosotide in the plasma membrane (Ganser-Pornillos et al., 2008). The capsid 
protein forms the canonical cone-like core of the viral particles (FIGURE) encapsulating 
the RNA genome (Ganser-Pornillos et al., 2008), while the nucleocapsid protein is 
responsible for condensing the RNA genome (Briggs and Krausslich, 2011). Lastly, p6 is 
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necessary for efficient budding of the virions from infected cells as well as facilitating the 
interaction between p55 and Vpr, a viral accessory gene, and aids in the incorporation of 
Vpr into the fully assembled virion (Paxton et al., 1993).   
 The Pol proteins (Integrase, Protease, Reverse transcriptase, and RNase H) are 
synthesized from the Pol-Gag precursor, p160. Synthesis of this fusion protein occurs due 
to a ribosomal frameshift event initiated by a cis-acting RNA motif in the distal region of 
the Gag RNA (Parkin et al., 1992).  When ribosomes recognize this motif, a frameshift 
occurs approximately five percent of the time, allowing for the entire pol reading frame 
to be translated without interruption (Parkin et al., 1992). Similarly to p55, during viral 
maturation, the virally encoded Protease that is packaged in the virion cleaves p160 into 
the aforementioned pol proteins (Parkin et al., 1992). HIV protease is a dimeric aspartyl 
protease that is packaged in the virion during viral maturation, and as mentioned above, is 
essential for the cleavage of both p55 and p160 (Pettit et al., 2004). Reverse transcriptase, 
a hallmark of retroviruses, produces double-stranded DNA from the viral RNA genome 
(Baltimore, 1970). During this process, RNase H is required to eliminate the original 
RNA template to ensure the complementary strand of DNA is synthesized (Flint et al., 
2008). The last pol protein, Integrase, facilitates the incorporation of the provirus DNA 
into the host cell’s genomic DNA (Flint et al., 2008).  
 The third gene, envelope (env), encodes for a 160 kDa glycoprotein known as 
gp160. Env functions as the initiator of virion and host cell interactions and is heavily 
glycosylated. HIV utilizes glycosylation of the env protein as a mechanism to evade the 
host immune response. Indeed, following translation gp160 is targeted to the Golgi, 
where N-linked glycans are added to roughly thirty sites on the gp160 surface (Go et al., 
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2013; Pritchard et al., 2015a). While still in the Golgi network, HIV utilizes Furin, a 
ubiquitous protease enriched in the trans-golgi, to cleave gp160 into its active subunits, 
gp120 and gp41 (Figure 1) (Freed and Mouland, 2006; Ganser-Pornillos et al., 2008; 
Pantophlet and Burton, 2006; Pritchard et al., 2015a). The env proteins are then 
transported to the cell membrane where they form a trimer of gp120-gp41 heterodimers 
(Figure 1). The gp120-gp41 trimer, along with the host cell’s lipid bilayer, form the 
envelope coating the HIV virion, where gp41 contains the transmembrane domain, and 
gp120 is located on the surface of the infected cell or virion (Capon and Ward, 1991). 
The gp160 trimer or viral spike is required to mediate infection into the host cell and the 
primary site of the immune system’s humoral response against HIV; the mechanism of 
each will be discussed later in this chapter.  
 In addition to Gag, Pol, and Env, the HIV genome encodes regulatory proteins 
Rev and Tat, as well as accessory proteins Nef, Vif, Vpr, and Vpu (Briggs and 
Krausslich, 2011; Cook et al., 2014). Both Rev and Tat are proteins produced from fully 
spliced mRNA. Rev, an RNA binding protein, is responsible for facilitating the shift from 
early to late phase gene expression. Tat acts as a transcriptional transactivator in HIV-1 
replication and works in aiding to produce full-length HIV-1 transcripts (Feinberg et al., 
1991; Felber et al., 1990). Unlike Rev and Tat, the accessory proteins are not required for 
viral replication but affect virulence.  
 Nef, or negative factor, is a protein encoded a single exon located partially within 
the 3’ Long terminal repeat (LTR) and is an early sign of HIV infection, as it is the first 
virally encoded protein to accumulate in an infected cell. Nef has been shown to increase 
virulence of the HIV via downregulation of CD4, the primary receptor necessary for 
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infection in T-Cells allowing for overexpression of Env on the cell surface. In addition, 
Nef has been shown to downregulate major histocompatibility complex (MHC) on the 
infected cell in an attempt to evade the host immune response (Lama et al., 2001; Ross et 
al., 1999). 
 Unlike Nef, Vpr, Vpu, and Vif are products of incomplete splicing of mRNA and 
therefore are only produced during the Rev induced late phase of infection. Similar to 
Nef, Vpu is a protein that aids in the propagation of HIV-1 through its ability to 
downregulate CD4, as well as the novel function of enhancing the release of viral buds 
through the acting as an antagonist to a human type 2 integral membrane protein, known 
as tetherin. Interestingly, Vpu, while found in HIV-1, is not encoded in HIV-2, perhaps 
due to its redundancy with Nef (Magadán et al., 2010; McNatt et al., 2013). Vpr, through 
an interaction with the c-termini of the p55 protein, accumulates in the viral particles and 
aids in the ability of HIV to infect non-dividing cells and inhibits cell division (Jowett et 
al., 1995). Finally, Vif, the last accessory protein, also packaged in the mature virion, is 
known to assist in the replication of HIV in non-CD4 expressing lymphocytes (Lake et 
al., 2003), through depletion of APOBEC3G, an endogenous enzyme known to inhibit 
retroviral replication in HIV-infected T-cells (Stopak et al., 2003).  
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Figure 1. Genome organization of HIV and HIV envelope structure.  
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Origin and genetic diversity of HIV 
 Based on phylogenic analysis of the HIV genome and pathogenesis, there are two 
types of HIV viruses: HIV-1 and HIV-2. While HIV-1 and HIV-2 can both lead to AIDS, 
and share traits such as mode of transmission, basic genetic composition, and replication 
pathways, HIV-2 accounts for only 2% of HIV incidence rates worldwide and is 
characterized by slower progression to AIDS and increased immunogenicity (Wu, 2015). 
Moreover, the two viruses only share an overall genetic sequence identity of less than 
50% (Wu, 2015). Unlike the worldwide epidemic of HIV-1, HIV-2 is largely contained to 
Western Africa, and is largely tolerated without the need of medication. Based on this, in 
general much less effort has been made to research HIV-2 biology. 
 Through phylogenetic analysis, it is hypothesized that HIV-1 and HIV-2 are 
derived from separate cross-species transmission incidents (Figure 2) (Hutchinson, 2001). 
HIV-1, is more closely related to chimpanzee simian immunodeficiency virus, SIVcpz, 
which suggests that the known HIV-1 progenitor was passed from chimpanzees, while 
HIV-2 is more closely related to an SIV strain known to infect sooty mangabeys (Figure 
2) (Sharp and Hahn, 2011). Moreover, HIV-1 viral strains can be further divided into four 
groups: major (M), outlier (O), non-outlier and non-major (N), and P (pending the 
identification of further human cases) (Figure 2).  These groups, likely emerged from 
three separate and independent transmission events. HIV-1 groups M and N are thought 
to have arisen from chimpanzees, with similar strains found in currently SIV infected 
chimps. Group O seems to be the true outlier, diverging from M and N, and only recently 
has thought to have stemmed from a progenitor in gorillas (Figure 2) (Sharp and Hahn, 
2011).  Interestingly, group P, having similar origins to Group O in gorillas, was 
	  	  
11	  
discovered in an HIV-1 infected Cameroonian woman in France, and despite extensive 
research in the area, only one other person (also from Cameroon) has been identified with 
the same virus (Sharp and Hahn, 2011).   
 The genetic diversity of HIV can be attributed to an inherent mechanism that the 
virus uses to produce rapid viral evolution. Most notably, reverse transcriptase, the 
enzyme required to generate DNA from a retroviral RNA genome, is highly error prone, 
with a mutation rate of approximately 3.4 x 10-5 mutations per base per replication cycle 
(Baltimore, 1970). With a genome of approximately 104 bases, and an estimated average 
of 1.03 x 1010 virions produced per day, this means that on average there is at least 1 
mutation per genome per cycle, and millions of viral mutants produced daily within every 
infected individual (Perelson et al., 1996).   
 The predominant group of HIV-1 currently in circulation is aptly named Main or 
Group M. This group can be further sub-divided into subtypes or clades that can be 
linked to specific geographic areas (Figure 3) (UNAIDS and Sabin, 2015). The world-
wide distribution of the  ten clades, denoted A to K, is depicted in Figure 3.  The 
distribution observed is likely due to a founder effect, which resulted in a local 
predominance of a certain transmitted subtype (Buonaguro et al., 2007).  HIV-1 subtypes 
A, B, and C are the most prevalent globally, with subtype C accounting for 
approximately 50% of all HIV-1 infections. As depicted in Figure 3, subtype A viruses 
are widely spread through eastern and central Africa and eastern Europe. Subtype B, on 
the other hand, is predominant in western and central Europe, Australia, the western 
hemisphere, Northern Africa, and Southeast Asia. Unsurprisingly, subtype C viruses are 
predominant in Sub-Saharan Africa, India, and other high-risk populated countries 
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(Buonaguro et al., 2007). In addition to the 10 subtypes of Group M, in areas where 
multiple subtypes are found, there are “intersubtype” recombinant forms that are believed 
to be created from individuals infected with multiple viral strains. These “intersubtypes” 
are known as circulating recombinant forms or CRF. CRFs currently account for ~20% of 
infections and represent predominant forms of the virus found in Southeast Asia and 
Western Africa (Figure 3) (Buonaguro et al., 2007). Interaction between the virus and 
host may differ between viral subtypes and can potentially influence HIV transmission 
and progression to AIDS. Further understanding of the mechanism of HIV infection may 
shed light on the inherent differences seen between subtypes.  
Currently, the earliest documented case of an individual infected with HIV-1 
Group M was from a city in the Democratic Republic of Congo now known as Kinshasa, 
concerning a sailor who passed away from AIDS-like symptoms in 1959. Despite mainly 
being restricted to Western Africa, genetic material from a less common subtype, Group 
O, was first found in the early 1970’s in the remains of a Norwegian family (Zhu et al., 
1998). 
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Figure 2. Phylogenetic Tree based on pol and env sequences. Most similarly related 
are grouped by color. Images depict main species infected. Tree adapted from Los 
Alamos HIV Phylogenetic Consortium.  
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Figure 3. World-wide distribution and prevalence of HIV-1.   
The distribution observed is likely due to a founder effect, which resulted in a local 
predominance of a certain transmitted subtype. HIV-1 subtypes A, B, and C are the most 
prevalent globally, with subtype C accounting for approximately 50% of all HIV-1 
infections. 
 
  
	  	  
15	  
Epidemiology, Transmission and Pathogenesis of HIV 
 Today, the routes through which HIV infection has spread are most commonly 
through sexual transmission and through the sharing of needles (UNAIDS, 2015; 
UNAIDS and Sabin, 2015). Bodily fluids such as blood, semen, pre-seminal fluid, rectal 
and vaginal secretions, and breast milk can carry and transmit the virus if they come in 
contact with mucosal membranes, damaged tissues, or, in the case of intra-venous drug 
use or blood transfusions, if they are directly injected into the bloodstream (Pritchard et 
al., 2015b). The most common route of HIV transmission is through exposure of free 
virus or cell-associated virus present in mucosal surfaces or semen (Haase, 1999; 
Mehellou and De Clercq, 2010; Moir et al., 2011).  While heterosexual intercourse is the 
most common globally, in first world countries such as the United States, the highest-risk 
population are those of the MSM (men who have sex with men) community, followed by 
heterosexual women (CDC, 2012).    
 While HIV transmission through intravenous drug use or blood transfusions 
seems clear, in order to establish and infection in either the female reproductive tract or 
through the rectal mucosa, HIV in semen must first cross the genital or rectal epithelium 
as well as bypass both innate and adaptive immune responses and then manage to 
establish an infection (Figure 4). Potential pathways for crossing the mucosal epithelium 
include mechanical mechanisms such as the virus traversing through micro-tears that can 
occur during sex due to friction. Lubricants and anti-microbial lotions can also increase 
HIV incidence rate by causing irritation to the epithelial layers. It is also hypothesized 
that the dendritic cells or Langerhans cells which can span the epithelial layers can 
potentially allow for HIV to cross the epithelium via mechanisms such as endocytosis,  
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Figure 4. HIV transmission through the vaginal or rectal lumen. 
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transcytosis, or binding to cell receptors such as DC-SIGN on dendritic cells 
(Geijtenbeek et al., 2000).  
 Early on in the discovery of HIV, physicians noticed that the hallmark of HIV and 
AIDS progression was the depletion of CD4+ T-cells (also known has TH or Helper T-
cells) in the patient. Once the CD4+ T-cell count fell below 200 per microliter of blood, 
an individual was classified as having AIDS and therefore susceptible to the AIDS-
related opportunistic infections and cancers. It has been shown that other cells expressing 
CD4, such as macrophages and dendritic cells, are also capable of being infected, which 
may mediate HIV transmission, but to a lesser degree. This can be attributed to the need 
of the co-receptors either CCR5 or CXCR4 found on helper T-Cells in order for the virus 
to effectively fuse to the cell (Alkhatib, 2007). Following the initial infection, it has been 
shown through rhesus macaque models of the infection that the preliminary site of CD4 
T-cell depletion is in the gut-associated lymphoid tissue (GALT); it is here that the virus 
first finds residence in the body, leading to rapid proliferation of the virus (Boggiano and 
Littman, 2007).  
 Within a few weeks post initial transmission, people infected with HIV typically 
suffer from flu-like symptoms, potentially due to the high viremia as well as proliferation 
and activation of cytotoxic T lymphocytes specific HIV flooding the immune system 
(Simon et al., 2006). Following the initial acute viremia, the immune system seems to be 
able to control the infection, leading to a precipitous drop in viral load and the recovery 
of CD4+ T-cells. This asymptomatic stage, common with many lentiviral infections, can 
last for years before the virus can rebound again leading to the fall of CD4+ T-cells 
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below 500 cells/microliter, which allows opportunistic infections to occur, resulting in 
the progression to AIDS and then ultimately to death (Coffin and Swanstrom, 2013).  
 The mechanism of HIV fusion is well established, with HIV’s envelope proteins 
gp120 and gp41 facilitating the interaction. In order for infection to occur, it has been 
found that both CD4 and a G-protein-coupled receptor (GPCR) need be on the surface of 
the cell (Alkhatib, 2007). CCR5 and CXCR4 are the most commonly used GPCRs for 
HIV infection, with CCR5 being the principal co-receptor (Alkhatib, 2007).  HIV isolates 
are commonly characterized by a preference for either CCR5 or CXCR4. Interestingly, it 
has been shown that CCR5-tropic viruses, also known as R5 isolates, are thought to be 
the first virus to infect cells during transmission by targeting macrophages and activated 
CD4+ memory T-cells (Freed and Mouland, 2006; Geijtenbeek et al., 2000). R5-tropic 
strains predominate the infection during early stages of HIV; however, as the virus 
mutates its preference for GPCRs changes as well, and the viral population selects for X4 
isolates, preferentially binding to CXCR4 (Waters et al., 2008). As the tropism changes 
from R5 to X4, so does the cell preference, with CXCR4 on naïve CD4+T-Cells  (Waters 
et al., 2008). This marketed switch from memory to naïve CD4+ T-cells is likely due to 
the T-cell population decreasing and the lack of available memory cells.  
 
Mechanism of HIV Fusion and the structure of HIV’s trimeric env spike  
 The HIV gp120 glycoprotein was first defined by as having two major features, 
the first being the gp120 core, and the variable regions. The gp120 core, composed of 
five constant regions, is responsible for the interactions that are necessary for the key 
binding events to occur for fusion. The second feature is the variable region defined as 
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the five variable loops, which have been shown to be mainly responsible for shielding 
and protecting the core from immune detection (Starcich et al., 1986). While this first 
designation of the regions remains largely correct, the V3 loop has been shown to 
mediate co-receptor binding (Tamamis and Floudas, 2014).  In addition to the variable 
loops of the gp120, the presence of the glycan shield aids in the virus’ ability to occlude 
key sites of its envelope in order to evade the immune system. First described as the 
‘silent face’ of the gp120 protein, the glycans on the surface of the protein account for 
50% of the total surface area (Wyatt et al., 1998). These glycans produced by the host 
during viral synthesis allow the virus to remain shielded from the potential immune 
response that host cells may deem it self (Wyatt et al., 1998). The variable regions and 
the glycan shield together with the virus’ mutation rate and the ability to hide conserved 
regions such as the co-receptor binding site at interfaces produced by the oligomerization 
of the Env trimer, have been the prevailing ideas for how the virus can evade the humoral 
response (Kwong et al., 2002; Labrijn et al., 2003; Moore and Sodroski, 1996).  
 During HIV fusion, gp120 of the HIV trimer engages with the CD4 receptor, 
leading to a conformational change that reveals the co-receptor binding site. It is then that 
the virus can bind to the co-receptor (CCR5 or CXCR4) and form a very stable 
attachment to the CD4+T-cell. Post attachment, the gp41 induces an additional 
conformational change where the N-terminus forms as a fusion peptide (HR1) that is 
inserted into the host cell to form a pre-hairpin intermediate state (Harrison, 2015). 
During this process, the gp120 proteins shed from the envelope spike and the fusion 
continues, where the individual monomers of  C-terminal heptad repeat region of gp41 
(HR2) bind to the N-terminal HR1, forming a six helical bundle composed of both the 
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HR1 and HR2, bringing the host membrane within close proximity to the viral membrane 
and anchoring to form a stable pore where the virus’ genomic and protein content can 
then be deposited (Chan et al., 1997; Chan and Kim, 1998).  
 There has been a great effort within the scientific community to understand the 
HIV envelope trimer in an attempt to understand how to develop an effective vaccine. To 
date, there has yet to be an effective vaccine developed despite clinical trials and massive 
efforts in design (Graham, 2002; McMichael, 2006; Picker et al., 2012; Watkins, 2008).  
Learning more about the structure and function of the envelope trimer has been an 
intensively studied area of HIV biology, as it is the primary focus for broadly neutralizing 
antibodies, an important arm of the humoral immune system (Mascola and Montefiori, 
2010). 
 The first crystal structure of HIV envelope protein gp120 was solved in 1998 to 
2.5 Å by Peter Kwong and Wayne Hendrickson at Columbia University (Kwong et al., 
1998; Rizzuto et al., 1998). In order for gp120 to be crystallized, the N-and C-termini of 
gp120 and variable loops V1/V2 and V3 were truncated to produce a core version of 
gp120, and N-linked glycans were truncated using enzymatic deglycosylation (Kwong et 
al., 1998). This structure contained the core gp120 from HIV strain HxBc2, a soluble 
version of CD4 containing the first two domains, and the fragment antigen binding (Fab) 
portion of 17b, an antibody known to recognize the co-receptor binding site on gp120 
(Kwong et al., 1998; Rizzuto et al., 1998).  The gp120 structure consisted of an inner and 
outer domain connected by a bridging sheet. Residue Phe43 of CD4 was shown to reach 
into a recessed hydrophobic pocket on gp120, defining for the first time HIV Env 
evolved to interact with its host receptor. 
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 The structure of the ectodomain of gp41, solved by two independent groups in 
1997, revealed a six-helical bundle in which two helical regions from each subunit of the 
trimer, HR1 and HR2, both formed an anti-parallel alpha-helical coiled coil (Chan et al., 
1997; Weissenhorn et al., 1997). The structure was interpreted as depicting the post-
fusion state of the gp41 domain, in which fusion peptide that is N-terminal to HR1 is 
embedded in the host cell membrane while the C-terminal transmembrane domain is 
embedded in the viral membrane.  
 While the gp120 and gp41 structures facilitated understanding the HIV spike and 
the neutralizing antibodies that can bind them, determining the structure of the trimeric 
gp160 complex remained an important area of research in order to learn more about the 
trimer structures in context. In 2006, the first images of the SIV Env trimer were revealed 
by electron tomography of SIV virions by Zhu et al.: the trimer was described as 
consisting of a head (composed of the gp120 proteins) and gp41 forming a tripod-like 
structure holding up the gp120 trimer (Zhu et al., 2006). Aspects of the model were 
refuted in 2008 when a group at the NIH published new structures of the HIV envelope 
trimer (Liu et al., 2008). It was in this study that we first saw visual confirmation that the 
conformational changes induced by the binding of CD4, first hypothesized in 1991 
(Sattentau and Moore, 1991), were valid. Interestingly, this study also found that CD4 
binding site antibodies such as b12 can also induce conformational changes (Liu et al., 
2008). Despite the low resolution of these structures (~20 Å), these early electron 
tomography efforts by Subramaniam were later validated by EM structures of a soluble, 
furin-cleaved form of a gp140 trimer comprising the gp160 ectodomain, which is 
produced by truncating gp160 prior to the predicted transmembrane domain of 
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gp41(Harris et al., 2011; Tran et al., 2012). Developed by the Moore lab at Cornell Weill 
(Sanders et al., 2002; Schulke et al., 2002), the SOSIP gp140 trimer is thought to be the 
most native-like soluble version of the trimer to date (Klasse et al., 2013; Schulke et al., 
2002). SOSIP gp140 trimers are soluble, furin-cleaved trimers that are stabilized through 
engineering of an intermolecular disulfide bond between the gp41 and gp120 subunits 
(SOS), which prevents dissociation of gp120 monomers (Schulke et al., 2002), and the 
substitution of a single residue in the gp41 subunit (I559P; IP), which was found to 
increase the proportion of soluble trimers (Sanders et al., 2002).  
 While the early electron tomography efforts by Subramaniam were crucial to 
understanding the envelope trimer on HIV virions, due to the low resolution of the cryo-
EM tomography/sub-tomogram averaging procedure required to produce the Env 
structures, the structures only depicted a rough outline of the shape of the trimer and 
gross conformational changes in the complex, and allowed modeling of the gp120 core 
region through docking of gp120 crystal structures into the EM maps. The gp41 subunit 
and the variable loops of gp120 in the context of the trimer remained largely a mystery 
until recent EM and crystal structures of SOSIP trimers were solved.   
 Within the past four years there has been technological advancements in the area 
of X-ray crystallography and molecular biology, which have allowed for the first high 
resolution structures of the HIV envelope trimer to be solved. The first structures 
involved a SOSIP trimer constructed form the clade-A HIV-1 isolate BG505, which 
naturally exhibited a more stable trimer that was efficiently cleaved into gp120 and gp41 
subunits (Sanders et al., 2013). Between 2013 and today, a series of high resolution X-ray 
and EM structures BG505 SOSIP.664 env trimer have been solved (Do Kwon et al., 
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2015; Julien et al., 2013b; Lyumkis et al., 2013; Pancera et al., 2014a; Scharf et al., 
2015). The X-ray crystallographic and EM structures solved to a range of  3Å-6Å 
allowed for greater understanding of the role of gp41 in the context of the trimer prior to 
fusion and provided information concerning the various loops that had been truncated in 
gp120 structures (Julien et al., 2013b; Lyumkis et al., 2013; Pancera et al., 2014a; Scharf 
et al., 2015). With the variable loops now intact, these data suggest that the variable loops 
V1, V2, and V3 encompass the trimer apex, aiding in trimer stabilization via previously-
undescribed inter-protomer contacts. In an attempt to mask the co-receptor binding site, 
V3 lies behind an N-linked glycan attached to gp120 position Asn197 of the adjacent 
protomer and beneath the V1-V2 loops (Julien et al., 2013b; Lyumkis et al., 2013).  
Through the most recent high-resolution structures, a more complete gp41 structure can 
be seen elucidating in further detail the interaction between gp41 and gp120 (Garces et 
al., 2015; Pancera et al., 2014a; Scharf et al., 2015).  It is within these structures that we 
first see gp41 hydrophobic residues wrap around the N-termini of the gp120 proteins to 
obtain a similar topology as seen with other viral spike proteins found in Ebola and 
influenza viruses (Garces et al., 2015; Pancera et al., 2014a).  
 The structures of the Env trimer described above were crucial to the 
understanding of the work described in the following chapters.  
 
The Anti-Viral Immune Response  
In order to develop effective therapeutics against HIV, it is important to understand the 
natural immune response against viruses. This section is dedicated to discussing the role 
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of the immune system during an active infection, in an effort to understand current 
limitations and find strategies to work around it.   
Innate Immune System 
 In order to protect an individual from an infection, the immune system must be 
able to perform the following four tasks: recognize the pathogen, respond to and clear the 
microorganism, self-regulate the response in order to keep homeostasis, allowing for 
minimal damage to the body, and finally, generation of an immunological memory so 
that when encountered by the pathogen again it can respond more effectively.    
 Leukocytes are the component of the blood responsible for both the innate and 
adaptive immune system. The innate cells are derived from a common myeloid 
progenitor in the bone marrow, and differentiate into dendritic cells, macrophages, 
granulocytes, and mast cells. Natural Killer cells (NK cells) are an innate immune cell 
derived from the common lymphoid progenitor; unlike other lymphocytes described later 
in the chapter, not antigen specific and have the ability to kill abnormal cells such as 
tumor cells and are thought to hold viral infections at bay until the adaptive immune 
system can respond. All of these cells get recruited to the location of the pathogen within 
the first few hours and days of the infection (Murphy et al., 2012).  
 The first method of defense to pathogens that the body employs is physical and 
chemical barriers at sites of transmission. The physical barriers include the skin, tight 
junctions between epithelial cells, cilia located in the nose, lung and gut “shield and 
sweep” the microbes away from vulnerable sites of infection, the production of mucus as 
a barrier, and peristalsis of the gut to name a few. If the organism has managed to escape 
the physical hurdles, it is then barred through a series of chemical barriers present in the 
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blood, extracellular fluid and epithelial secretion such as antimicrobial enzymes and 
peptides that are able to lyse bacterial cell membranes (Murphy et al., 2012). These 
antimicrobial peptides and enzymes are secreted by a group of epithelial cells known as 
paneth cells in the crypts of the small intestine, and by phagocytes such as macrophages 
and dendritic cells circulating in the blood and in infected tissues (Murphy et al., 2012).  
 Another innate response against pathogens is the complement system, consisting 
of a series of proteins in the plasma. The complement pathway can be activated directly 
by the pathogen, that leads to a cascade of events on the microbe’s surface and leads to 
the degradation of the pathogen by phagocytes. If all the above fail to stop the entry of 
the pathogen, the immune system is poised and ready to defend (Murphy et al., 2012).   
 Phagocytosis and the ability to recognize the pathogen as foreign are two 
processes of the innate immune system that are particularly important in protecting the 
host from microbial pathogens. Phagocytosis performed by cells, including macrophages 
and dendritic cells, work in the removal of the pathogen in two ways: first by the 
degradation of the microbe and second by the presentation of pathogen-derived peptide 
antigen (Medzhitov, 2007; Medzhitov and Janeway, 2000). In the case of viruses, as well 
as bacterial infections, the viral genomic material and proteins are distinguished from self 
by a series of receptors known as pattern recognition receptors or PRRs. PRRs are 
expressed on innate immune cells and work by recognizing the pathogen-associated 
molecular patterns (PAMPs) that are present on the pathogen but not on self.  Depending 
on what it detects, the PRRs are present on either the on the cell membrane surface or 
within the cytoplasm, where they can detect various viral components (Murphy et al., 
2012). It is the detection of these PAMPs through the PRRs that activates the innate 
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immune cells as well as catalyzes the adaptive immune system through the gene 
expression of inflammatory cytokines and co-stimulatory molecules (Murphy et al., 
2012). PRRs including toll-like receptors (TLRs) and Rig-I-like helicases (RLHs) are 
known to be especially important in sensing viral infections. In the case of HIV, TLR7/8 
and 9 sensing single stranded RNA and CpG methylated DNA has been implicated in 
aiding the humoral immune response against the HIV-1 spike (Moody et al., 2014).  RIG-
I, a RNA helicase like domain widely expressed across various tissues and cell types has 
also been implicated in innate sensing of HIV by the detection of viral RNA in the 
cytoplasm of infected cells (Solis et al., 2011).  
  In addition to engulfment of the pathogen via phagocytosis, macrophages and 
dendritic cells secrete cytokines such as IL-8 and IL-12 to recruit and activate cells to the 
site of the infection, as well as the secretion of TNF-α, which leads to the increase in 
vascular permeability to allow for entry of immune cells, complement, and antibodies to 
the damaged tissue (Murphy et al., 2012). In the case of HIV infection, immune cells, 
including macrophages, neutrophils and monocytes, secrete chemokines CCL3 and 
CCL4, which are known to compete with HIV-1 binding to the co-receptor site CCR5, as 
described in this chapter (Altfeld and Gale, 2015). 
 
Adaptive Immune Response 
 Leukocytes responsible for the adaptive immune response are known as 
lymphocytes and are derived from the common lymphocyte progenitor (Murphy et al., 
2012). Unlike the common-myeloid progenitor cells, lymphocytes are mainly antigen 
specific and aid in both the clearance of a pathogen, as well as immunological memory of 
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the pathogen. Lymphocytes can be differentiated into two major groups: B- and T- 
lymphocytes. B- and T- lymphocytes have complementary but different roles in the 
adaptive immune system. Moreover, they aid in separating the adaptive immune response  
into two branches: cell mediated immunity where the protective function is associated 
with cells utilizing mainly Cytotoxic T-lymphocytes (CTLs or CD8+ T-cells), and the 
humoral immune response, which utilizes antibodies produced by B lymphocytes (B-
Cells) as the primary mode of protection (Murphy et al., 2012).  
 The dendritic cell acts as a bridge between the innate and adaptive immune 
system by presenting antigenic peptides produced from phagocytosis of a pathogen to T-
cells. These antigenic peptide fragments are presented by proteins known as MHC 
molecules, which are on the surface of antigen-presenting cells, in the case of class II 
MHC molecules, or all nucleated cells, in the case of class I MHC molecules. The MHC, 
or major histocompatibility complex, is a large cluster of genes that encodes proteins 
involved in antigen presentation to T-cells. The MHC is highly polymorphic, such that 
class I and class II MHC molecules exist in many allelic forms within a population, and 
the receptor on T-cells (TCR; T-cell Receptor) can only recognize an antigenic peptide in 
the context of a particular MHC allele; i.e., T-cell recognition of antigen is “MHC-
restricted” (Neefjes et al., 2011).  
 In cell mediated immunity, naïve T-cells are activated by an antigen presenting 
cell (most commonly dendritic cells) expressing MHC molecules and co-stimulatory 
molecules B7.1 and B7.2. Upon activation, the T-cells produce IL-2, leading to 
proliferation and differentiation of antigen-specific T-cells. Class I MHC molecules 
present peptides derived from proteins synthesized within the cell to CD8+ T- 
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lymphocytes, which are then activated to kill the cells displaying aforementioned peptide-
MHC complexes. Class II MHC proteins present peptides derived from proteins degraded 
in endocytic vesicles to CD4+T-lymphocytes (T-helper cells); these cells then 
differentiate to become specialized effector cells, TH1, TH2, TH17 or TFH (Murphy et al., 
2012; Neefjes et al., 2011). While the main function of CD8+ T-cells is to kill virally-
infected cells, the CD4+ T-cell subtypes are responsible for regulating many functions. 
CD4 TH1 cells aid in activating infected macrophages and provide T-cell help to B-cells 
for antibody production. CD4 TH2 cells aid B-cells in allergy and parasitic infections; TFH 
cells, found primarily in the lymph nodes and the tonsils, aid in B-cell isotype switching 
and antibody production; lastly CD4 TH17 and CD4 regulatory T-cells act in 
juxtaposition to one another, with TH17 cells promoting the neutrophil response thus 
increasing inflammatory signaling, versus suppression of T-cell responses by CD4 Treg 
cells (Crotty, 2011).  
 Unlike T-cell mediated immunity, where cytotoxic lymphocytes can only 
eliminate infected cells, the humoral immune system has the potential to both eliminate 
infected cells and prevent infection by neutralizing the free pathogen.  After an antigen 
binds to the B-Cell Receptor of a naïve B-cell and is stimulated by a CD4 T-helper cell, 
the B-cell will proliferate and can differentiate into plasma cells. Plasma cells are the cell 
line of defense for the humoral immune system, producing a soluble form of the B-cell 
receptor known as an antibody.  
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Antibodies 
 Antibodies can be found in nearly all body fluids, or humours, including milk, 
tears, bile, and saliva; however, they are most prevalent in blood serum (Murphy et al., 
2012). Direct evidence of antibodies in serum first were reported by Kabat and Tiselus in 
1939, in electrophoresis experiments of serum from immunized rabbits.  In the 
experiment, rabbits were immunized with ovalbumin (OVA) and later blood was drawn 
and serum prepared. The serum was then aliquoted into two fractions; one sample was 
left untreated, while the other was incubated with OVA and then centrifuged to remove 
any aggregated immune complexes. Electrophoresis of the serum confirmed that it can be 
separated into four distinguishable serum fractions corresponding to serum albumin, and 
three unknown fractions of α, β, γ globulins. When the electrophoresis profiles of the 
treated and untreated serum were compared, Kabat and Tiselus noticed a significant 
decrease in the γ-globulin peak in the treated serum sample (Tiselius and Kabat, 1939). 
Therefore, they deduced that the γ-globulin fraction must be the one containing the serum 
antibodies, which was then coined immuno-globulin to differentiate this fraction of 
proteins from any other protein in the serum (Tiselius and Kabat, 1938; Tiselius and 
Kabat, 1939).  Later, immunoglobulins were further classified into five major classes: 
IgA, IgD, IgE, IgG and IgM, with IgG being most abundant in the body (Murphy et al., 
2012).  
 The basic organization of an antibody is a Y-shaped structure consisting of four 
peptide chains, two light chains (kappa or lambda), and two heavy chains with each chain 
approximately 25 kilodaltons (kDa) and between 50 -70kDa in molecular weight 
respectively (Figure 5).  Each light chain is linked to a heavy chain by a disulfide bond at 
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the c-terminus of the light chain, and by non-covalent interaction to form a heterodimer. 
Within every antibody two identical heavy-light chain heterodimers form a “dimer of 
heterodimers” linked by a series of disulfide bonds between the two heavy chains 
(Murphy et al., 2012; Pieper et al., 2013).  
 All immunoglobulin subtypes share a common structure, and can be distinguished 
from one another through the constant domains of their heavy chains. IgG, the most 
abundant antibody in the body also has the most basic structure. The structures of both 
the heavy and light chains reveal a series of domains known for a signature 
immunoglobulin fold consisting of two β-sheets connected via hydrophobic bonds and a 
inter-disulfide bond. Each light chain has two immunoglobulin domains, and the heavy 
chain of IgGs contains five (Edelman, 1973; Marx, 1975). 
 The first Ig-domain on both heavy and light chain arm is a highly variable region 
conferring the antigen specificity of the antibody known as the VH or VL, respectively. It 
is in these variable regions that all differences found in specificity of the antibody can be 
traced to variations in the amino acid sequences within the specific regions of variable 
domains known as the complementarity-determining regions (CDRs). The CDRs of both 
the heavy and light chains form a surface at the tip of the antibody that is complementary 
to the antigen it is specific for. There are three CDR regions in each heavy and light 
variable domain (CDR1, CDR2, CDR3). The remaining regions of the variable domains 
are less variable and lie between the CDRs, and are known as the framework regions 
(FR1-4). Named for their utility, structurally, these regions form the framework of the 
variable domains while the CDRs form three loops joining the beta strands (Chang et al., 
1985; Colman et al., 1974). 
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 The remaining three domains of the IgG heavy chain and one domain of the light 
chain are relatively invariable in amino acid sequence and are known as constant regions 
CH1-3 and CL, respectively. After the digestion of an IgG with papain, a proteolytic 
enzyme, the product is three fragments: two identical “arms” containing the antigen 
binding sites, termed the Fraction antigen binding fragments or Fab Fragments (VH-
CH1/VLCL), and a third fragment of similar molecular weight to the Fab fragments (50 
kDa) that lacked antigen binding capabilities but crystallized readily during storage of the 
proteins, dubbed the Fc fragment, which was later found to be a dimer of CH2-CH3 
domains of the heavy chains (Marx, 1975) (Figure 5). The Fc fragment joins the two Fab 
arms through a short flexible linker known as the hinge region.  This overall Y-shaped 
dimeric antibody structure leads to two identical antigen binding sites on each 
immunoglobulin monomer, both with the ability to bind to two of the same antigen on a 
given surface resulting in an increase in apparent affinity of the antibody to the antigen 
known as avidity. The concept of avidity, important to antibody function (Murphy et al., 
2012), will be discussed later in this chapter.  
 The generation of antibody diversity is primarily though VDJ recombination. 
During VDJ recombination, the variable region of the heavy chain is encoded by three 
separate gene segments: V(variable), D (diversity), and J (joining), with the VH gene 
segment encoding amino acids 1-94 and the JH segment encoding for amino acids 98-113 
while the DH gene segment joins the two larger segments encoding for amino acids 95-97 
(Tonegawa, 1983). These gene segments are located on chromosome 14 and are referred 
to as the heavy chain multigene family, which has been found to have 39 VH segments 
followed by the D locus containing 23 functional DH segments and 6 JH segments. 
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Downstream to VDJ fragments are a series of genes that encode the different constant 
regions of the immunoglobulin classes.  
  A similar process occurs for the light chains of antibodies, with the kappa and 
lambda light chain loci found on chromosome 2 and 22, respectively. Unlike the heavy 
chain, the variable domain of the light chain is encoded by two gene segments (V and J). 
In the kappa chain family there are 85 Vκ  segments upstream to four functional Jκ 
fragments and 1 Constant Cκ gene fragment. The lambda gene locus is slightly different 
as there are 30 Vλ  segments upstream to four functional Jλ fragments and four Constant 
Cλ gene fragments. While the limited variable fragments in the lambda compared to the 
kappa may lead to reduced diversity of the lambda VL domains, it makes up for it with 
the four function Cλ gene segments, allowing for four different λ-chain subtypes to be 
produced (Murphy et al., 2012).  
 During B-cell maturation in the bone marrow, the heavy chain gene 
rearrangements occur first, followed by light chain gene rearrangement, and the result of 
both leads to each B-cell containing two genes encoding for both a fully functional heavy 
and light variable region. At this point, the B cell is now mature and committed to 
produce the specific antibody composed of a heavy and light chain variable domains 
assembled through gene rearrangements.  
 The diversity of the antibody is derived from a number of factors in the bone 
marrow including through the combinatorial pairing of various germ-line gene segments, 
heavy and light chain pairings, and nucleotide additions. Once the B-cell leaves the bone 
marrow, a process known as affinity maturation can occur to add even greater diversity to 
the antibody repertoire. After the naïve mature B cell encounters an antigen, the T-cell-
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dependent B cell response is initiated.  The B cell travels to sites known as the germinal 
centers in secondary lymphoid organs such as the lymph nodes and the spleen. It is here 
that affinity maturation can occur through two different but related processes: somatic 
hypermutation and clonal selection.  
 During somatic hypermutation (SHM), the B cell already primed by the antigen is 
stimulated to proliferate and during this process the BCR locus undergoes somatic 
mutation at a rate approximately 105 greater than normal mutation rate (Maul and 
Gearhart, 2010). This process of SHM is catalyzed by an enzyme, activation induced 
deaminase (AID), which converts cytosine to uracil. Each mutation is typically a single 
nucleotide substitution, and usually occurs within mutation “hotspots,” characteristically 
in the CDR regions of the variable domains and less often within the framework regions 
(Peled et al., 2008; Victora and Mesin, 2014; Victora and Nussenzweig, 2012). In 
addition to SHM, clonal selection occurs in the germinal center with the help of TFH cells 
and follicular dendritic cells that reside there. It is here that follicular dendritic cells 
present the antigen to the germinal B cells and stimulation through cross-talk of TFH cells, 
and allow for rounds of positive selection of B cells with high affinity to the antigen 
(Victora and Mesin, 2014; Victora and Nussenzweig, 2012). At the end of this entire 
process, the B cell can now become either a memory B cell, or a plasma cell expressing 
fully matured antibodies with higher affinities to the antigen and a longer life span than 
the plasma cells at the start of the infection (Dörner and Radbruch, 2007; Kurosaki et al., 
2015).     
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Antibody Mediated Effector Functions 
 Once mature, antibodies are effective in sequestering the pathogen via three 
distinct pathways, activation of complement, opsonization, and neutralization. In the 
classical complement pathway, antibodies, typically IgM or IgG, play a key role in 
catalyzing the complement pathway by forming antigen-antibody complexes, leading to a 
conformational change in the antibody and exposing a receptor for the first complement 
protein to bind. This binding event then leads to the standard cascade of events in the 
complement system leading to the formation of a pore in the microbe, resulting in lysis 
and engulfment of the pathogen.  Neither truly part of the innate or adaptive system, 
complement straddles the line between each and plays an important role in the 
elimination of a pathogen (Murphy et al., 2012; Pieper et al., 2013).  
 Opsonization occurs when antibodies target a pathogen that can replicate outside 
of the host cell and coat the surface of the microbe. The aggregation of the antibodies on 
the surface then trigger phagocytosis from macrophages and neutrophils. Similarly, when 
antibodies are bound to a pathogen it can initiate effector functions through Fc-mediated 
recruitment of NK and CD8+ T- Cells resulting of direct killing of the antigen, this 
process is known as Antibody mediated cellular-cytotoxicity (ADCC) (Murphy et al., 
2012; Pieper et al., 2013).  
 Lastly, and possibly the most efficient way that antibodies can eradicate an 
infection is through neutralization of the pathogen. This is particularly useful for viruses 
attempting to gain entry to a cell for replication. Antibodies can effectively neutralize 
viruses by either blocking the cellular receptors needed for the virus to bind to the cell, or 
through disruption of the fusion mechanism on the virus (Corti and Lanzavecchia, 2013; 
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Dörner and Radbruch, 2007). There are two different models to address how 
neutralization of viruses may occur.  The first, known as the occupancy model, assumes 
that the antibodies, similarly to their role in opsonization, merely occupy and coat the 
viral surface of the antibody, making it difficult for the virus to approach the cell (Burton 
et al., 2000; Klasse and Sattentau, 2002; Parren et al., 2000), In the alternative model, 
known as the critical binding site model, antibodies hinder fusion by binding to the 
necessary sites for binding to the host (Parren et al., 2000).   
      
 
 
Figure 5. The IgG Structure.  
The antibody is composed of two Fab regions consisting of the entire light chain (VLCL) 
and the VHCH1 domains of the heavy chain, a region known as an Fc, which is a dimer 
of heavy chain domains CH2-CH3. The antigen binding sites are located at the tip of the 
Fab regions at the interface between VH and VL. The maximum distance between these 
two antigen binding sites is approximately 15nm.    
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Broadly Neutralizing Antibodies against HIV 
  
 The HIV Envelope spike contains the only sites on the HIV virion that can be 
targeted by neutralizing antibodies. The virus employs various well-characterized 
mechanisms in order to evade the immune response against the trimer spike, such as 
rapid mutation and glycan shielding that make it difficult to boost an effective antibody 
response. In fact, only 15% of HIV-infected individuals develop neutralizing antibodies 
against heterologous HIV-1 strains, leaving the majority of the HIV-infected population 
with a handicapped immune response. Looking at the numbers closer, the situation 
appears even more bleak, with only 1% of HIV-positive individuals capable of 
developing broad and potent neutralizing antibody responses (Sather et al., 2012). 
Moreover, despite being able to produce these broad and potent neutralizing antibodies, 
these antibodies are no longer effective against the viral strains circulating in the patients’ 
body (Doria-Rose et al., 2009; Euler et al., 2010; van Gils et al., 2009; van Gils and 
Sanders, 2013).   
 The first anti-HIV broadly neutralizing antibody was isolated from a phage 
display library derived from the bone marrow of an asymptomatic HIV+ patient in 1994 
(Burton et al., 1994). The antibody, b12, was found to bind the CD4 binding site of 
gp120 and was broadly neutralizing against a panel of HIV-1 isolates (Burton et al., 
1994). The isolation of b12 gave hope to the HIV field that other broadly neutralizing 
antibodies could be found, and soon after, a handful of more broadly neutralizing 
antibodies were isolated. Among these were 2F5 and 4E10, both broadly neutralizing 
antibodies specific for the MPER region of gp41, and 2G12, a carbohydrate-binding 
antibody, specific to the high mannose patch of glycans on gp120 (Buchacher et al., 
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1994; Purtscher et al., 1994; Stiegler et al., 2001; Trkola et al., 1996). Despite being 
described as broadly neutralizing antibodies, these early antibodies had limited potency 
and breadth but were found to protect against SIV in non-human primate models and 
found to delay viral rebound after anti-retroviral cessation in patients (Ferrantelli et al., 
2004; Hessell, 2007; Hessell et al., 2009; Hofmann-Lehmann et al., 2001; Mascola, 1997, 
1999, 2000; Trkola et al., 2005) 
 Technological advancements in single B cell cloning methods (Scheid et al., 
2009a)led to the discovery of dozens of new broadly neutralizing antibodies (McCoy et 
al., 2012; Pejchal et al., 2011; Scheid et al., 2009b; Scheid et al., 2011a; Sok et al., 2014; 
Walker et al., 2011; Wu et al., 2010a). Discovery of this new generation of broadly 
neutralizing antibodies was only made possible through development of a new single B 
cell cloning technique that allowed for identification and enrichment of memory B cells 
from HIV-infected patients (Scheid et al., 2009a). In addition to expanding the library of 
broadly neutralizing antibodies, it was also found that this generation of broadly 
neutralizing antibodies also aided in defining and identifying new and different sites of 
vulnerability on the HIV envelope spike. The major epitopes of these new broadly 
neutralizing antibodies include previously described epitopes (Figure 6) such as the CD4 
binding site (CD4bs) (Diskin et al., 2011b; Scheid et al., 2011a; Wu et al., 2010a); the 
MPER region of gp41 (Huang et al., 2012b); as well as new epitopes such as the 
quaternary epitope at the apex of the trimer defined by a glycan at Asn160 of gp120 
(Julien et al., 2013a; McLellan et al., 2011; Walker et al., 2011; Walker et al., 2009a) the 
V3 loop including Asn332 and other glycans on the gp120 outer domain (Garces et al., 
2014; Julien et al., 2013a; Kong et al., 2013; Mouquet et al., 2012b; Walker et al., 2011), 
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and epitopes spanning interface of gp41 and gp120 (Blattner et al., 2014; Huang et al., 
2014; Scharf et al., 2014; Scharf et al., 2015). Other epitopes on the env trimer that 
induce neutralizing antibodies include the CD4-induced  (CD4i) site, whose footprint is 
the partial co-receptor binding site (Diskin et al., 2010; Kwong et al., 1998).  
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Figure 6. Location of bNAb epitopes on HIV-1 Env trimer. The approximate location 
of epitopes (shown only once per trimer) are highlighted on a surface representation of 
Env derived from electron microscopy, structure EMD-5782 [1▪]: CD4-binding site Ab 
epitope (red), V1/V2 loop/Asn160 Ab epitope (green), V3 loop/Asn332 Ab epitope 
(blue), 8ANC195 epitope (yellow), 35O22 epitope (cyan), PGT151 epitope (pink), 
MPER epitope (gray). N-linked glycans shown as grey sticks were added to all potential 
N-linked glycosylation sites present in the coordinates for BG505 SOSIP Env (PDB 
4NCO) [2▪] using Glyprot [3]. Representative bNAbs targeting each epitope are listed 
(Sievers et al., 2015). 
 
Figure borrowed from: Sievers,	  Stuart	  A.;	  Scharf,	  Louise;	  West,	  Anthony	  P.	  Jr;	  Bjorkman,	  Pamela	  J.	  Current Opinion in HIV and AIDS. 10(3):151-159, May 2015.	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Limitations of Broadly Neutralizing Antibodies against HIV  
 Despite the discovery of these extremely broad and potent neutralizing antibodies, 
clinical trials and animal studies have shown that the use of a single broadly neutralizing 
antibody as a treatment to HIV+ individuals is not enough for sterilizing protection from 
the virus (Caskey et al., 2015; Diskin et al., 2013a; Diskin et al., 2013b; Horwitz et al., 
2013; Klein et al., 2012a; Klein et al., 2012b; Klein et al., 2014a).  
 Combination therapy using a minimum of three antibodies was found to be 
required to suppress viremia in a humanized mouse model (Klein et al., 2012b). One 
reason for this may be elucidated by delving deeper into the natural envelope landscape 
of the HIV virion. The first images of intact HIV virion by electron tomography revealed 
a small number of Env trimers on the surface of the HIV virions (Zhu et al., 2003; Zhu et 
al., 2006), consistent with earlier biochemical studies of purified HIV (Chertova et al., 
2002b). The cryoEM images demonstrated relatively few spikes on the virion surface, 
with an average of 14±7 on any given virion (Zhu et al., 2003; Zhu et al., 2006). Nearest 
neighbor analysis of the HIV envelope spikes on intact HIV virions revealed that the 
separation between most spikes on HIV virions exceeds the 15nm separation between the 
two antigen-combining sites of a typical antibody (Figure 7) (Zhu et al., 2006). 
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Figure 7. Comparison of enveloped virus and contributions of spike density to nearest 
neighbor distances for HIV. 
A.   Influenza type A virus 
B.   Measles virus 
C.   Respiratory Syncytial virus 
D.   Hepatitis B virus 
E.   HIV-1 virus  
F.   Distribution of nearest neighbor distances between HIV spikes derived from 40 
HIV virions imaged through cryo-ET. Average number of spikes on surface ~14.  
G.   IgG Antibody. The maximum distance between the two antigen binding sites is 
roughly 15nm.  
 
Figure adapted from Klein, J. S. and P. J. Bjorkman (2010). "Few and far between: how 
HIV may be evading antibody avidity." PLoS Pathog 6(5): e1000908.  
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 In a novel hypothesis first described in the Bjorkman lab in 2010 by Joshua Klein, 
the ability for HIV to escape from and poor efficacy of broadly neutralizing antibodies to 
treat infection was hypothesized to be due to the sparse landscape of env trimers on the 
surface of HIV virions (Klein and Bjorkman, 2010). Klein and Bjorkman postulated that 
large inter-spike distances creates a barrier for an antibody to bind bivalently to virions 
by crosslinking between adjacent spikes (Klein and Bjorkman, 2010). By contrast, for 
viruses in which we are able to mount an effective humoral response, such as hepatitis B, 
measles, and influenza, viral spikes cover the surface the of the virion, lending to 
numerous epitopes for an antibody to bind bivalently (Figure 7). It was therefore 
suggested that most anti-HIV antibodies bind monovalently to HIV virions; i.e., using 
only one Fab arm (Klein and Bjorkman, 2010), which would not allow anti-HIV 
antibodies to take advantage of avidity effects to overcome the reduced binding affinity 
that would result from mutations in HIV Env. 
 
Antibody Affinity vs. Avidity 
 Antibody affinity can be described as the binding strength between a monovalent 
antigen and the antigen-binding site of one Fab arm (Eisen and Siskind, 1964; Pauling et 
al., 1944). The affinity of an antibody-antigen interaction can be described as the 
equilibrium constant KD =kd /ka=[Ab][Ag]/[Ab:Ag], where [Ab], [Ag] and [Ab:Ag] are 
the concentrations of the antibody, antigen, and the complex, respectively, and ka  and kd 
are the association and disassociation rate constants (Mattes, 2004). A high affinity can 
typically be described as having a fast association rate with a slow dissociation rate. 
However, as stated, this definition only describes a monovalent interaction with one Fab 
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arm and a single antigen. In the case of an IgG in which there are two available antigen 
binding sites, binding to an antigens tethered to a surface such as a viral membrane, the 
functional affinity changes due to the ability of an antibody to bind bivalently. The 
change in functional, or apparent affinity, is known as avidity. Once the first Fab is able 
to bind to the antigen on the surface, the second Fab binding will likely occur if there are 
many epitopes on the surface that are within reach for the antibody to bind (Karush, 
1976). Thus the ability to bind bivalently is dependent on geometric factors such as 
spaces of the tethered antigen, in this case, the viral spikes.  
 Therefore, in the case of neutralizing antibodies against HIV, even when the 
affinity of an individual Fab is high, because of the low density of spikes on the viral 
surface, its apparent affinity, or avidity, will be much lower than if the spikes were 
available at high density on the surface. Another means by which IgG antibodies could 
bind HIV virions with avidity would be through bivalent binding achieved by 
simultaneous binding of both Fabs to the adjacent epitopes within the same Env trimer. 
However, the distribution of antibody epitopes on the HIV Env trimer, combined with the 
architecture of IgG antibodies, suggests that most or all anti-HIV antibodies cannot use 
both Fabs to bind a single Env trimer (Klein and Bjorkman, 2010). The inability to bind 
with avidity leaves anti-HIV antibodies vulnerable to substitutions in HIV Env that are 
produced as a result of the high mutation rate of HIV reverse transcriptase; i.e., anti-HIV 
antibodies cannot generally use avidity effects to overcome the reduced binding affinities 
resulting from Env mutation (Klein and Bjorkman, 2010).  
 The work described in the subsequent chapters attempts to overcome HIV’s 
evasion strategy of low spike density through the design of novel antibody architectures. 
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Chapter 2 will describe early attempts to design a bivalent reagent of HIV, making only 
modest improvements to the original antibody against HIV, but later repurposed as a 
potent reagent against SIV. Chapter 3 will describe a novel strategy using double-
stranded DNA as a molecular ruler to measure distances between epitopes on a single 
envelope spike to produce antibody reagents capable of bivalent binding via intra-spike 
crosslinking. Chapter 4 will discuss new protein linkers that can be utilized to substitute 
for the DNA linkers in promising candidates found in Chapter 3. Chapter 5 will delve 
deeper into preliminary research converter the optimal bivalent reagent to an all protein-
based therapeutic. Additionally, I will discuss some early work in investigating how 
cancer therapeutics can teach us how to make better HIV immunotherapies in Chapter 6. 
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Chapter Two 
Investigating the use of CD4-CD4i antibody reagents to clear SIV in Chimpanzees 
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 This chapter describes the characterization of an antibody-based reagent for the 
treatment of an endangered population of chimpanzees infected with SIV in Tanzania. 
My contribution to this work involved the repurposing and redesign of a reagent from 
previous research that I had done prior to beginning as a graduate student at Caltech. I 
designed and performed initial characterization of the second generation reagents that 
were later tested for use against SIV. This work was a collaboration with Anthony West 
and Alysia Ahmed in the Bjorkman lab, Hannah Barbian and other members of Beatrice 
Hahn’s lab at UPENN, and Michael Farzan at HMS. Portions of this chapter have been 
published as Barbian, H. J., Decker, J.M., Bibollet-Ruche, F., Galimidi, R.P et al. 
(2015). "Neutralization properties of simian immunodeficiency viruses infecting 
chimpanzees and gorillas." MBio 6(2).  
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Abstract 
 
Like HIV-1 in humans, SIVcpz is pathogenic in wild-living chimpanzees and has a 
substantial negative impact on their health, reproduction, and life span. While HIV-1 
infection can be controlled by anti-retroviral therapy, treating wild-living chimpanzees is 
not feasible.  However, it might be possible to curb ongoing transmission of SIVcpz in 
select communities using AAV-mediated antibody gene transfer approaches to reduce 
viral load in infected chimpanzees. This would require the availability of antibodies that 
can neutralize SIVcpz with both breadth and potency.  To screen for such antibodies, we 
generated a panel of genetically diverse infectious molecular clones of SIVcpz and 
SIVgor (n=12) from fecal consensus sequences.  Testing sera from a small number of 
long-term HIV-1 infected (captive) chimpanzees, we failed to detect cross-reactive 
neutralizing antibodies. However, analysis of over 50 monoclonal antibodies known to 
potently neutralize diverse strains of HIV-1 identified reagents that also had potent anti-
SIVcpz activity in TZM-bl cells. All of these reagents were composed of the D1/D2 
domain of human CD4 linked to a natural antibody or the Fc region of an antibody. 
Synthesis of modified CD4-based antibodies revealed that potency could be further 
increased with the addition of a CCR5 mimetic or fusion (T20) peptide to the Fc portion 
of the reagent.  In contrast to broadly cross-reactive neutralizing antibodies such as 
VRC01, PG9, and PGT121, which had minimal activity against SIVcpz, these reagents 
(CD4-218.3-E51-E3, CD4-218.3-E51-YE3, and CD4-218.3-E51-T20), neutralized all 12 
SIVcpz and SIVgor strains in TZM-bl cells with IC50 titers ranging from 0.02 to 8.8 
ug/ml.  These same constructs were also capable of blocking SIVcpz replication in 
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primary chimpanzee CD4+ T cells.  We have thus identified monoclonal antibody-like 
reagents that neutralize a panel of divergent SIVcpz strains with both breadth and 
potency. Used in combination, these reagents might prove useful for vector-mediated 
antibody gene transfer approaches aimed at protecting select chimpanzee communities 
against the spread of SIVcpz infection in the wild.    
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Introduction  
 
 Human immunodeficiency virus type 1 (HIV-1) derived from the chimpanzee 
simian immunodeficiency virus (SIVcpz) (Sharp and Hahn, 2011). Prior to the late 
2000’s, SIVcpz was thought to have a non-pathogenic phenotype and resemble natural 
SIV infection of other non-human primates (Keele et al., 2009). This original notion was 
based off limited data from two studies where one chimpanzee was infected naturally 
with SIVcpz, and two primates challenged with SIVcpz. Unlike HIV-1 in humans, these 
studies showed that the chimpanzees did not present signatures of HIV infection such as 
loss of T-cell function and decline in CD4+ T cells (Keele et al., 2009). However, 
through long-term studies following chimpanzees at the Gombe National Park in 
Tanzania this hypothesis was proved false. Similarly to HIV-1, recent studies of the wild 
living chimpanzees in this area have shown that SIVcpz infection is pathogenic and 
associated with AIDS-like disease including CD4+ T-cell depletion and similar morbidity 
and mortality rates (Keele et al., 2009; Rudicell et al., 2010). 
 The Gombe National Park located in western Tanzania spans twenty square miles 
of forest and is home to the Gombe Stream Research Center, founded in 1965 by Jane 
Goodall. Within the park are three separate chimpanzee communities known as Kalande, 
Kasekela, and  Mitumba (Goodall, 1983). Our basic understanding of primates is largely 
due to Goodall’s work with these communities, as each member has been under 
continuous observation for at least thirty years. The two largest communities the 
Kasekela and Mitumba, have been studied extensively by a research team led by Jane 
Goodall, and information regarding their social structure, individual life histories, and 
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reproductive and social behavior is well documented (Goodall, 1983; Keele et al., 2009). 
The chimpanzees in this area have become increasingly more endangered due to human 
population growth and deforestation in the area, and chimpanzees living in this area have 
become increasing more isolated (Keele et al., 2009; Thaxton, 2006 ). In addition, all 
three chimpanzee communities have a growing number of SIVcpz infected individuals 
(Keele et al., 2009).  
 Similar to HIV-1, sexual contact and mating within the community is the most 
common form of SIVcpz, as well as mother to infant SIVcpz transmission through breast 
milk has also been seen (Keele et al., 2009; Rudicell et al., 2010). SIVcpz infected 
individuals have been studied post-mortem and found to have exhibited severe 
lymphopenia, follicular hyalinization in the spleen, and liver and muscle atrophy, as well 
as destruction of the gut associated lymphoid tissues (GALT); these findings all agree 
with the hallmark symptoms of an AIDS-like illness  (Keele et al., 2009). SIVcpz 
infection also has been shown to lead to a 10-16 fold increase risk of death compared to 
uninfected cohorts (Keele et al., 2009; Rudicell et al., 2010). Efforts from the scientific 
community have been made to intervene and attempt to save this declining community 
(Barbian et al., 2015; Rudicell et al., 2010).  
 Since these primate communities live in the wild, typical anti-retroviral therapy 
such as HAART, where constant administration of the drug is needed, would not be a 
realistic option. One potential option would be gene delivery of an antibody based 
reagent through the use of Adeno-Associated virus (AAV) as a gene-therapy vector. 
AAV, a non-virulent commensal virus found ubiquitously in humans, is a member of the 
parvoviridae family has been used in primate and human clinical trials and has been 
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shown to be tolerated and relatively safe (Balazs et al., 2012; Balazs and West, 2013; 
Gardner et al., 2015). Efforts to further reduce immunogenicity are described in 
Appendix A of this thesis.  Broadly neutralizing antibodies have been shown to protect 
against a chimeric simian-human immunodeficiency virus (SHIV) in non-human 
primates (Barouch et al., 2013; Gardner et al., 2015; Shingai et al., 2013). The goal of 
this study was to develop an antibody based reagent that can be delivered through AAV 
to SIVcpz infected chimpanzees in the wild (Figure 1).  
 Since SIV and HIV both utilize CD4 as well as co-receptor binding to gain entry 
into the host cell, and because of the high sequence similarity between human and simian 
CD4 was observed (Figure 2), our collaborators at UPENN performed a screen of CD4 
binding site antibodies in an in-vitro neutralization assay against a panel of HIV, SIVcpz 
and SIVgor strains (Barbian et al., 2015). Unfortunately, none of the CD4bs antibodies 
were able to neutralize the SIV strains despite showing great potency against HIV (Figure 
3) (Barbian et al., 2015). 
 Previous published work from the Bjorkman lab described a new class anti-HIV 
reagents composed of the first two domains of CD4 linked to the N-terminus of an IgG 
that recognizes the CD4 induced co-receptor binding site of the HIV envelope trimer 
(West et al., 2010). We found that these bivalent reagents were expressed well, and were 
relatively stable under typical storage conditions. These reagents also showed great 
promise as therapeutic reagent demonstrating broad neutralization capabilities against a 
panel of HIV-1 isolates equal to or greater than many broadly neutralizing antibodies at 
the time (West et al., 2010). 
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Figure 1. Schematic of experimental outline for administration of AAV expressing anti-
SIV antibody reagents in the wild.  
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Figure 2. Amino acid sequence comparison of human and chimpanzee CD4 domains 
1-2. Amino acid sequences of CD4 from human and chimpanzees show a 98% sequence 
identity between the two proteins. Amino acid differences are highlighted in yellow.  
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Figure 3.* Neutralizing capacity of CD4 binding site (CD4bs) antibodies. (A) The 
ability of CD4bs monoclonal antibodies (listed on the right) to neutralize HIV-1, SIVcpz, 
and SIVgor strains (listed on the bottom) is shown. Numbers indicate IC50s (in 
micrograms per milliliter) in TZM-bl cells, averaged from three different experiments, 
with a heat map indicating the relative neutralization potency. The highest antibody 
concentration was 10 µg/ml. A herpes virus antibody (anti-HSV-gD) was used as a 
negative control. 
 
*Adapted from Figure 2 of Barbian, H. J., Decker, J.M., Bibollet-Ruche, F., Galimidi, 
R.P et al. (2015). "Neutralization properties of simian immunodeficiency viruses 
infecting chimpanzees and gorillas." MBio 6(2). 
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 Our contribution to this SIVcpz study was the development of second generation 
reagents based on the CD4-CD4i antibody architecture in a deliverable AAV format. 
Because of the high sequence similarity between domains 1-2 of human and chimpanzee 
CD4, we believed that our previously designed reagents may be effective against 
chimpanzee SIV strains (Figure 4).  
 Second generation CD4-CD4i antibody reagents were designed to containing 
different protein linkers (Table 1; and described in greater detail in Chapter 4) in an 
attempt to see if rigidity and length of the linker contributed to potency. CD4-CD4i 
Antibody-peptide fusion constructs were designed to include CCR5-mimetic peptides at 
the C-terminus of the Fc. These CCR5-mimetics had been previously shown to inhibit 
HIV-1 infection in vitro (Chiang et al., 2012; Kwong et al., 2011).  
 Lastly, a CD4-CD4i antibody fusion construct was designed to include the FDA 
approved entry-inhibitor Fuzeon at the C-terminus of the Fc region. Fuzeon, or T-20, is a 
synthetic peptide corresponding to the HR-2 domain of gp41 was found to inhibit fusion 
through disruption of the gp41 conformational changes associated with membrane fusion 
(Kilby et al., 1998). T-20 was the first of a novel class of anti-retroviral drugs used in 
combination therapy for the treatment of HIV-1 infection (Harris et al., 2012). Due to 
bioavailability and the known short half-life of peptide drugs, T-20 must be administered 
twice daily through subcutaneous injection. However effective, due to its complicated 
synthesis process, prescribed dosage, and limited availability, T-20 regimens currently 
cost an estimated $25,000 per person per year (Harris et al., 2012). Currently, because 
HAART treatment has been found to be so effective, T-20 is only taken by patients who 
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are infected with multi-drug resistant forms of HIV-1 (Harris et al., 2012). We proposed 
that the fusion of T-20 to the CD4i based reagents could enhance neutralization of HIV-1 
In addition, a lower effective dose would be needed for this reagent due to its 
multivalency and the incorporation of an Fc would increase the half-life in-vivo through 
FcRn mediated antibody recycling (Murphy et al., 2012). 
Figure 4 depicts schematics for all of the second generation reagents designed. 
 
 
 
Figure 4. Schematic of antibody based reagents  
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Materials and Methods 
 
Materials. Genes encoding the variable regions (variable heavy and variable light, 
VH and VL, or the intact light chain VL-CL, where CL refers to the constant light domain) 
of the E51Ab were synthesized (BlueHeron Biotechnologies or Integrated DNA 
Technologies). Intact IgG genes were constructed by subcloning the relevant variable 
sequences onto a human IgG1 sequence.  
 CD4-IgG heavy chain constructs (denoted by the prefix CD4HC-) by fusing the 
DNA encoding the CD4 hydrophobic leader sequence and first two domains (D1-D2; 
residues 1 to 182 of the mature CD4 protein) first to a (Gly4Ser)7 (noted as GS7) linker 
sequence flanked by restriction sites NgOMIV and NheI, to the N-terminus of the mature 
E51 IgG sequence. Various other synthetic linkers (Table 1) were used, and were 
swapped out of the plasmid through restriction digest cloning. Oligos corresponding to 
CCR5 and gp41 mimetic peptides were synthesized and pieced together through sticky 
end PCR and cloned into the CD4-CD4i construct through restriction digest cloning.  
Protein expression and purification. 
All other constructs were subcloned into the mammalian expression vector pTT5 (NRC 
Biotechnology Research Institute), and the corresponding proteins were expressed 
transiently in suspension HEK 293-6E cells (NRC Biotechnology Research Institute) 
using 25-kDa linear polyethylenimine (PEI) (Polysciences) as described previously (West 
et al., 2010). The heavy chain and light chain vectors were mixed at a 1:1 ratio by mass. 
Cell culture supernatants were collected six days post transfection. Supernatants were 
passed over protein A resin (Thermo Fisher Scientific), eluted using pH 3.0 citrate buffer, 
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and then immediately neutralized. All reagents were then subjected to size exclusion 
chromatography in 20 mM Tris (pH 8.0)-150 mM NaCl using a Superdex 200 16/60 or 
10/30 column (GE Healthcare). Final yields of purified reagents are given in Table S1 in 
the supplemental material. 
In vitro neutralization assays. A previously described pseudovirus neutralization assay 
that measures the reduction in luciferase reporter gene expression in the presence of a 
potential inhibitor following a single round of pseudovirus infection in TZM-bl cells was 
used to evaluate the neutralization potencies of the reagents. Pseudoviruses were 
generated by cotransfection of HEK 293T cells with an Env expression plasmid and a 
replication-defective backbone plasmid. Neutralization assays were performed either by 
our laboratory or by the Hahn lab as described (Barbian et al., 2015). Briefly, for all 
assays done in-house, each sample was tested in triplicate (our assays) or duplicate 
(CAVD assays), with 200 infectious viral units per well incubated with a threefold 
dilution series and with 75 µg/ml DEAE-dextran. After a 1-h incubation at 37°C, 10,000 
TZM-bl cells were added to each well and incubated for 2 days. Cells were then lysed 
and assayed for luciferase expression using BriteLite plus (PerkinElmer) and a Victor3 
luminometer (PerkinElmer).  Percentage neutralization was determined by calculating the 
difference in luminescence between test wells (cells plus virus plus reagent) and cell 
control wells (cells only), dividing this value by the difference between the virus control 
wells (cells plus virus) and cell control wells, subtracting from 1, and multiplying by 100. 
Nonlinear regression analysis was used to calculate concentrations at which half-maximal 
inhibition was observed (IC50s).  
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Linker ID  Linker Composition  
L1 GlySer-polyPro(Glyc)-polyPro(Glyc)-polyPro(Glyc) 
L3 GlySer-polyPro-GlySer(Glyc)-polyPro 
L5 GlySer-polyPro-b2m-polyPro 
L7 polyPro-b2m-GlySer-b2m-GlySer 
L8 GlySer-polyPro-b2m-GlySer-b2m-polyPro 
L14 GlySer-polyPro-ZAG-polyPro 
L17 GlySer-GlySer-ZAG-GlySer-ZAG-polyPro 
218 
GSTSGSGKPGSGEGSTKGGSTSGSGKPGSGEGSTKGG
STSGSGKPGSGEGSTKG 
(G4S)7 GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 
 
Table 1. Description of structured linker designs. (Gly4Ser)n=Gly-Gly-Gly-Gly-Ser 
sequence with n number of repeats; GlySer = (N-term: AGS(GGS)3; Middle: (GGS)4; C-
term: (GGS)3GAS]2S); GlySer(Glyc)=Gly-Gly-Ser sequence with an embedded potential 
N-linked glycosylation site (Asn-Ser-Ser); polyPro=proline-rich hinge sequence from 
IgA1; polyPro(Glyc)=proline-rich hinge sequence from IgA1 with an embedded potential 
N-linked glycosylation site (Asn-Ser-Ser); β2m=β-2-microglobulin; Ub=ubiquitin; 
ZAG=Zn-α2-glycoprotein  
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Results  
Linkage between CD4 domain and CD4i antibody effects neutralization potency.  
CD4-CD4i antibody reagents containing linkers of various length, glycosylation, and 
flexibility were tested against a panel of HIV and SIV strains (Table 1). An antibody 
against a herpes viral protein (gD) was used as a control in order to determine if the 
parental antibody was instrumental at all in neutralization. In general, CD4-CD4i 
constructs neutralized viral strains more effectively than sCD4 alone. Contribution of the 
E51 antibody can be seen when comparing data against anti-gD reagents.  
  Interestingly, previously published CD4-GS7-E51 IgG was among the worst 
neutralizers in this assay, despite previous data proving otherwise. This raises questions 
about the stability of the protein. CD4-E51 reagents containing L7 and L8 linkers 
displayed the weakest capacity to neutralize viral strains effectively only neutralizing 1 
viral strain each. Both L7 and L8 linkers were designed to be more rigid, each containing 
two copies of the beta-2 microglobulin (b2m) protein. L5, a similar linker containing only 
one copy of b2m performed much better neutralizing 8 out of the 10 strains tested. The 
most promising linkers by far were those with the shorter flexible linkers, L1 and 218 
respectively, suggesting that the ability to orient rather than distance is preferred.    
 Moreover, the stability of these linkered reagents must be revisited. The most 
promising linker 218 showed signs of degradation 1 month post production after storage 
in Phosphate Buffered Saline solution at 4°C (Figure 5). Edman Sequencing of a similar 
reagent containing a 218 linker showed cleavage is occurring within the linker itself and 
not at the junction sites (data not shown).     
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Figure 5. SDS Page analysis shows proteolytic cleavage of 218 linker over time. 
Freshly prepared CD4-218-E51 IgG was compared to a prep of the same reagent 
expressed and purified one month earlier. The gel clearly shows proteolytic cleavage 
within the linker.   
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The addition of a C-terminal fusion inhibitor seemed to only modestly improve the 
overall reagent. (Table 3). The greatest improvements were found with the CCR5 
mimetic peptide Y3. The addition of T-20 peptide as well as Y3 allowed for 
neutralization of previously resistant strains, suggesting the functionality of the peptide.  
 
Discussion 
Through this study we designed potent broadly neutralizing antibody reagents capable of 
neutralizing both HIV and SIV strains. This work provides a promising new avenue for 
CD4-CD4i antibody reagents. Further investigation to optimize the linker between the 
CD4 D1-D2 domains and the CD4i antibody as linker choice was an important 
determinate in predicting neutralization activity.  
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IC50 ug/ml 
Virus  Virus Group 
CD4      
218       
E51        
IgG 
CD4     
218       
E51      
IgG -E3 
CD4        
218          
E51         
IgG-Y3 
CD4        
218          
E51         
IgG-T20 
SG3 HIV-1 0.15 0.25 0.07 0.44 
YU-2 HIV-1 0.72 1.11 0.53 1.28 
JRCSF HIV-1 NT NT 5.89 NT 
EK505 SIVcpzPtt NT NT 8.83 0.84 
GAB-1 SIVcpzPtt 0.82 0.35 0.15 0.59 
GAB-2 SIVcpzPtt 3.70 2.61 1.24 3.08 
LB715 SIVcpzPtt 3.88 7.19 0.44 2.29 
MB897 SIVcpzPtt 7.02 NT 2.94 7.75 
MT145 SIVcpzPtt 2.10 2.00 0.08 1.69 
BF1167 SIVcpzPts 1.95 2.26 0.80 1.22 
TAN-1 SIVcpzPts 3.91 7.82 1.57 1.61 
TAN-2 SIVcpzPts 1.59 2.69 0.68 1.73 
TAN-3 SIVcpzPts 1.66 1.84 0.66 1.08 
TAN-13 SIVcpzPts 1.96 2.92 0.60 0.55 
SIVgor SIVgor 1.34 4.28 0.98 0.86 
 
<1 ug/ml 1-3 ug/ml 3-7 ug/ml 7-10  ug/ml >10 ug/ml 
 
Table 3. Linkage between CD4 domain and CD4i antibody effects neutralization 
potency.  In-vitro neutralization assay data of CD4-LINKER-CD4i Antibody reagents. 
Numbers indicate IC50 in microgram per milliliter. Heat map indicates relative 
neutralization ability with warmer colors indicating greater neutralization potency.  
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Chapter Three  
Intra-spike crosslinking overcomes antibody evasion by HIV-1  
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 This chapter describes the development of a series of broadly neutralizing 
antibody-based reagents capable of intraspike cross-linking on an HIV envelope spike. 
These bivalent engineered reagents bind with high-avidity leading to  >100 fold average 
increased neutralization potencies. These data further validate a hypothesis first described 
in Pamela Bjorkman’s lab suggesting that the low spike density on HIV-1 virions evolved 
to facilitate antibody evasion. Here we also describe a novel molecular tool to measure 
distances on a virtually sub-nanometer scale.  
 
 
This work was published as:  
Galimidi, R. P., Klein, J. S., Politzer, M. S., Bai, S., Seaman, M. S., Nussenzweig, M. 
C., et al. (2015). Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell, 
160(3), 433–446. http://doi.org/10.1016/j.cell.2015.01.016 
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SUMMARY 
 
Antibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We 
postulated that anti-HIV-1 antibodies primarily bind monovalently because HIV’s low 
spike density impedes bivalent binding through inter-spike crosslinking, and the spike 
structure prohibits bivalent binding through intra-spike crosslinking. Monovalent binding 
reduces avidity and potency, thus expanding the range of mutations permitting antibody 
evasion. To test this idea, we engineered antibody-based molecules capable of bivalent 
binding through intra-spike crosslinking. We used DNA as a “molecular ruler” to 
measure intra-epitope distances on virion-bound spikes and construct intra-spike 
crosslinking molecules. Optimal bivalent reagents exhibited up to 2.5 orders-of-
magnitude increased potency (>100-fold average increases across virus panels) and 
identified conformational states of virion-bound spikes. The demonstration that intra-
spike crosslinking lowers the concentration of antibodies required for neutralization 
supports the hypothesis that low spike densities facilitate antibody evasion and the use of 
molecules capable of intra-spike crosslinking for therapy or passive protection.  
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INTRODUCTION 
 
The HIV-1 envelope (Env) spike trimer, a trimer of gp120 and gp41 subunits, is the only 
target of neutralizing antibodies. The spike utilizes antibody-evasion strategies including 
mutation, glycan shielding, and conformational masking (West et al., 2014). While 
important, these features are not unique to HIV-1: other viruses employing these 
strategies elicit IgG antibody responses that provide sterilizing immunity or viral 
clearance. A potentially unique antibody-evasion strategy for HIV-1 involves hindering 
IgGs from using both antigen-binding fragments (Fabs) to bind bivalently to spikes 
(Klein and Bjorkman, 2010; Mouquet et al., 2010). This is accomplished by the small 
number and low density of Env spikes (Chertova et al., 2002a; Liu et al., 2008; Zhu et al., 
2006), which prevent most IgGs from inter-spike crosslinking (bivalent binding between 
spikes), and the architecture of the Env trimer, which impedes intra-spike crosslinking 
(bivalent binding within a spike trimer) (Klein et al., 2009a; Luftig et al., 2006).  
On a typical virus with closely-spaced envelope spikes, an IgG antibody can bind 
using both Fabs to crosslink neighboring spikes, leading to a nearly irreversible antibody-
antigen interaction (Mattes, 2005). Avidity effects from bivalent binding of IgG 
antibodies have been shown to be critical for neutralization of many viruses, including 
polio and influenza (Icenogle et al., 1983; Schofield et al., 1997). By contrast, the small 
number of spikes (~14) present on the surface of HIV-1 (Chertova et al., 2002a; Liu et 
al., 2008; Zhu et al., 2006) impedes simultaneous engagement of both antibody 
combining sites (Klein and Bjorkman, 2010; Mouquet et al., 2010): most spikes are 
separated by distances that far exceed the ~15 nm reach of the two Fab arms of an IgG 
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(Liu et al., 2008; Zhu et al., 2006) (Figure 1A). Inter-spike crosslinking might still be 
possible if spikes could freely diffuse within the viral membrane. However, cryo-electron 
tomography of HIV-1 (Zhu et al., 2006) and evidence for interactions between the 
cytoplasmic tail of gp41 and the matrix protein of HIV (Bhatia et al., 2009; Crooks et al., 
2008; Yu et al., 1992) suggest that a virion’s spike distribution is likely to be relatively 
static over time scales relevant to neutralization. Taken together, the mechanisms to 
hinder inter- and intra-spike crosslinking imply that most anti-HIV-1 IgGs bind 
monovalently to virions. 
It seems an unlikely coincidence that HIV-1, among the most adept of viruses at 
evading antibody-mediated neutralization, has an unusually low density of surface 
envelope spikes with restricted mobility as well as an unusually high mutation rate. We 
speculated that HIV-1 evolved a low spike density to hinder bivalent binding by 
antibodies(Klein and Bjorkman, 2010) and postulated that the combination of 
predominantly monovalent IgG binding and HIV-1’s rapid mutation rate creates an 
additional effective antibody evasion strategy (Klein and Bjorkman, 2010). If the affinity 
between an IgG Fab and a viral spike is high enough, monovalent IgG binding to a virion 
should not, in and of itself, hinder or prevent viral neutralization. Thus affinity-matured 
anti-Env IgGs raised against a particular strain of virus can effectively neutralize 
autologous virus (Klein et al., 2013; West et al., 2014). However, upon mutation of an 
antibody epitope on Env, the low affinity of the monovalent Fab-antigen interaction 
would result in either complete loss of neutralization or neutralization only at very high 
concentrations. These concepts are illustrated by comparisons of binding and 
neutralization for variants of IgG and Fab forms of palivizumab, a neutralizing IgG 
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against respiratory syncytial virus (RSV) (Wu et al., 2005), a virus with a high density of 
Env spikes (Liljeroos et al., 2013). Palivizumab Fabs with fast off-rates/low affinities 
exhibited 2-3 log improvements in neutralization potencies when converted to bivalent 
IgGs and the potencies of the IgGs were not affected by mutations that increased the off-
rates of their corresponding monovalent Fabs by >100-fold (Wu et al., 2005), illustrating 
the importance of avidity for IgGs with weak or moderate affinity Fabs. However, high 
affinity/slow off-rate palivizumab Fabs were equally as potent as their IgG counterparts, 
which could bind bivalently to RSV through inter-spike crosslinking. In the palivizumab 
example, binding and neutralization potencies were evaluated for a single strain of virus 
and antibodies. In the case of HIV-1, we are interested in the effects of mutations in the 
virus on binding of the same antibody, but the effects of mutation are expected to be 
similar. Thus we postulate that avidity effects through bivalent binding can serve as a 
buffer to dampen the effects of viral mutations on neutralization potencies of IgGs.  
This line of reasoning suggests that bivalent HIV-1 binders would be optimal for 
passive prevention or immunotherapy, but because inter-spike distances are not constant 
even on a single virion, it is not possible to engineer reagents that could consistently 
accomplish inter-spike crosslinking. In contrast, reagents that can bind bivalently to a 
single trimeric spike would function independently of both spike density and distribution 
(Pace et al., 2013). To test the idea that intra-spike crosslinking results in increased 
neutralization potency, we used molecular rulers to map epitopes on virion-bound HIV-1 
spikes and created new molecules designed to synergize through bivalent interactions 
within single Env trimers (Figure 1A). We developed methods to produce multiple 
combinations of Env-binders separated by different distances by attaching broadly 
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neutralizing antibody (bNAb) Fabs to variable-length double-stranded DNA (dsDNA) 
(Figure 1B; Figure S1). We chose dsDNA as a linker because its long persistence length 
(460-500 Å (Bednar et al., 1995) compared with ~30 Å for peptides (Zhou, 2004)) 
permits its use as a molecular ruler with 3.4 Å/basepair (bp) increments. Here we show 
that homo- and hetero-diFabs joined by optimal-length dsDNA bridges can achieve 
neutralization potency increases of 2-3 orders of magnitude and provide evidence that the 
synergy results from intra-spike crosslinking. Upon determining the optimal distances 
between Env trimer-bound Fabs, we show that it is possible to convert the dsDNA bridge 
to a protein linker to create a protein-based reagent with similar synergistic properties. 
These results illustrate the importance of avidity in antibody-pathogen interactions, 
elucidate mechanisms by which HIV-1 evades the host immune system, and are relevant 
to the choice of potential protein therapeutics to be delivered to prevent or treat HIV-1 
infections. 
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Figure 1. IgG and diFab reagents binding to viral spikes. (A) Top: IgG binding 
monovalently to spikes on HIV-1 surfaces, which include a small number (~14) and low 
density of Env (Chertova et al., 2002a; Liu et al., 2008; Zhu et al., 2006). Bottom: Homo-
diFab reagent binding bivalently to HIV-1 Env by intra-spike crosslinking. Schematic 
representations of Env adapted from figures in (Liu et al., 2008). (B) Schematic of 
method used to produce homo- and hetero-diFabs. See also Figure S1. 
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Supplemental Figure 1. Production of Fabs connected with dsDNA linkers, is related to 
Figure 1 by showing details in the production and characterization of homo- and hetero-
diFabs. 
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RESULTS 
Homo-diFabs exhibit length-dependent avidity effects consistent with intra-spike 
crosslinking 
 Fabs were modified to contain a free thiol and then conjugated to maleimide-
activated single-stranded DNA (ssDNA) (Figure 1B). Different lengths of dsDNA 
(designed to lack secondary structures (Zadeh et al., 2011) (Supplementary Experimental 
Procedures) were annealed with and ligated to the ssDNA-Fab conjugates to create 
homo- or hetero-diFabs, in which the two Fabs were the same or different, respectively. 
Dynamic light scattering confirmed that conjugates with longer DNA bridges were more 
extended (Figure 2A), supporting the use of dsDNA as a ruler. Inter-Fab distances 
calculated from dsDNA lengths were regarded as approximate because the DNA linkers 
included short regions of ssDNA (persistence length 22 Å) (Chi et al., 2013) to permit 
orientational flexibility.  
We first determined the optimal dsDNA linker for a homo-diFab constructed from 
3BNC60, a bNAb against the CD4 binding site (CD4bs) on the gp120 subunit of Env 
(Scheid et al., 2011b), by evaluating homo-diFabs with different dsDNA lengths using in 
vitro neutralization assays. The 50% inhibitory concentrations (IC50s) against HIV-1 
strain 6535.3 depended on the dsDNA length, with the most potent homo-diFab 
containing a bridge of 62bp (211 Å) (Figure 2B; Figure S2). This length is close to the 
predicted distance (~198 Å) between the C-termini of adjacent 3BNC60 Fabs bound to 
the open structure of an HIV-1 trimer (Merk and Subramaniam, 2013) (Figure 3, Figure 
S3). Bridge lengths of ~60bp also exhibited the best potencies for 3BNC60 homo-diFabs 
against DU172 HIV-1 and for homo-diFabs constructed from VRC01 (Wu et al., 2010b), 
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a related CD4bs bNAb (Figure S2). The ~100-fold increased potency of 3BNC60-62bp-
3BNC60 compared with 3BNC60 IgG against HIV-1 6535.3 (Figure 2B) suggested 
synergy resulting from avidity effects due to bivalent binding. The bivalent interaction 
likely resulted from intra-spike crosslinking rather than inter-spike crosslinking since the 
latter should not manifest with a sharp length-dependence because inter-spike distances 
are variable within and between virions (Liu et al., 2008; Zhu et al., 2006).  
To formally assess the extent to which inter-spike crosslinking could contribute to 
synergy, we evaluated homo-diFabs constructed from the V1V2 loop-specific bNAb 
PG16 (Walker et al., 2009b), which cannot crosslink within a single spike because only 
one anti-V1V2 Fab binds per Env trimer (Julien et al., 2013c). PG16 homo-diFabs with 
different dsDNA bridges did not exhibit length-dependent neutralization profiles against 
strain 6535.3 (Figure 2B) and other viral strains (Figure S2D). However, increased 
potencies were observed for PG16 homo-diFabs with ≥ 70bp or 80bp (≥248 Å or 272 Å) 
bridges, perhaps reflecting increased inter-spike crosslinking with longer separation 
distances (Figure 2B; Figure S2D).  
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Figure 2. Characterization of homo-diFabs. 
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Supplemental Figure 2. 
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Figure 2. Characterization of homo-diFabs. (A) Dynamic light scattering 
measurements of hydrodynamic radii for IgG and Fab proteins, different lengths of 
dsDNA alone, and di-Fabs with different dsDNA linkers. (B) Effects of dsDNA bridge 
length on neutralization potencies of 3BNC60 and PG16 homo-diFabs against the Tier 
1B HIV-1 strain 6535.3. Neutralization IC50s are plotted against the length of the dsDNA 
linker. IC50s for the parent IgG and Fab are indicated as red and blue lines, respectively. 
(C) Neutralization of primary HIV-1 strains by b12 and PG16 homo-diFabs, each 
constructed with a 60bp dsDNA bridge. IC50s are reported for the homo-diFabs, the 
parental Fabs and IgGs, and dsDNA alone. As a measure of potential synergy, the molar 
ratio of the IC50 values for the IgG and the homo-diFab is listed for each strain in 
parentheses beside the IC50 for the homo-diFab. See also Figure S2. 
 
Supplemental Figure 2. Effects of dsDNA bridge length on neutralization potencies of 
homo-diFabs, is related to Figure 2 by showing length dependence plots for additional 
homo-diFab reagents. 
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Figure 3. Comparison of intra-spike distances for three conformations found for 
virion-associated HIV-1 Env spike trimers. 
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Figure 3. Comparison of intra-spike distances for three conformations found for 
virion-associated HIV-1 Env spike trimers. (A) Three conformations of Env trimers 
shown as surface representations (top row: gp120 coordinates only) and schematically 
(bottom two rows). Schematic representations of Env trimers adapted from figures in 
(Liu et al., 2008). Env spikes are shown as seen from above (top and middle rows) and 
the side (bottom row). V1V2 loops are cyan, V3 loops are purple, the CD4 binding site is 
yellow, the remainder of gp120 is maroon, gp41 is green, and the membrane bilayer is 
gray. The closed structure (PDB code 4NCO) was observed for unliganded trimers (Liu 
et al., 2008) and trimers associated with Fabs from potent VRC01-like (PVL) antibodies 
(Lyumkis et al., 2013; Merk and Subramaniam, 2013). The open structure was observed 
for trimers associated with CD4 or the Fab from the CD4-induced antibody 17b (Merk 
and Subramaniam, 2013; Tran et al., 2012) (coordinates obtained from S. Subramaniam). 
The partially-open structure was observed for trimers associated with the Fab from b12 
(Liu et al., 2008; Merk and Subramaniam, 2013) (PDB code 3DNL). (B) Measured 
distances between homo-diFabs bound to HIV-1 trimer structures. Fabs from the 
indicated bNAbs shown bound to the gp120 portions of Env in the three conformation 
shown in panel A. Fabs are shown as ribbons; gp120 subunits are shown as surface 
representations with V1V2 loops in cyan, V3 in purple, the CD4 binding site in yellow, 
and the remainder of gp120 in maroon. The distance between the Cys233heavy chain carbon-
  atoms of adjacent bound Fabs is indicated by a gray line as an approximation of an 
optimal length for a dsDNA bridge attached to Cys233heavy chain. Assuming three-fold 
symmetry of trimers, only one distance is possible for bound 3BNC60, b12, and 10-1074 
homo-diFabs. See also Figure S3. 
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Supplemental Figure 3. Measured distances between hetero-diFabs bound to HIV-1 
trimer structures, is related to Figure 3 by showing additional distance measurements 
between Fabs on trimer structures. 
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Comparison of homo-diFabs that can or cannot exhibit intra-spike crosslinking 
To evaluate the potential for intra-spike crosslinking across different viral strains, we 
compared homo-diFabs designed to be capable (b12 and 3BNC60) or incapable (PG16) 
of intra-spike crosslinking (Figure 2C). To minimize inter-spike crosslinking, the homo-
diFabs were constructed with 60–62bp bridges. The b12-60bp-b12 homo-diFab exhibited 
increased potency compared with b12 IgG in 21 of 25 strains in a cross-clade panel of 
primary HIV-1, with potency increases ≥10-fold for 16 strains and a geometric mean 
potency increase of 22-fold. 3BNC60-62bp-3BNC60 showed even more consistent 
synergy, being more potent than 3BNC60 IgG against all 25 strains tested, with ≥10-fold 
increases for 20 strains and a mean increase of 19-fold. By contrast, the PG16-60bp-
PG16 homo-diFab showed potency increases compared with PG16 IgG against only six 
strains, with relatively small (2- to 7-fold) increases in five strains and an overall 2.8-fold 
mean potency change.  
 
Hetero-diFabs exhibit dramatic potency increases consistent with intra-spike 
crosslinking  
To determine whether heterotypic bivalent binding can produce synergy and to measure 
distances between epitopes, we used dsDNA to link Fabs recognizing different epitopes 
on gp120. We first evaluated hetero-diFabs constructed with Fabs from V1V2 (PG16 or 
PG9) (Walker et al., 2009b) and CD4bs (b12 or 3BNC60) (Roben et al., 1994; Scheid et 
al., 2011b) bNAbs linked with 60bp dsDNA bridges. PG16-60bp-b12 hetero-diFabs were 
evaluated in neutralization assays against HIV-1 strains SC4226618 (more sensitive to 
b12 than PG16) and CAP210 (more sensitive to PG16 than b12). According to the model 
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being tested, in the absence of synergistic binding; i.e., when only one Fab can bind to a 
spike at a time, a hetero-diFab would be no more potent than a non-covalent mixture of 
the dsDNA and the two Fabs against each viral strain, whereas synergistic binding would 
result in avidity effects exhibited by increased potency of the hetero-diFab. For both viral 
strains, the PG16-60bp-b12 hetero-diFab was ~10-fold more potent than the mixture of 
Fabs plus dsDNA or the more potent of the two Fabs alone (Figure 4; Figure S4). To 
more systematically explore potential synergy, we evaluated PG16-60bp-b12 against a 
25-member panel of HIV-1 strains, finding synergistic effects (between 2- and 145-fold 
more potent than the corresponding non-covalent mixture for most strains; geometric 
mean improvement of 4.7-fold) (Table S1). When Fabs from PG16 or PG9 were 
combined with a more potent CD4bs-recognizing bNAb (3BNC60), the resulting hetero-
diFabs exhibited greater synergy – several examples of >150-fold improvement for 
PG16-60bp-3BNC60 and PG9-60bp-3BNC60 and geometric mean potency 
improvements of 29- and 68-fold, respectively (Figure 4, Tables S2,S3). Other hetero-
diFabs, constructed with combinations of Fabs recognizing the CD4bs (3BNC60 (Scheid 
et al., 2011b)), the gp120 V3 loop (10-1074 (Mouquet et al., 2012a)), and a gp41 epitope 
(10E8 (Huang et al., 2012a)), also showed synergistic effects (Figure 4, Table S4), and a 
3BNC60-60bp-b12 hetero-diFab exhibited up to 660-fold synergy and a geometric mean 
potency increase of 90-fold (Figure 4, Table S5). In contrast, analogous IgG heterodimers, 
constructed with two different Fabs linked to a single Fc (Schaefer et al., 2011), did not 
show synergy when evaluated against the same viruses, demonstrating that synergistic 
effects required optimal separation distances that permitted each Fab to achieve its 
specific binding orientation (Figure S4; Tables S1-S5). We conclude that hetero-diFabs 
	  	  
111	  
can achieve synergy through simultaneous recognition of two different epitopes on the 
same HIV-1 Env trimer.  
To more precisely define optimal intra-epitope separation distances, we evaluated 
hetero-diFabs with different bridge lengths, finding length-dependent synergy effects. For 
example, PG16–3BNC60 hetero-diFabs with 40bp and 50bp dsDNA bridges showed 
improved neutralization potencies when compared to the 60bp (204 Å) version, achieving 
≥100-fold potency increases against over half of the tested strains and geometric mean 
improvements of 98- and 107-fold, respectively (Figure 4, Table S4). The 40bp and 50bp 
bridges (136 Å and 170 Å, respectively) corresponded to the approximate separation 
distances between PG16 and 3BNC60 Fabs when bound to the same gp120 within a 
trimer (147 Å) or to neighboring protomers within open or partially-open trimers (167 Å) 
(Figure S3). In a second length dependency example, 10-1074-40bp-3BNC60 was more 
potent than 10-1074-60bp-3BNC60 (Figure 4, Table S4). The ~136 Å distance between 
the two Fabs in 10-1074-40bp-3BNC60 corresponded to the approximate separation 
between these Fabs bound to the same gp120 (141 Å), while 60bp more closely 
approximated Fabs bound to neighboring protomers on an open trimer (193 Å) (Figure 
S3). The 40bp and 50bp versions of 10E8–3BNC60 showed consistent synergy (Figure 4, 
Table S4); however, the lack of structural information concerning 10E8 binding to Env 
trimer hindered interpretation of 10E8-containing hetero-diFabs. 
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Figure 4. Synergistic dsDNA-based hetero-diFabs. Neutralization of primary HIV-1 
strains by hetero-diFabs. IC50s are reported for the hetero-diFabs. See Tables S1-S5 for 
IC50s of parental Fabs and IgGs, dsDNA alone, and the non-covalent mixtures of Fabs 
and dsDNA. As a measure of potential synergy of each hetero-diFab, the molar ratio of 
the IC50 values for the non-covalent mixture and the hetero-diFab is listed for each strain 
in parentheses beside the IC50 for the hetero-diFab. NT = not tested. See also Figure S4. 
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Supplemental Figure 4. Examples of neutralization data for hetero-diFabs, is related to 
Figure 4 by showing example neutralization curves for data shown in Figure 4. 
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Table S1. IC50 values for neutralization of primary HIV-1 strains by PG16-60bp-
b12 hetero-diFab, related to Figure 4.  IC50s are reported for the hetero-diFab, the 
parental Fabs and IgGs, the dsDNA bridge alone, and a non-covalent mixture of the Fabs 
and the dsDNA bridge. As a measure of potential synergy of the hetero-diFab, the molar 
ratio of the IC50 values for the non-covalent mixture and the hetero-diFab is listed for 
each strain in parentheses beside the IC50 for the hetero-diFab. 
 
  
6535.3 B 1B >1000 1.1 (145x) 160 >200 17 360 60
SC422661.8 B 2 >1000 0.28 (15x) 4.2 65.0 4.7 9.5 3.0
PVO.4 B 3 >1000 15 (>13x) >200 150 16 4700 700
TRO.11 B 2 >1000 18 (0.8x) 15 >200 6.5 7600 700
TRJO4551.58 B 3 >1000 8.5 (10x) 85 64 2.1 7900 700
CAAN5342.A2 B 2 >1000 28 (3x) 87 65 6.0 6800 700
THRO4156.18 B 2 >1000 3.1 (11x) 35 >200 2.7 100 10
RHPA4259.7 B 2 >1000 0.28 (4x) 1.0 1.5 <0.1 6.0 0.73
Du156.12 C 2 >1000 0.07 (11x) 0.8 0.8 <0.1 150 4.8
Du172.17 C 2 >1000 0.14 (16x) 2.2 2.6 <0.1 100 10
Du422.1 C 2 >1000 <0.04 (>17x) 0.6 1.0 0.3 60 2.0
ZM197M.PB7 C 1B >1000 2.8 (1x) 3.8 5.5 2.4 1000 620
ZM214M.PL15 C 1B >1000 11 (>18x) >200 >200 >330 380 43
ZM233M.PB6 C 2 >1000 <0.04 (1x) <0.10 <0.1 <0.1 4500 700
ZM249M.PL1 C 2 >1000 0.21 (2x) 0.4 0.4 <0.1 240 23
ZM53M.PB12 C 2 >1000 0.70 (2x) 1.2 1.0 <0.1 890 190
ZM109F.PB4 C 1B >1000 1.5 (4x) 6.4 6.7 30 3400 700
ZM135M.PL10a C 2 >1000 68 (>3x) >200 >200 >330 5900 700
CAP45.2.00.G3 C 2 >1000 <0.04 (>1x) <0.10 <0.1 <0.1 40 3.4
CAP210.2.00.E8 C 2 >1000 0.56 (4x) 2.2 11.0 <0.1 70 50
Q842.d12 A 2 >1000 0.21 (0.5x) <0.10 <0.1 <0.1 4200 700
Q259.d2.17 A 2 >1000 0.42 (2x) 0.8 0.61 <0.1 7500 700
3718.v3.c11 A 2 >1000 0.56 (3x) 2.0 <0.1 <0.1 690 126
0330.v4.c3 A 2 >1000 0.14 (1x) <0.10 <0.1 <0.1 5600 700
3415.v1.c1 A 2 >1000 0.42 (3x) 1.4 1.22 <0.1 200 53
Geometric Mean IC50 (nM) 1.1
Arithmetic Mean IC50 (nM) 7.0
Mean Fold Improvement Over Mixture (Geometric) 4.7
Mean Fold Improvement Over Mixture (Arithmetic) 6.3
IC50 (nM)
PG16 
IgG b12 Fab
b12 
IgGdsDNA PG16-60bp-b12Virus Clade
Mix of  
PG16, 
b12, 
dsDNA
PG16 
FabTier
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Table S2. IC50 values for neutralization of primary HIV-1 strains by PG16-3BNC60 
hetero-diFabs, related to Figure 4. IC50s are reported for the hetero-diFab, the parental 
Fabs and IgGs, the dsDNA bridge alone, and a non-covalent mixture of the Fabs and the 
dsDNA bridge. As a measure of potential synergy of the hetero-diFab, the molar ratio of 
the IC50 values for the non-covalent mixture and the hetero-diFab is listed for each strain 
in parentheses beside the IC50 for the hetero-diFab. 
 
 
 
  
6535.3 B 1B >1000 0.31 (351x) 0.23 (474x) 0.66 (165x) 109 >200 17 27 4.0
SC422661.8 B 2 >1000 0.021 (86x) 0.01 (180x) 0.05 (36x) 1.8 65.0 4.7 1.0 0.3
PVO.4 B 3 >1000 0.04 (40x) 0.03 (53x) 0.04 (40x) 1.6 150 16 1.3 0.1
TRO.11 B 2 >1000 0.03 (67x) 0.03 (67x) 0.05 (40x) 2.6 2.0 >200 6.5 1.3 0.2
TRJO4551.58 B 3 >1000 0.04 (145x) 0.03 (193x) 0.1 (58x) 5.8 64 2.1 4.8 <0.1
CAAN5342.A2 B 2 >1000 0.22 (118x) 0.17 (153x) 0.5 (52x) 42.6 26 65 6.0 6.2 3.6
THRO4156.18 B 2 >1000 0.59 (80x) 0.38 (124x) 1.2 (39x) >10 47 >200 2.7 23 3.5
RHPA4259.7 B 2 >1000 0.007 (200x) 0.007 (200x) 0.02 (70x) 1.4 1.5 <0.1 1.5 0.3
Du156.12 C 2 >1000 0.007 (114x) 0.007 (114x) 0.04 (20x) 0.8 0.8 <0.1 9.4 0.3
Du172.17 C 2 >1000 0.06 (70x) 0.06 (70x) 0.36 (12x) 4.2 2.6 <0.1 210 16
Du422.1 C 2 >1000 0.36 (14x) 0.41 (12x) 0.25 (20x) 5.0 1.0 0.3 >200 >330
ZM197M.PB7 C 1B >1000 0.06 (107x) 0.06 (107x) 0.18 (35x) 6.4 5.5 2.4 15 3.8
ZM214M.PL15 C 1B >1000 0.001 (9000x) 0.002 (4500x) 0.007 (1280x) 2.4 9.0 >200 >330 6.9 1.7
ZM233M.PB6 C 2 >1000 0.001 (100x) 0.001 (100x) 0.007 (14x) 0.1 <0.1 <0.1 14 1.4
ZM249M.PL1 C 2 >1000 0.01 (60x) 0.01 (60x) 0.03 (20x) 0.6 0.4 <0.1 2.7 0.3
ZM53M.PB12 C 2 >1000 0.04 (25x) 0.03 (33x) 0.13 (8x) 1.0 1.0 <0.1 5.2 1.3
ZM109F.PB4 C 1B >1000 0.03 (133x) 0.03 (133x) 0.12 (33x) 4.0 6.7 30 39 0.3
ZM135M.PL10a C 2 >1000 0.06 (83x) 0.06 (83x) 0.14 (36x) 5.0 >200 >330 3.7 0.4
CAP45.2.00.G3 C 2 >1000 <0.0007 (>143x) <0.0007 (>143x) 0.003 (33x) 0.1 <0.1 <0.1 >200 50
CAP210.2.00.E8 C 2 >1000 0.05 (52x) 0.02 (130x) 0.11 (24x) 2.6 11.0 <0.1 >200 59
Q842.d12 A 2 >1000 0.001 (200x) 0.001 (200x) 0.007 (29x) 0.2 <0.1 <0.1 0.21 0.09
Q259.d2.17 A 2 >1000 0.01 (80x) 0.01 (80x) 0.03 (27x) 0.8 0.61 <0.1 3.7 0.03
3718.v3.c11 A 2 >1000 0.03 (13x) 0.03 (13x) 0.12 (3x) 0.4 <0.1 <0.1 >200 >330
0330.v4.c3 A 2 >1000 0.002 (50x) 0.001 (100x) 0.007 (14x) 0.1 <0.1 <0.1 0.62 0.2
3415.v1.c1 A 2 >1000 0.01 (120x) 0.01 (120x) 0.05 (24x) 1.2 1.22 <0.1 4.6 0.9
Geometric Mean IC50 (nM) 0.022 0.020 0.075
Arithmetic Mean IC50 (nM) 0.083 0.068 0.24
Mean Fold Improvement Over Mixture (Geometric) 98 107 29
Mean Fold Improvement Over Mixture (Arithmetic) 120 145 42
Virus Clade dsDNA PG16-40bp-3BNC60
PG16-60bp-
3BNC60
PG16-50bp-
3BNC60Tier
IC50 (nM)
PG16-
3BNC60 
heterodimer
Mix of  
PG16, 
3BNC60, 
dsDNA
PG16 
Fab
PG16 
IgG
3BNC60 
Fab
3BNC60 
IgG
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Table S3. IC50 values for neutralization of primary HIV-1 strains by PG9-60bp-
3BNC60 hetero-diFab, related to Figure 4. IC50s are reported for the hetero-diFab, the 
parental Fabs and IgGs, the dsDNA bridge alone, and a non-covalent mixture of the Fabs 
and the dsDNA bridge. As a measure of potential synergy of the hetero-diFab, the molar 
ratio of the IC50 values for the non-covalent mixture and the hetero-diFab is listed for 
each strain in parentheses beside the IC50 for the hetero-diFab. 
 
  
6535.3 B 1B >1000 <0.03 (>767x) 23 18 4.0 27 4.0
SC422661.8 B 2 >1000 <0.03 (>47x) 1.4 14 6.9 1.0 0.3
PVO.4 B 3 >1000 <0.03 (>40x) 40 1.2 59 57 1.3 0.1
TRO.11 B 2 >1000 <0.03 (>40x) 2.6 1.2 54 71 1.3 0.2
TRJO4551.58 B 3 >1000 <0.03 (>187x) 5.6 32 7.6 4.8 <0.1
CAAN5342.A2 B 2 >1000 0.07 (229x) >10 16 25 26 6.2 3.6
THRO4156.18 B 2 >1000 0.21 (152x) >10 32 <0.1 110 23 3.5
RHPA4259.7 B 2 >1000 <0.03 (>20x) 0.6 0.2 <0.1 1.5 0.3
Du156.12 C 2 >1000 <0.03 (>53x) 1.6 0.6 0.3 9.4 0.3
Du172.17 C 2 >1000 <0.03 (>273x) 8.2 2.2 3.1 210 16
Du422.1 C 2 >1000 <0.03 (>160x) 9.3 4.8 0.6 1.8 >200 >330
ZM197M.PB7 C 1B >1000 0.07 (143x) 10 5.4 5.1 15 3.8
ZM214M.PL15 C 1B >1000 0.21 (39x) 16 8.2 >200 >330 6.9 1.7
ZM233M.PB6 C 2 >1000 <0.03 (>3x) <0.1 <0.1 <0.1 14 1.4
ZM249M.PL1 C 2 >1000 <0.03 (>27x) 0.8 0.2 0.3 2.7 0.3
ZM53M.PB12 C 2 >1000 <0.03 (>33x) 0.63 1.0 0.4 0.5 5.2 1.3
ZM109F.PB4 C 1B >1000 <0.03 (>280x) 8.4 6.8 2.1 39 0.3
ZM135M.PL10a C 2 >1000 <0.03 (>140x) 4.2 160 >330 3.7 0.4
CAP45.2.00.G3 C 2 >1000 <0.03 (>3x) <0.1 <0.1 <0.1 >200 50
CAP210.2.00.E8 C 2 >1000 <0.03 (>140x) 4.2 1.6 2.0 >200 59
Q842.d12 A 2 >1000 <0.03 (>7x) 0.2 <0.1 <0.1 0.21 0.09
Q259.d2.17 A 2 >1000 <0.03 (>33x) 1.0 0.4 0.2 3.7 0.03
3718.v3.c11 A 2 >1000 <0.03 (>27x) 0.8 <0.1 <0.1 >200 >330
0330.v4.c3 A 2 >1000 <0.03 (>7x) 0.2 <0.1 <0.1 0.62 0.2
3415.v1.c1 A 2 >1000 <0.03 (>67x) 2.0 1.0 1.2 4.6 0.9
Geometric Mean IC50 (nM) 0.038
Arithmetic Mean IC50 (nM) 0.049
Mean Fold Improvement Over Mixture (Geometric) 68
Mean Fold Improvement Over Mixture (Arithmetic) 121
Virus Clade dsDNA PG9-60bp-3BNC60
Mix of  PG9, 
3BNC60, 
dsDNA
PG9-
3BNC60 
heterodimer
Tier PG9 IgG 3BNC60 Fab
3BNC60 
IgGPG9 Fab
IC50 (nM)
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Table S4.  IC50 values for neutralization of primary HIV-1 strains by 10-1074-
3BNC60 and 10E8-3BNC60 heterodi-Fabs, related to Figure 4.  IC50s are reported for 
the hetero-diFab, the parental Fabs and IgGs, the dsDNA bridge alone, and a non-
covalent mixture of the Fabs and the dsDNA bridge. As a measure of potential synergy of 
the hetero-diFab, the molar ratio of the IC50 values for the non-covalent mixture and the 
hetero-diFab is listed for each strain in parentheses beside the IC50 for the hetero-diFab. 
  
THRO4156.18 B 2 >1000 24 (2.5x) 19 (3x) 62 68 >1000 >330 71 3.5
Du172.17 C 2 >1000 0.64 (19x) 4.0 (3x) 12 22 11.24 0.81 210 16
CAP45.2.00.G3 C 2 >1000 40 (11x) 260 (2x) 430 >330 NT >330 >1000 50
CAP210.2.00.E8 C 2 >5000 56. (11x) 79 (8x) 620 >330 >1000 >330 >1000 59
Geometric Mean IC50 (nM) 14 35
Arithmetic Mean IC50 (nM) 30 90
Mean Fold Improvement Over Mixture (Geometric) 8.70 3.30
Mean Fold Improvement Over Mixture (Arithmetic) 9.3 3.1
CAAN5342.A2 B 2 >1000 7.3 (>46x) 10(>32x) 25 (>13x) >330 >550 8.3 12 3.8
QH-0692 B 2 >1000 1.2 (34x) 1.4 (30x) 1.3 (32x) 42 13 3.1 7.6 0.93
Du422.1 C 2 >1000 2.2 (8x) 3.6 (5x) 5.0 (3x) 17 4.5 3.5 >1000 >330
CAP45.2.00.G3 C 2 >1000 11 (2x) 15 (1x) 17 (1x) 19 20 2.4 >1000 50
T250-4 AG 2 >1000 0.92 (53x) 0.66 (74x) 12 (4x) 49 21 1.4 >1000 NT
Geometric Mean IC50 (nM) 2.9 3.5 8
Arithmetic Mean IC50 (nM) 4.5 6.1 12
Mean Fold Improvement Over Heterodimer (Geometric) 16 13 5.8
Mean Fold Improvement Over Heterodimer (Arithmetic) 20 15 7.6
IC50 (nM)
Virus Clade dsDNA
10-1074-
40bp-
3BNC60
10-1074-
60bp-
3BNC60
mix                   
10-1074, 
3BNC60,  
dsDNA
10-1074- 
3BNC60 
heterodimer
10-1074 
Fab 10-1074 IgGTier
Virus Clade dsDNA 10E8-40bp-3BNC60
10E8-50bp-
3BNC60Tier 10E8 Fab 10E8 IgG
3BNC60 
Fab
3BNC60 
IgG
3BNC60 
Fab
3BNC60 
IgG
IC50 (nM)
10E8-60bp-
3BNC60
10E8- 
3BNC60 
heterodimer
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Table S5. IC50 values for neutralization of primary HIV-1 strains by 3BNC60-60bp-
b12 hetero-diFab, related to Figure 4. IC50s are reported for the hetero-diFab, the 
parental Fabs and IgGs, the dsDNA bridge alone, and a non-covalent mixture of the Fabs 
and the dsDNA bridge. As a measure of potential synergy of the hetero-diFab, the molar 
ratio of the IC50 values for the non-covalent mixture and the hetero-diFab is listed for 
each strain in parentheses beside the IC50 for the hetero-diFab. 
 
  
6535.3 B 1B >1000 0.22 (>172x) 38 27 4.0 360 60
SC422661.8 B 2 >1000 <0.04 (>30x) 1.2 1.0 0.3 30 1.9
PVO.4 B 3 >1000 0.04 (50x) 2.0 1.3 0.1 4700 >330
TRO.11 B 2 >1000 <0.04 (>55x) 2.2 1.3 0.2 7600 >330
TRJO4551.58 B 3 >1000 <0.04 (>165x) 6.6 4.8 <0.1 7900 >330
CAAN5342.A2 B 2 >1000 0.3 (72x) 21.6 6.2 3.6 6800 >330
THRO4156.18 B 2 >1000 0.52 (23x) 11.8 23 3.5 100 5.2
RHPA4259.7 B 2 >1000 <0.04 (>70x) 2.8 1.5 0.3 6.0 0.73
Du156.12 C 2 >1000 <0.04 (>205x) 8.2 9.4 0.3 150 4.8
Du172.17 C 2 >1000 0.22 (117x) 25.8 210 16 100 3.7
Du422.1 C 2 >1000 0.15 (13x) 2.0 >200 >330 60 2.0
ZM197M.PB7 C 1B >1000 0.22 (91x) 20 15 3.8 1000 100
ZM214M.PL15 C 1B >1000 0.15 (81x) 12.2 6.9 1.7 380 43
ZM233M.PB6 C 2 >1000 0.07 (320x) 22.4 14 1.4 4500 >330
ZM249M.PL1 C 2 >1000 <0.04 (>155x) 6.2 2.7 0.3 240 23
ZM53M.PB12 C 2 >1000 0.07 (149x) 10.4 5.2 1.3 890 190
ZM109F.PB4 C 1B >1000 0.07 (660x) 46.2 39 0.3 3400 >330
ZM135M.PL10a C 2 >1000 0.07 (69x) 4.8 3.7 0.4 5900 >330
CAP45.2.00.G3 C 2 >1000 0.07 (29x) 2.0 >200 50 40 3.4
CAP210.2.00.E8 C 2 >1000 1.3 (>154x) >200 >200 59 1680 160 
Q842.d12 A 2 >1000 <0.04 (>15x) 0.60 0.21 0.09 4200 >330
Q259.d2.17 A 2 >1000 <0.04 (>110x) 4.40 3.7 0.03 7500 >330
3718.v3.c11 A 2 >1000 5.67 (35x) >200 >200 >330 690 126
0330.v4.c3 A 2 >1000 <0.04 (>40x) 1.60 0.62 0.2 5600 >330
3415.v1.c1 A 2 >1000 0.07 (94x) 6.60 4.6 0.9 200 53
Geometric Mean IC50 (nM) 0.091
Arithmetic Mean IC50 (nM) 0.360
Mean Fold Improvement Over Mixture (Geometric) 90
Mean Fold Improvement Over Mixture (Arithmetic) 74
Virus Clade dsDNA 3BNC60-60bp-b12
Mix of   
3BNC60, 
b12, 
dsDNA
Tier
IC50 (nM)
3BNC60 
Fab
3BNC60 
IgG b12 Fab b12 IgG
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A hetero-diFab constructed with a protein linker exhibits synergistic potency 
increases  
Bivalent molecules involving dsDNA linkers were effective for demonstrating synergistic 
neutralization, but a protein reagent would be preferable as an anti-HIV-1 therapeutic. 
We recently described a series of protein linkers of various lengths and rigidities (Klein et 
al., 2014b) that can mimic the properties of different lengths of dsDNA. Thus we can 
substitute a comparable protein linker for an optimal dsDNA bridge to create a protein 
reagent capable of simultaneous binding to two different epitopes on a single HIV-1 
spike trimer. As a proof-of-principle example, we used sortase-catalyzed protein ligation 
and click chemistry (Witte et al., 2013) to construct a bivalent reagent analogous to 
PG16-40bp-3BNC60 by substituting the dsDNA linker with 12 domains of a designed 
tetratricopeptide-repeat (TPR) protein (Kajander et al., 2007a) (Figure 5A; Figure S5). 
We chose a TPR linker because tandem repeats of TPR domains form a rigid rod-like 
structure whose length corresponds predictably with the number of repeats, with each 
domain contributing ~10 Å (Kajander et al., 2007a). PG16 Fab was expressed with a C-
terminal sortase signal, and the C-terminus of the 3BNC60 Fab was modified to include 
twelve TPR repeats and a sortase signal. The tagged Fabs were covalently attached to 
peptides containing click handles using sortase-catalyzed ligation, and then incubated to 
allow the click reaction to form PG16 Fab linked to 3BNC60 Fab by twelve TPR repeats 
(PG16-TPR12-3BNC60). Together with the remnants of the click handles, the linker 
would occupy ~131 Å, approximately the same length as the dsDNA linker in PG16-
40bp-3BNC60 reagent (Figure 5A; Figure S5). The protein-based molecule, PG16-
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TPR12-3BNC60, exhibited between 11- and >200-fold synergy against 12 primary HIV-
1 strains (Figure 5B; 33-fold geometric mean increased potency). 
Simulations of the effects of avidity on IgG binding to tethered antigens 
To better understand the effects of avidity arising from bivalent binding of IgGs to 
antigens tethered to a surface such as a viral membrane, we used modeling software to 
simulate the saturation of surface-bound antigens by monovalent Fabs and bivalent IgGs. 
We chose a 1 hour incubation time based upon conditions under which in vitro 
neutralization assays are conducted (Montefiori, 2005). We varied the density of the 
tethered antigens, the concentrations of Fab or IgG, and investigated a range of intrinsic 
association and dissociation rate constants for the binding interaction. The fraction of 
antigen bound by a Fab or IgG was calculated as a function of on- and off-rates (ka and 
kd), whose ratio (kd/ka) is equal to the affinity (KD, or equilibrium dissociation constant). 
We compared saturation by Fabs (top row), IgGs in which only monovalent binding was 
permitted (center row), and IgGs that bound bivalently through crosslinking of 
neighboring antigens (bottom row) (Figure 6A). As expected, saturation by Fabs and 
IgGs was nearly identical for monovalent binding conditions (Figure 6A, first two rows). 
By contrast, across a range of input concentrations, there were ka and kd combinations for 
IgGs binding bivalently that exhibited saturation binding under conditions in which 
monovalent Fabs and IgGs binding monovalently did not (Figure 6A, bottom row). Thus, 
consistent with experimental results in the palivizumab/RSV system (Wu et al., 2005), 
the simulations suggested that bivalency through crosslinking can rescue binding of IgGs 
whose Fabs exhibit weak binding affinities as a result of fast dissociation rate constants, 
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whereas IgGs whose Fabs exhibit high affinities because of slow dissociation rates did 
not display strong avidity enhancement.  
The simulations also demonstrate that the effects of avidity on binding are a 
complicated mixture of kinetics, input concentration, and incubation time. At any 
particular concentration, the threshold at which avidity is observed is controlled by 
kinetics rather than affinity because different combinations of kinetic constants yield the 
same KD. The kinetic threshold at which avidity effects are observed varies depending on 
the difference between the input concentration and the KD. For concentrations near or 
below the KD, there is a kinetic threshold such that for on- and off-rates slower than ~103 
M-1s-1 and ~10-5 s-1, respectively, avidity enhancement is not observed (Figure 6A). The 
binding reactions are also affected by the length of incubation, such that the lower the 
input concentration, the longer it takes to reach saturation (Figure 6B).  
 We note that the simulations model binding interactions only, whereas our homo- 
and hetero-diFabs were evaluated for their ability to enhance neutralization of viral 
infectivity, a process more complicated than binding. For example, neutralization 
mechanisms may involve conformational changes in Env that were not accounted for in 
our binding simulation. In addition, kinetics constants for antibody-mediated 
neutralization of HIV-1 are not known, nor is the fraction of Env spikes on a virion that 
are required for neutralization or for fusion. In any case, it appears that the kinetic 
properties of the bNAb Fab components in our reagents were appropriate to realize 
avidity-enhanced neutralization since hetero-diFab reagents displayed ~100-fold mean 
improved neutralization potencies. The data therefore support the hypothesis that intra- 
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spike crosslinking by anti-HIV-1 binding molecules represents a valid strategy for 
increasing potency and resistance to HIV-1 Env mutations. 
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Figure 5. Synergistic protein-based hetero-diFab. (A) Schematic representation of 
PG16-TPR12-3BNC60 (not to scale). Approximate lengths are indicated (120 Å for the 
TRP12 linker plus ~11 Å for the fused click handles). (B) Neutralization of primary HIV-
1 strains. IC50s are reported for PG16-TPR12-3BNC60, the parental components of the 
reagent (PG16 Fab and 3BNC60 Fab-TPR12), and TPR12 alone. As a measure of 
potential synergy of PG16-TPR12-3BNC60, the molar ratio of the IC50 values for the 
most potent component and PG16-TPR12-3BNC60 is listed for each strain in parentheses 
beside the IC50 for PG16-TPR12-3BNC60. See also Figure S5  
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Figure S5. Size exclusion chromatography profiles for PG16-TPR12-3BNC60, 
related to Figure 5  
SEC runs from which PG16-TPR12-3BNC60 was isolated from fractions 10.3 mL – 11.8 
mL. SEC profiles are shown for 3BNC60 Fab-TPR12 and PG16 Fab for comparison. 
Fractions were assayed by 10% SDS-PAGE (data not shown). 
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Figure 6. Simulations of avidity effects due to bivalent binding of IgG to a tethered 
antigen. (A) The fraction of tethered antigen bound by different concentrations of IgG or 
Fab after 1 hour shown as a heat map (cooler colors representing a lower percentage 
bound and warmer colors representing a higher percentage bound) as a function of kinetic 
constants for the IgG-antigen or Fab-antigen interaction. The fraction of antigen bound 
by a Fab or IgG was calculated as a function of ka and kd. The intrinsic affinities are 
strongest in the lower right corner (1 pM) and weakest in the upper left corner (100 mM) 
of each graph. For IgG, binding was forced to 100% monovalent binding (middle row) or 
100% bivalent binding (bottom row). Saturation by Fabs and IgGs was nearly identical 
for monovalent binding conditions because the binding kinetics of IgGs would be 
enhanced by at most 2-fold. Comparisons of the simulations for bivalent binding (bottom 
row) and monovalent binding (top two panels) showed regions of saturation binding 
resulting from avidity effects. (B) The fraction of antigen bound as a function of time for 
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IgGs binding to surface-tethered antigens at an input concentration of 10 nM. When the 
dissociation rate constant of the Fab portion of the IgG is slow (top panel) and the input 
concentration is approximately 100-fold higher than the affinity of the Fab, IgGs can 
reach saturation binding after an hour whether binding monovalently or bivalently to the 
surface – therefore avidity effects are not apparent after an hour. However, weakening the 
affinity of the Fab by making the dissociation rate 1000-fold faster (bottom panel) 
prevents saturation when binding monovalently, but has no affect on saturation when 
binding bivalently – thus avidity effects are apparent throughout the incubation. 
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DISCUSSION 
We engineered new HIV-1 spike-binding molecules designed to bind bivalently to 
demonstrate the importance of avidity effects in antibody efficacy in HIV-1 
neutralization and to establish that lack of bivalent binding by physiologic IgGs is an 
additional antibody evasion strategy utilized by HIV-1.  
The importance for HIV-1 in maintaining a low spike density to avoid inter-spike 
crosslinking by IgGs was suggested by the relatively small improvements in 
neutralization potencies of intact anti-HIV-1 IgGs compared with their Fab counterparts 
(Klein and Bjorkman, 2010) and by the discovery that polyreactivity increased the 
apparent affinity of anti-HIV-1 antibodies through a mechanism of heteroligation 
(Mouquet et al., 2010). Comparison of the neutralization potencies of IgGs versus Fabs in 
the current study provides further support for the observation that anti-HIV-1 IgGs 
generally exhibit relatively small increased potencies compared to Fabs. To quantify 
potential avidity effects, we previously defined the molar neutralization ratio (MNR) for 
IgG versus Fab forms of an antibody as IC50 Fab (nM)/IC50 IgG (nM). In the absence of 
avidity or other advantages of the IgG compared with the Fab (e.g., increased size), the 
ratio would be 2.0 (Klein and Bjorkman, 2010). In the current study, the mean MNR for 
PG16, an IgG that cannot exhibit intra-spike crosslinking (Julien et al., 2013c), was 8.0 
(data from Figure 2C), similar to the 10.5 mean MNR in a previous study (West et al., 
2012). These values are lower than MNRs observed for IgGs against densely-packed 
viruses, which can be over 1000, but are consistent with a limited amount of inter-spike 
crosslinking by anti-HIV-1 IgGs whose epitopes on neighboring spikes are accessible to 
simultaneous engagement of the combining sites of the two Fabs of an IgG, which are 
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separated by ~150 Å (Klein and Bjorkman, 2010). Our current results suggested that 
inter-spike crosslinking can be increased by creating homo-diFabs with 70bp–100bp 
dsDNA linkers (Figure 2B, Figure S2D). These linkers would separate the combining 
sites of the Fabs by ≥240–340 Å, distances that should enhance inter-spike crosslinking.  
Indirect evidence for the hypothesis that HIV-1 evolved a low spike density to 
avoid inter-spike crosslinking IgGs comes from studies of a cytoplasmic tail deletion in 
the simian immunodeficiency virus (SIV) spike trimer. Cytoplasmic tail deletion has been 
suggested to increase the number of spikes per virion (Zingler and Littman, 1993) and/or 
the spike mobility in the virion bilayer (Crooks et al., 2008), both of which could enhance 
inter-spike crosslinking. Although tail-deleted mutant viruses can be produced in vitro, 
propagation of the virus in macaques favors viruses containing the full-length envelope 
spike (Zingler and Littman, 1993). These findings are consistent with the idea that an 
intact host immune system selects against those viruses that facilitate the ability of host 
IgGs to bind bivalently through inter-spike crosslinking.  
Here we present a method to create potential intra-spike crosslinking antibody-
based molecules using dsDNA- and protein-based linkers, and demonstrate that these 
reagents can exhibit up to three orders of magnitude increases in neutralization potency. 
We argue that the optimized versions of our new molecules achieve potency increases 
through intra-spike, rather than inter-spike, crosslinking because (i) distances measured 
between epitopes on virion-bound spike trimers corresponded to approximate intra-
epitope distances on HIV-1 spike trimer structures, and (ii) increases in inter-spike 
crosslinking by homotypic and heterotypic reagents should not exhibit sharp linker 
length-dependent neutralization potencies since distances between spikes vary within a 
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single virion and between virions. The latter point is valid even if HIV-1 spikes are 
clustered on mature virions, as suggested by fluorescence nanoscopy (Chojnacki et al., 
2012), but not cryoelectron microscopy (Liu et al., 2008; Zhu et al., 2006). Whether HIV-
1 spikes cluster upon encountering a target cell to form an entry claw (Sougrat et al., 
2007) is not relevant to the mechanism of action of our reagents, since neutralization 
assays are conducted by incubating potential inhibitors with virions prior to addition of 
target cells (Montefiori, 2005), a mechanism that is also presumably relevant for most in 
vivo interactions of antibody and antibody-like inhibitors. Because avidity effects require 
recognition of two or more antigens tethered to the same surface, another potential action 
of our reagents, inter-virion crosslinking, would not result in avidity effects by analogy to 
the lack of avidity enhancement for an IgG binding two soluble antigens, one per Fab. In 
this respect, we note that although IgAs are capable of inter-virion crosslinking (Stieh et 
al., 2014), conversion of IgG bNAbs to IgAs did not result in potency increases (Kunert 
et al., 2004; Wolbank et al., 2003). 
The use of dsDNA- and protein-based molecular rules to measure inter-epitope 
distances presented here can be used to probe conformations of virion-bound Env trimers. 
By contrast, EM and X-ray structures (Bartesaghi et al., 2013; Julien et al., 2013b; 
Lyumkis et al., 2013; Pancera et al., 2014b) cannot capture dynamic information 
concerning Env conformations during neutralization. Single-molecule fluorescence 
resonance energy transfer (smFRET) measurements suggested that Env trimers on the 
surface of HIV-1 virions transition between different conformations (Munro et al., 2014), 
and spike trimers have been visualized by EM in different conformations: the closed 
structure of unliganded trimers and trimers associated with VRC01-like bNAbs 
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(Bartesaghi et al., 2013; Liu et al., 2008; Lyumkis et al., 2013) (also observed in Fab-
bound crystal structures (Julien et al., 2013b; Pancera et al., 2014b)), a CD4- and/or 17b-
bound open structure (Liu et al., 2008; Tran et al., 2012), and a partially-open b12-bound 
structure (Liu et al., 2008) (Figure 3A). Homo- and hetero-diFabs joined by different 
lengths of dsDNA bridges offer a new methodology to probe Env trimer conformational 
states on virions and potentially to address strain-specific conformational differences.  
Homo-diFabs constructed from VRC01-like bNAbs showed greatest potency 
when binding to epitopes separated by distances most closely approximating the open 
structure (Liu et al., 2008; Tran et al., 2012), rather than the closed structure observed for 
soluble and virion-associated spike trimers bound to VRC01-like Fabs (Bartesaghi et al., 
2013; Liu et al., 2008; Lyumkis et al., 2013) (Figure 2B, 3; Figure S3-S4). These results 
suggest that optimal intra-spike crosslinking molecules can inhibit a different state than 
recognized by monovalent Fabs binding to spike trimers in static EM and X-ray 
structures (Bartesaghi et al., 2013; Liu et al., 2008; Lyumkis et al., 2013; Merk and 
Subramaniam, 2013; Tran et al., 2012). If so, one Fab of a homo-diFab could first bind to 
its epitope on a closed trimer, allowing the second Fab to latch on to a transiently-
populated open form of that trimer. Alternatively, binding of the first Fab may trap the 
trimer into a conformation, allowing increased accessibility of the second Fab, or both 
Fabs could bind simultaneously to a transiently-appearing open trimer. Interestingly, the 
distance dependence of two CD4bs antibodies, 3BNC60 and b12, was more strongly 
pronounced for a Tier 1B HIV-1 strain, 6535.3, than for Tier 2 or 3 strains against which 
the homo-diFabs were tested (Figure 2B, Figure S2). Tier categorization of HIV-1 strains 
refers to the sensitivity of a strain to antibody neutralization, with Tier 1 strains being 
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more sensitive in general to antibodies than Tier 2 or 3 strains (Seaman et al., 2010). The 
differences in length dependence for CD4bs homo-diFabs may reflect differences in 
conformational variability within Env trimers from different tiers, with Tier 1 Env 
perhaps more easily able to adopt the open conformations likely recognized by the 
CD4bs antibodies with optimal bridge lengths.  
For the PG16-3BNC60 hetero-diFabs, the optimal 40bp and 50bp bridge lengths 
(136 Å and 170 Å, respectively) corresponded to the approximate separation distances 
between PG16 and 3BNC60 Fabs when bound to the same gp120 within a trimer (147 Å) 
or to neighboring protomers within open or partially-open trimers (167 Å) (Figure S3). In 
a second hetero-diFab bridge length dependency example, 10-1074-40bp-3BNC60 was 
more potent than 10-1074-60bp-3BNC60 (Figure 4, Table S4). The ~136 Å distance 
between the two Fabs in 10-1074-40bp-3BNC60 corresponded to the approximate 
separation between these Fabs bound to the same gp120 (141 Å), while 60bp more 
closely approximated Fabs bound to neighboring protomers on an open trimer (193 Å) 
(Figure S3). In general, it is more difficult to deduce information about Env trimer 
conformations recognized by hetero-diFabs because the intra-epitope distance is the same 
in the three conformations for Fabs binding to the same gp120 subunit within an Env 
trimer (Figure S3), and length-dependence data for some of the hetero-diFabs, e.g., 10-
1074-40bp-3BNC60, was consistent with binding to a single gp120 within an Env trimer 
as well as to adjacent gp120s (Figure S2). However, whether binding to the same or to 
adjacent protomers within the spike trimer, the increased synergy of optimal hetero-
diFabs suggested a mechanism in which the more potent/tighter-binding Fab of the 
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hetero-diFab initially bound to the viral spike, thereby allowing the second Fab, even 
when only weakly neutralizing on its own, to attach.  
In summary, our results demonstrated that optimal length homo- and hetero-
diFabs are capable of synergistic effects that increased neutralization potencies, and in 
some cases, allowed neutralization of viral strains resistant to conventional IgGs. These 
results are consistent with the hypothesis that most anti-HIV-1 IgGs bind monovalently to 
single Env spikes, which leaves them vulnerable to Env mutations that weaken 
monovalent interactions but would still permit bivalent interactions (Klein and Bjorkman, 
2010). The demonstration that anti-HIV-1 reagents designed to be capable of intra-spike 
binding with avidity can more potently and broadly neutralize HIV-1 than conventional 
anti-spike IgGs is relevant to the choice of anti-HIV-1 proteins or genes to be delivered 
passively to prevent infection or suppress active infections. Bi-specific antibodies that 
simultaneously bind to HIV-1 Env and to CD4 or CCR5 host receptors on the target cell 
represent a conceptually distinct method to increase the potency and breadth of anti-HIV-
1 reagents (Pace et al., 2013). In contrast to these reagents, antibodies that achieve 
synergy via bivalent binding to Env by intra-spike crosslinking offer significant 
advantages for passive delivery; for example, neutralizing antibodies against HIV-1 Env 
protect more effectively in vivo than antibodies against CD4 (Pegu et al., 2014), and anti-
self antibodies such as anti-CD4 IgGs have short half-lives in vivo (Bruno and Jacobson, 
2010). We propose that the ideal therapeutic molecule would utilize avidity achieved by 
intra-spike crosslinking to reduce the concentration required for sterilizing immunity and 
render the low spike density of HIV-1 irrelevant to its efficacy. Moreover, analogous to 
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using several drugs or antibodies during anti-retroviral therapy, simultaneous binding to 
different HIV-1 epitopes should reduce or abrogate sensitivity to Env mutations. 
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EXPERIMENTAL PROCEDURES 
 
Expression and purification of Fabs 
Genes encoding IgG light chain genes were modified by site-directed mutagenesis to 
replace Cys263Light Chain, the C-terminal cysteine that forms a disulfide bond with 
Cys233Heavy Chain, with a serine. Modified light chain genes and genes encoding 6x-His- or 
StrepII-tagged Fab heavy chains (VH–CH1–tag) were subcloned separately into the pTT5 
mammalian expression vector (NRC Biotechnology Research Institute). Fabs were 
expressed by transient transfection in HEK 293-6E (NRC Biotechnology Research 
Institute) cells as described (Diskin et al., 2011a) and purified from supernatants by Ni-
NTA or StrepII affinity chromatography followed by size exclusion chromatography in 
PBS pH 7.4 using a Superdex 200 10/300 or Superdex 200 16/600 column (Amersham 
Biosciences).  
 
IgG heterodimers 
Bispecific IgGs were constructed using “knobs-into-holes” mutations (Thr366Trp on one 
heavy chain, and Thr366Ser, Leu368Ala, and Tyr407Val on the other heavy chain 
(Atwell et al., 1997)) to promote Fc heterodimerization, and crossover of the heavy and 
light chain domains of one half of the bispecific IgG to prevent light chain mispairing 
(Schaefer et al., 2011). Heterodimerizing leucine zipper sequences (O'Shea et al., 1993) 
followed by either a 6x-His or Strep II tag sequence (Schmidt and Skerra, 2007) were 
added to the C-termini of the heavy chains. The VH domain on one heavy chain of each 
heterodimer was replaced by the VL domain, and the corresponding light chain was 
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constructed with the VH domain joined to the CL domain as described (Schaefer et al., 
2011). Heterodimeric IgGs were expressed by transient transfection and isolated from 
supernatants by Protein A chromatography followed by Strep II and Ni-NTA 
chromatography. Heterodimers were further purified by size exclusion chromatography 
using a Superdex 200 10/300 or 16/600 column (Amersham Biosciences) equilibrated in 
PBS pH 7.4.  
  
DNA conjugation to Fabs 
 The NUPACK server (Zadeh et al., 2011) was used to predict thermally-stable 
DNA sequences lacking secondary structures to make dsDNA bridges. Bridge and linker 
sequences are listed in table below. 
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 DNA was conjugated to free thiol-containing Fabs using a modified version of a 
previously-described protocol (Hendrickson et al., 1995). Briefly, Fabs were reduced in a 
buffer containing 10mM TCEP-HCl pH 7-8 for two hours, and then buffer exchanged 
three times over Zeba desalting columns (Thermo Scientific). The percentage of reduced 
Fab was determined using Invitrogen’s Measure-IT Thiol Assay. Concurrently, a 5-20 
base ssDNA containing a 5’ amino group (Integrated DNA Technologies, IDT-DNA) 
was incubated with a 100-fold molar excess of an amine-to-sulfhydryl crosslinker (Sulfo-
SMCC; Thermo Scientific) for 30 minutes to form a maleimide-activated DNA strand, 
which was buffer exchanged as described above. The reduced Fab and activated ssDNA 
were incubated overnight, and the Fab-ssDNA conjugate was purified by Ni-NTA or 
StrepII affinity chromatography (GE Biosciences) to remove unreacted Fab and ssDNA.  
ssDNA was synthesized, phosphorylated, and PAGE purified by Integrated DNA 
Technologies. For di-Fabs containing dsDNA bridges longer than 40bp, complementary 
ssDNAs were annealed by heating (95˚C) and cooling (room temperature) to create 
dsDNA containing overhangs complementary to the Fab-ssDNA conjugates. dsDNA was 
purified by size exclusion chromatography (Superdex 200 10/300) and incubated 
overnight with the corresponding tagged Fab-ssDNA conjugates. Homo- and hetero-
diFab reagents were purified by Ni-NTA and StrepII affinity chromatography when 
appropriate to remove free DNA and excess Fab-ssDNA conjugates, treated with T4 
DNA ligase (New England Biolabs), and purified again by size exclusion 
chromatography (Figure S1B). To make di-Fabs containing dsDNA bridge lengths less 
than 40bp, two complementary ssDNA-conjugated Fabs were incubated at 37˚C without 
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a dsDNA bridge and then purified as described above. Protein-DNA reagents were stable 
at 4°C for >6 months as assessed by SDS-PAGE. 
 
Characterization of DNA-Fab reagents 
Fractions from the center of an SEC elution peak were concentrated using Amicon Ultra-
15 Centrifugal Filter Units (Millipore) (MW cutoff = 10 kDa) to a volume of 500 µL, and 
DLS measurements were performed on a DynaPro® NanoStarTM (Wyatt Technology) 
using the manufacturer’s suggested settings. Hydrodynamic radii were determined as 
described (Dev and Surolia, 2006). Briefly, a nonlinear least squares fitting algorithm 
was used to fit the measured correlation function to obtain a decay rate. The decay rate 
was converted to the diffusion constant that can be interpreted as the hydrodynamic 
radius via the Stokes-Einstein equation. 
 
Hetero-diFab with TPR linker 
PG16-TPR12-3BNC60, a C-to-C linked hetero-diFab containing 12 consensus 
tetratricopeptide-repeat (TPR) domains (Kajander et al., 2007a) as a protein linker (Klein 
et al., 2014b), was prepared from modified PG16 and 3BNC60 Fabs using a combination 
of sortase-catalyzed peptide ligation and click chemistry (Witte et al., 2013). The C-
terminus of the PG16 Fab heavy chain was modified to include the amino acid sequence 
GGGGASLPETGGLNDIFEAQKIEWHEHHHHHH, comprising a flexible linker, the 
recognition sequence for S. aureus Sortase A (underlined), a BirA tag, and a 6x-His tag. 
The C-terminus of The 3BNC60 Fab heavy chain C-terminus was modified to include a 
(Gly4Ser)3 linker followed by 12 tandem TPR domains and the amino acid sequence 
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ASGGGGSGGGGSGGGGSLPETGGHHHHHH, comprising a second (Gly4Ser)3 linker, 
the Sortase A recognition sequence (underlined), and a 6x-His tag. The Fabs were 
expressed in HEK-6E cells and purified with Ni-NTA and gel filtration chromatography 
as described above. Peptides (GGGK with C-terminal azide and cyclooctyne click 
handles) were synthesized by GenScript, and sortase-catalyzed peptide ligation was used 
to attach the azide-containing peptide to PG16 Fab and the cyclooctyne-containing 
peptide to the 3BNC60-TPR12 fusion protein as described (Guimaraes et al., 2013). 
Approximate yields after each sortase reaction were ~30%. Peptide-ligated PG16 and 
3BNC60 Fabs were passed over a Ni-NTA column to remove His-tagged enzyme and 
Fabs that did not lose their His tags during the reaction, mixed at equimolar ratios, and 
the click reaction was accomplished by incubating overnight at 25˚C. The approximate 
yield for the click reaction was ~65%. The resulting PG16-TPR12-3BNC60 hetero-diFab 
was purified by size exclusion chromatography to remove unreacted Fabs for an overall 
yield of ~22%. 
 
Measurements of intra-spike distances 
To derive predicted distances between two adjacent Fab bound to HIV-1 Env, we 
superimposed Fabs bound to their epitopes on the structures of Env trimers in three 
different conformations: closed (a 4.7 Å crystal structure of a gp140 SOSIP trimer; PDB 
code 4NCO), open (a 9 Å EM structure of a SOSIP trimer–17b Fab complex (Tran et al., 
2012); coordinates obtained from S. Subramaniam), partially-open (an ~20 Å EM 
structure of a viral spike bound to b12 Fab; PDB code 3DNL). The positions of the CH1 
and CL domains in Fab structures used for docking were adjusted to create Fabs with the 
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average elbow bend angle found in a survey of human Fab structures (Stanfield et al., 
2006). The VH-VL domains of the adjusted Fabs were then superimposed on crystal 
structures of Fab-gp120 or Fab-gp140 complexes (PDB codes 3NGB, 2NY7 and 4CNO 
for complexes with VRC01, b12 and PGT122 Fabs, respectively) or a PG16-epitope 
scaffold complex (PDB code 4DQO). The position on Env trimer of 10-1074, a clonal 
variant of the PGT121-PGT123 family (Mouquet et al., 2012a), was approximated using 
the 4CNO gp140–PGT122 structure. In other cases, related antibodies, e.g., PG9/PG16 
and VRC01/3BNC117/3BNC60, were also assumed to bind similarly. The complex 
structures were superimposed on the Env trimer structures by aligning the common 
portions. The distance between the Cys233heavy chain carbon-  atoms of adjacent Fabs was 
then measured using PyMol (Schrödinger, 2011) to approximate the length of dsDNA 
bridges attached to Cys233heavy chain. Measurements derived using other EM structures for 
the closed and open trimers (PDB codes 3DNN, 3J5M and 3DNO) or using a recent 3.5 
Å Env trimer crystal structure (Pancera et al., 2014b) resulted in differences of ≤10 Å for 
analogous distance measurements. 
 
In vitro neutralization assays 
Neutralization of pseudoviruses derived from primary HIV-1 isolates was 
monitored by the reduction of HIV-1 Tat-induced luciferase reporter gene expression in 
the presence of a single round of pseudovirus infection in TZM-bl cells as described 
(Montefiori, 2005). In some cases, DEAE-dextran, an additive used to enhance viral 
infection of target cells (Montefiori, 2005), led to false positive neutralization signals for 
dsDNA alone and for dsDNA-containing reagents, presumably because of interactions 
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between dextran and DNA (Maes et al., 1967). Dextran was eliminated from assays in 
which the dsDNA linker alone reduced infectivity, in which case the pseudovirus 
concentration was increased by 2.5-40–fold, allowing for comparable infectivity as in the 
presence of dextran.  
Pseudoviruses were generated by co-transfecting HEK293T cells with vectors 
encoding Env and a replication-deficient HIV-1 backbone as described (Montefiori, 
2005) or obtained from the Fraunhofer Institut IBMT (6535.3, CAAN5342, CAP45, 
CAP210.200.E8, DU172, DU422, QH-0692, THRO4156.18, TRO.11, ZM53, ZM214, 
ZM233, ZM249). Neutralization assays were preformed in-house (Figure 2-4) and by the 
Collaboration for AIDS Vaccine Discovery (CAVD) core neutralization facility for 
testing against a panel of isolates (Figure 2C; Tables S1-S5). Some of the in-house data 
were derived from neutralization assays that were prepared by a Freedom EVO® (Tecan) 
liquid handler. Reagents (prepared as 3-, 4-, or 5-fold dilution series; each concentration 
in duplicate or triplicate) were incubated with 250 (when DEAE-dextran was added) or 
>1000 viral infectious units at 37°C for one hour prior to incubation with reporter cells 
(10,000/well) for 48 hours. Luciferase levels were measured from a cell lysate using an 
Infinite 200 Pro microplate reader (Tecan) after addition of BrightGlo (Promega). Data 
were fit by Prism (GraphPad) using nonlinear regression to derive IC50 values. IC50s 
derived from independent replicates of manual and robotic assays generally agreed within 
2-4 fold. Average IC50 values reported in the figures and tables are geometric means 
calculated using the formula (∏ai)(1/n); i = 1, 2, …, n. Geometric means are suitable 
statistics for data sets covering multiple orders of magnitude (Sheskin, 2004), as is the 
case for neutralization data across multiple viral strains. Fold improvements were 
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calculated as the ratio of the geometric mean IC50 values for the reagents being 
compared. 
 
Simulation of Fab and IgG saturation of surface-bound antigens 
Numerical analysis (Mathematica, v. 10) was used to simulate saturation of surface-
bound antigens by monovalent Fabs (Equation 1), bivalent IgGs to unpaired antigen (Ag) 
(Equation 2), and paired antigen (pAg) (Equations 3,4), where “paired antigen” was 
defined as antigens that are spaced such that an IgG can bind two epitopes simultaneously 
(e.g., intra-spike crosslinking of two epitopes on the same viral spike or inter-spike 
crosslinking between two viral spikes). In the bivalent model (Equations 3,4), the surface 
concentrations of antigen and IgG-antigen complexes were approximated by the inverse 
of the volume of a sphere (Vs) with radius equal to the hydrodynamic radius of the 
molecule multiplied by Avogadro’s number (Na) as described previously (Müller et al., 
1998). 
Fab binding to antigen: 𝐹𝑎𝑏 + 𝐴𝑔 ⇄ 𝐹𝑎𝑏 − 𝐴𝑔 
)[+,-./0])2 = 𝑘, 𝐹𝑎𝑏 𝐴𝑔 − 𝑘) 𝐹𝑎𝑏 − 𝐴𝑔  [1] 
 
IgG binding to unpaired antigen: 𝐼𝑔𝐺 + 𝐴𝑔 ⇄ 𝐼𝑔𝐺 − 𝐴𝑔 
)[708./0])2 = 2𝑘, 𝐼𝑔𝐺 𝐴𝑔 − 𝑘) 𝐼𝑔𝐺 − 𝐴𝑔  [2] 
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IgG binding to paired antigen: 𝐼𝑔𝐺 + 𝑝𝐴𝑔 ⇄ 𝐼𝑔𝐺 − 𝑝𝐴𝑔 𝐼𝑔𝐺 − 𝑝𝐴𝑔 + 𝑝𝐴𝑔 ⇄ 𝐼𝑔𝐺 − 𝑝𝐴𝑔; )[708.</0])2 = 2𝑘, 𝐼𝑔𝐺 𝑝𝐴𝑔 − 𝑘)[𝐼𝑔𝐺 − 𝑝𝐴𝑔] =>?	  AB − )[708.</0C])2  [3] )[708.</0C])2 = 𝑘, 𝐼𝑔𝐺 − 𝑝𝐴𝑔 =>?	   B 𝑝𝐴𝑔 =>?	  AB − 2𝑘) 𝐼𝑔𝐺 − 𝑝𝐴𝑔; =>?	  AB [4] 
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Chapter Four 
The design and characterization of structured protein linkers with differing flexibilities 
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 This chapter describes the characterization of engineered protein linkers. This 
work was a collaboration between Joshua Klein, Siduo Jiang, Jennifer Keeffe, and 
myself. Joshua Klein, Siduo Jiang and I each contributed equally to this work. The 
conception and many of the initial designs of linkers were by Joshua Klein. Joshua also 
performed early experiments and analyzed initial data. Siduo Jiang cloned, expressed, 
and purified protein linker reagents, as well as performed experiments, analyzed data, and 
aided in the design of various protein linkers. My contribution to this work was the 
design of a subset of the structured linkers, and cloning, expression, and purification of 
linker reagents, and performance experiments; as well as analysis and characterization of 
the protein linkers. In addition, throughout Siduo Jiang’s time as an undergraduate 
researcher in the lab, I was his primary mentor, and oversaw all of the work that was 
done.  
 
This chapter was previously published as: 
 Klein, J. S.*, Jiang, S.*, Galimidi, R. P.* et al. (2014). "Design and characterization of 
structured protein linkers with differing flexibilities." Protein Eng Des Sel 27(10): 325-
330.  
*These authors all contributed equally to this work.  
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Abstract 
Engineered fusion proteins containing two or more functional polypeptides joined by a 
peptide or protein linker are important for many fields of biological research. The 
separation distance between functional units can impact epitope access and the ability to 
bind with avidity; thus the availability of a variety of linkers with different lengths and 
degrees of rigidity would be valuable for protein design efforts. Here, we report a series 
of designed structured protein linkers incorporating naturally-occurring protein domains 
and compare their properties to commonly-used Gly4Ser repeat linkers. When 
incorporated into the hinge region of an immunoglobulin G (IgG) molecule, flexible 
Gly4Ser repeats did not result in detectable extensions of the IgG antigen binding 
domains, in contrast to linkers including more rigid domains such as β2-microglobulin, 
Zn-α2-glycoprotein, and tetratricopeptide repeats (TPRs). This study adds an additional 
set of linkers with varying lengths and rigidities to the available linker repertoire, which 
may be useful for the construction of antibodies with enhanced binding properties or 
other fusion proteins.   
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Introduction  
 Fusion proteins are engineered biomolecules containing parts from two or more 
genes synthesized as a single multi-functional construct. These have been critical in many 
areas of biological research including affinity purification (Lichty et al., 2005) and 
protein stabilization for structure determination (Zou et al., 2012). Bi-specific fusion 
proteins have also been utilized as biopharmaceuticals, with an active drug domain fused 
to a carrier domain, allowing for the drug’s proper transport (Chen et al., 2013). Such 
proteins have been designed to penetrate epithelial membranes including the blood brain 
barrier, as well as to target a specific cell population (Pardridge, 2010). Due to the 
modularity of protein domains in the generation of functional constructs, fusion proteins 
will likely have increasing importance in research and drug design. 
The successful construction of fusion proteins relies on the proper choice of a 
protein linker as direct fusion of two domains can lead to compromised biological 
activity (Bai et al., 2005; Zhang et al., 2009). Several studies have utilized existing 
databases to compile and characterize linkers in naturally occurring multi-domain 
proteins (Argos, 1990; George and Heringa, 2002). These studies have yielded amino 
acid sequence propensities for natural linkers of various sizes and lengths, as well to 
information on rigidity and secondary structure. This information has helped the 
empirical design of linkers that are customized for particular applications.  
Linkers can be classified into three groups: flexible, rigid, and cleavable (Chen et 
al., 2013). Flexible linkers are generally composed of small, non-polar or polar residues 
such as Gly, Ser, and Thr. The most common is the (Gly4Ser)n linker (Gly-Gly-Gly-Gly-
Ser)n, where n indicates the number of repeats of the motif. Poly-glycine linkers have also 
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been evaluated, but the addition of a polar residue such as serine can reduce linker-
protein interactions and preserve protein function. Due to their flexibility, these linkers 
are unstructured and thus provided limited domain separation in a previous study (Evers 
et al., 2006). As a result, more rigid linkers including poly-proline motifs (Schuler et al., 
2005) and an all alpha-helical linker A(EAAAK)nA (Arai et al., 2001) have been 
developed.  
We are interested in using relatively rigid protein linkers to separate anti-HIV 
binding proteins at distances that would permit bi- or multivalent binding to HIV Env 
glycoproteins with the objective of creating reagents capable of cross-linking epitopes 
within a single Env trimer (intra-spike crosslinking). Such reagents would take advantage 
of avidity effects to minimize HIV’s ability to evade neutralizing antibodies by rapidly 
mutating to lower the affinity between the HIV epitopes and the antigen recognition 
fragment (Fab) of the antibody (Klein et al., 2009b). Although the architecture of the HIV 
spike trimer does not permit intra-spike cross-linking by most natural antibodies (Klein 
and Bjorkman, 2010; Zhu et al., 2006), it may be possible to create reagents capable of 
bivalent binding to an HIV Env trimer by fusing two identical reagents or two different 
reagents with an appropriate length linker. Here we report the design, construction, and 
characterization of a series of structured protein linkers incorporating both rigid and 
flexible domains that can be used to achieve a variety of different desired separations. 
The linkers were incorporated into the hinge region of an intact IgG antibody and 
evaluated for their relative lengths and rigidities by dynamic light scattering. 
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Methods 
Plasmid construction and protein purification 
Genes encoding designed linkers were synthesized (Blue Heron Bio) with restriction sites 
for the enzymes NheI (5’ end) and either NgoMIV or HindIII (3’ end). These sites were 
also introduced into the gene, encoding the heavy chain of the HIV-neutralizing antibody 
b12 (Roben et al., 1994) such that the insert would be located between hinge region 
residues His235 and Thr236. Constructs encoding the b12 heavy chain gene with a linker 
inserted in the hinge region were subcloned into the pTT5 mammalian expression vector. 
The b12-linker IgGs were expressed transiently in HEK-6E cells by co-transfecting the 
b12-linker heavy chain genes with the b12 light chain gene as described (Diskin et al., 
2011a).  
IgG-linker fusion constructs were purified by protein A affinity chromatography 
(GE Healthcare) followed by purification and analysis by size exclusion chromatography 
(SEC) using a Superdex 200 10/300 GL column (GE Healthcare) in phosphate-buffered 
saline, 0.05% w/v sodium azide, pH 7.4.  
Dynamic light scattering (DLS) 
Fractions corresponding to the center of the SEC elution peak were concentrated using 
Amicon Ultra-15 Centrifugal Filter Units (Millipore) with a molecular weight cutoff of 
100 kDa to a volume of 80-400 uL and concentrations of 0.5-1 mg/mL. Concentration 
differences within this range were not observed to affect the hydrodynamic radius values 
determined by DLS (data not shown). Sample sizes ranging from 80-350 µL were loaded 
into a disposable cuvette, and measurements were performed on a DynaPro® NanoStarTM 
(Wyatt Technology) using the manufacturer’s suggested settings. A fit of the second 
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order autocorrelation function to a globular protein model was used to derive the 
hydrodynamic radius. 
 
Results and Discussion 
Design and identity of designed linkers 
In order to design potential structured linkers, we surveyed the Protein Data Bank (PDB) 
to find structures that were relatively elongated and rigid, or represented small globular 
proteins. We chose Zn-α2-glycoprotein (ZAG; PDB code: 1ZAG) as an example of a 
relatively elongated and rigid structure (Sanchez et al., 1999), and β2-microgloblin (β2m; 
PDB code: 1LDS) and ubiquitin (Ub; PDB code: 1UBQ) as examples of small globular 
proteins (Figure 1a). ZAG is a 31.5 kDa protein with a class I MHC heavy chain-like fold 
and a separation distance between the N- and C-termini of approximately 45 Å. β2m is a 
stable 12 kDa protein with an immunoglobulin constant region-like fold that forms a rigid 
structure with a separation distance between the N- and C-terminus of approximately 35 
Å (Trinh et al., 2002). Likewise, Ub is a compact, stable 8.5 kDa protein with an N- and 
C-terminal separation distance of about 37 Å (Vijay-Kumar et al., 1987). In addition to 
the structured linkers chosen from the PDB, proline-rich linkers were designed from the 
hinge sequence from IgA1 (polyPro and polyPro(Glyc)). This glycosylated region 
confers rotational flexibility of the Fab relative to the Fc in the context of wildtype 
dimeric IgA1 (Bonner et al., 2008). In addition, glycosylation has been shown to 
potentially increase stability of polypeptide linkers (Imperiali and O’Connor, 1999). 
ZAG, β2m, and Ub proteins were joined in various combinations with short linker 
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regions, either (Gly2Ser)n repeats, glycosylated proline-rich sequences (polypro(Glyc)), 
or unglycosylated proline-rich sequences (polypro), to create linkers L1 – L12 (Table 1).   
We also created linkers using tetratricopeptide repeat domains (TPRs; PDB code: 
2AVP; L13-L16; Table 1; Figure 1a) (Kajander et al., 2007b) that are found in natural 
proteins such as HSP70/90 (Scheufler et al., 2000). These domains are optimal for use as 
potential structured linkers because the length of a set of tandem TPR domains 
corresponds predictably with the number of repeats. Each repeat consists of 34 amino 
acids with a defined sequence motif that forms two α-helices (D'Andrea and Regan, 
2003). Seven to eight TPRs form a complete superhelical turn with a pitch of about 72 Å. 
For our TPR linkers, we used a consensus sequence defined by the amino acid of the 
greatest global propensity in the natural database of the TPR domains at each position, 
which was shown to form a stable superhelix and was therefore named the consensus 
TPR sequence or cTPR (Main et al., 2003).  
Finally, for comparison, we constructed a series of (Gly4Ser)n linkers (L17 – L24; 
Table 1) in order to determine the effect of increasing the number of flexible Gly4Ser 
repeats on the hydrodynamic radius of the IgG. The complete sequence of each linker is 
given in Table 2. 
As a scaffold for comparing the designed structured linkers, we inserted each into 
the hinge region of an intact IgG antibody (the anti-HIV antibody b12) (Roben et al., 
1994). We chose the hinge region of an IgG, which encompasses the amino acids 
between the C-terminus of the heavy chain portion of the antigen-binding fragment (Fab) 
and the N-terminus of the Fc, to insert the linkers because it can tolerate large protein  
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Figure 1. (A) Schematic of wildtype IgG (left) and IgG with a designed linker in its 
hinge region (middle). IgG domains are color coded as shown in the right panel. (B) 
Ribbon diagrams for domains used in structured linkers shown to scale (pdb codes: ZAG 
(1ZAG), β2m (1LDS), cTPR (2FO7), ubiquitin (1UBQ)). The cTPR structure shown 
contains 8 tandem repeats. N- and C-terminal residues are shown as sticks, color-coded 
blue for the N-terminus and red for the C-terminus.  
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Linker Name Description 
L1 GPcPcPc GlySer-polyPro(Glyc)-polyPro(Glyc)-polyPro(Glyc) 
L2 GPPcP GlySer-polyPro-polyPro(Glyc)-polyPro 
L3 GPGcP GlySer-polyPro-GlySer(Glyc)-polyPro 
L4 GPPP GlySer-polyPro-polyPro-polyPro 
L5 GPbP GlySer-polyPro-β2m-polyPro 
L6 GPbG GlySer-polyPro-β2m-GlySer 
L7 PbGbG polyPro-β2m-GlySer-β2m-GlySer 
L8 GPbGbP GlySer-polyPro-β2m-GlySer-β2m-polyPro 
L9 GPUG GlySer-polyPro-Ub-GlySer 
L10 GPZP GlySer-polyPro-ZAG-polyPro 
L11 GGZGZP GlySer-GlySer-ZAG-GlySer-ZAG-polyPro 
L12 GcGcP GlySer(Glyc)- GlySer(Glyc)-polyPro 
L13 cTPR3 (G4S)3-cTPR3-(G4S)3 
L14 cTPR6 (G4S)3-cTPR6-(G4S)3 
L15 cTPR9 (G4S)3-cTPR9-(G4S)3 
L16 cTPR12 (G4S)3-cTPR12-(G4S)3 
L17 GS1 (G4S)1 
L18 GS2 (G4S)2 
L19 GS3 (G4S)3 
L20 GS5 (G4S)5 
L21 GS6 (G4S)6 
L22 GS7 (G4S)7 
L23 GS8 (G4S)8 
L24 GS9 (G4S)9 
Table 1. Description of structured linker designs. (Gly4Ser)n=Gly-Gly-Gly-Gly-Ser 
sequence with n number of repeats; GlySer = (N-term: AGS(GGS)3; Middle: (GGS)4; C-
term: (GGS)3GAS]2S); GlySer(Glyc)=Gly-Gly-Ser sequence with an embedded potential 
N-linked glycosylation site (Asn-Ser-Ser); polyPro=proline-rich hinge sequence from 
IgA1; polyPro(Glyc)=proline-rich hinge sequence from IgA1 with an embedded potential 
N-linked glycosylation site (Asn-Ser-Ser); β2m=β-2-microglobulin; Ub=ubiquitin; 
ZAG=Zn-α2-glycoprotein; cTPRX=consensus tetratricopeptide repeat sequence with X 
number of repeats.  
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insertions (Redpath et al., 1998). In addition, extension in the hinge region could 
potentially increase the separation distance of the Fab arms (Figure 1b). 
 
Characterization of the IgGs containing structured linkers 
The b12 IgG proteins containing linkers L1 – L24 were expressed by transient 
transfection in HEK 293-6E mammalian cells and purified by affinity and size exclusion 
chromatography. Visualization by SDS-PAGE for IgGs containing the L1 – L8 linkers 
showed that all proteins were purified to >95% homogeneity (Figure 2). Under reducing 
conditions, two heavy chain bands were observed for b12-L1, which contained a linker 
containing three potential N-linked glycosylation sites, indicating the presence of 
multiple glycosylated isoforms. An overlay of the chromatograms derived from SEC 
showed that the IgGs containing the L1 – L8 structured linkers all exhibited a decrease in 
retention volume relative to wild type IgG, consistent with the expected increases in the 
radius of gyration (Rg) of each of the constructs due to the addition of a structured linker 
(Figure 3).  
We next derived the hydrodynamic radii using dynamic light scattering (DLS) for 
wildtype b12 and the b12 proteins containing designed linkers. DLS measures 
fluctuations in the intensity of scattered light of a protein solution over time, which can 
be used to calculate an autocorrelation function of intensity (Nobbmann et al., 2007). 
Typical monodisperse samples (including our hinge-linked antibodies) generate an 
exponential decay in the autocorrelation. A least squares fit can be performed to calculate 
the decay constant, which directly relates to the diffusion coefficient. The diffusion 
coefficient is then inversely related to the characteristic hydrodynamic radius RH, which 
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 Figure 2. SDS-PAGE analysis of b12 IgG-structured linker proteins run under 
reducing (left) and non-reducing (right) conditions. 
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Figure 3. Overlay of size exclusion chromatograms for IgGs containing flexible and 
structured protein linkers. Structured linkers (L1-L8) exhibited larger decreases in 
retention volume with respect to wildtype compared to Gly4Ser linkers, which exhibited 
little to no decrease depending on the number of repeats. Structured cTPR linkers also 
exhibited consistent decreases in retention volume as a function of the number of repeats.  
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reflects the radius of a hypothetical solid sphere that would diffuse at the same rate as the 
protein. The RH value is not a direct measurement of the length that the linker contributes 
to the size of the IgG. However, comparative analysis can yield rank order differences for 
the relative lengths and rigidity of the various linkers. For example, if the separation 
between the IgG Fc and Fab domains were increased by the addition of a designed hinge 
linker, we would expect an observable increase in the RH of the fusion construct 
compared to the parental b12 IgG due to increased size of the diffusion sphere.   
The hydrodynamic radii were measured by DLS for each of the b12 IgG-linker 
fusion proteins and compared with an internal wildtype b12 IgG control (Figure 4). By 
comparing constructs containing elongated or small protein domain linkers, cTPR repeat 
linkers, and flexible (Gly4Ser)n linkers of various lengths (L17 – L24), we could directly 
compare the effects of incorporating different lengths of flexible versus structured 
proteins linkers. 
We observed a consistent trend for the RH values between glycosylated and non-
glycosylated linkers (L1, L2, L3, L12 vs. L4). The incorporation of three potential N-
linked glycosylation sites in proline-rich linkers derived from the hinge region of IgA1 
(L1) appeared to increase the RH relative to constructs containing similar linker 
sequences with only one (L2) or no (L4) N-linked glycosylation sites, possibly through 
stabilization of the folded state and leading the linker to adopt a more extended 
conformation (Shental-Bechor and Levy, 2008). While the addition of only a single 
potential N-linked glycosylation site did not seem to affect the diffusion rate of proline-
rich linkers (compare L2 and L4), a single potential N-linked glycosylation in the GGSG-
NSS-GSGG region of a combination proline-rich and Gly2Ser linker (L3) increased its  
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Figure 4. Comparative analysis by DLS of the hydrodynamic radii (RH) of designed 
linkers in the context of the b12 IgG. 
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RH beyond the RH of a proline-rich linker with three potential N-linked glycosylation 
sites (L1). These data are consistent with the observation that N-linked glycosylation 
confers rigidity in the backbone of a flexible linker (Liu et al., 2000), suggesting these 
reagents contained linkers with a more extended conformation. Thus incorporating 
potential N-linked glycosylation sites within flexible linkers may be a general method to 
increase linker rigidity. 
Adding a single  β2m domain to a linker increased the RH of the b12-linker 
protein to a similar degree as a proline-rich repeat relative to IgG (compare L5 to L2, L4, 
and IgG), suggesting that the structured β2m domain provided similar bulk and 
separation to the polyPro repeat. However, adding a second tandem β2m repeat separated 
from the first with a (Gly2Ser)4 sequence, did not increase the RH appreciably (compare 
L8 and L5; L7 and L6). These results suggested that coupling a flexible Gly-Ser linker 
with the rigid β2m domain partially diminished the separation between Fc and Fab 
regions provided by β2m alone. A similar observation was made for hinge constructs 
containing ZAG (L10 and L11). A linker containing ZAG alone increased the 
hydrodynamic radius of the b12-linker protein compared to IgG and more than the IgG–
proline-rich linker (compare L10 to L2 and L4). However, replacement of the proline-
rich domain by ZAG that was flanked at both termini by a (G2S)4 peptide resulted in a 
decrease in hydrodynamic radius (compare L10 and L11). 
We also investigated ubiquitin as a structured linker (L9). However, initial 
characterization by SDS-PAGE showed degradation at the linker site (data not shown). In 
addition, DLS measurements revealed that a purified sample of b12-L9 had a smaller RH 
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than IgG similar to a Fab or Fc region alone, further suggesting ubiquitin-specific 
degradation (Figure 4).  
 
cTPR linker series 
cTPR constructs were generated with 3, 6, 9, or 12 tandem repeats. All cTPR linkers 
were flanked by (Gly4Ser)3 sequences (Table 2). The constructs exhibited a consistent 
decrease in elution volume on SEC as a function of the repeat length (Figure 3). These 
constructs also predictably increased the RH of the linked IgG with increased number of 
tandem repeats (Figure 4). The hydrodynamic radius of the cTPR12 construct 
corresponded to approximately the size of L4, which contained a proline-rich linker. 
These data suggested that, unlike with repeated domains of the structured linkers, the 
increase in separation between the Fab and Fc correlated predictably with the number of 
cTPR repeats despite the presence of Gly4Ser peptides flanking the N- and C-termini.  
 
(Gly4Ser)n linker series 
In order to compare our structured linkers to the typical unstructured Gly-Ser linkers 
commonly used in protein design and engineering, we constructed, expressed, and 
purified eight IgG-(G4S)n variants. In contrast to the SEC profiles for the structured linker 
constructs, there were only small differences in elution volume for the IgGs including 
Gly4Ser linkers (L17 – L24). These differences often did not correlate with molecular 
mass as IgG-GS9, the IgG with the largest linker, eluted at approximately the same 
volume as wildtype IgG, which eluted after some of the constructs with shorter linkers 
(Figure 3).  
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Unlike proline-rich linkers and rigid linkers consisting of natural protein domains 
such as β2m, Gly4Ser linkers that did not contain a potential N-linked glycosylation site 
did not detectably increase the hydrodynamic radius of the IgG, suggesting that these 
linkers did not provide increased separation between the Fab and Fc domains (Figure 4). 
These results were consistent with the observation that Gly4Ser linkers did not provide 
significant separation between the joined domains in the context of other fusion proteins 
(Arai et al., 2001). Measurements of IgG-GS9 from two preparations showed only a 
slight difference in RH (0.1 nm), indicating that these measurements were quite robust 
and relatively small differences in RH may be significant. 
Optimized linkers are important for the construction of multifunctional fusion 
proteins, in terms of both immunogenicity and conformational dynamics. Different linker 
compositions can alter their effective length and rigidity. In this study, we used SEC and 
DLS to characterize designed linkers in the context of an IgG to determine whether these 
linkers could increase the distance between the antigen binding fragments. We found that 
flexible Gly4Ser linkers did not increase the RH of fused reagents, suggesting that these 
linkers did not provide increased separation between the Fab and Fc domains even with 
up to nine Gly4Ser repeats, in agreement with previous studies (Arai et al., 2001). By 
contrast, the structured helical cTPR linkers provided consistent increases in RH and SEC 
elution volume as a function of repeat number, indicating that these repeats can be used 
to increase the separation distance between two proteins or domains. Our other designed 
linkers, including those containing naturally occurring proteins such as β2m and ZAG, 
yielded increases in the observed RH by as much as twice the RH of a naturally-occurring 
IgG. The systematic characterization of the lengths and rigidity properties of the 
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structured protein linkers and a range of (Gly4Ser)n linkers reported here provide a new 
set of tools to the available linker repertoire for engineering fusion proteins. 
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Table 2. Complete sequences of designed linkers. Linkers L1-L21 were inserted into 
the hinge region of b12 IgG between residues His235 and Thr236. Linkers L22-L24 were 
inserted into the same hinge between residues Cys231 and Asp232. 
Linker	   Name	   Complete	  Sequence	  
L1	   GPcPcPc	   AGSGGSGGSGGSPVPSTPPTNSSSTPPTPSPSPVPSTPPTNSSSTPPTPSPSPVPSTPPTNSSSTPPTPSPSAS	  
L2	   GPPcP	   AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSPVPSTPPTNSSSTPPTPSPSPVPSTPPTPSPSTPPTPSPSAS	  
L3	   GPGcP	   AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSGGSGNSSGSGGSPVPSTPPTPSPSTPPTPSPSAS	  
L4	   GPPP	   AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSPVPSTPPTPSPSTPPTPSPSPVPSTPPTPSPSTPPTPSPSAS	  
L5	   GPbP	  
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYSRHPAENGKSNFLNCY
VSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHV
TLSQPKIVKWDRDPVPSTPPTPSPSTPPTPSPSAS	  
L6	   GPbG	  
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYSRHPAENGKSNFLNCY
VSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHV
TLSQPKIVKWDRDGGSGGSGGSGGSAS	  
L7	   PbGbG	  
AGPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEV
DLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKW
DRDGGSGGSGGSGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKN
GERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDGG
SGGSGGSGAS	  
L8	   GPbGbP	  
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSIQRTPKIQVYSRHPAENGKSNFLNCY
VSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHV
TLSQPKIVKWDRDGGSGGSGGSGGSIQRTPKIQVYSRHPAENGKSNFLNCYVSGFH
PSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQP
KIVKWDRDPVPSTPPTPSPSTPPTPSPSAS	  
L9	   GPUG	  
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSQIFVKTLTGKTITLEVEPSDTIENVKAK
IQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGGGSGGSGGSG
GSAS	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L10	   GPZP	  
AGSGGSGGSGGSPVPSTPPTPSPSTPPTPSPSDGRYSLTYIYTGLSKHVEDVPAFQAL
GSLNDLQFFRYNSKDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMETLKDI
VEYYNDSNGSHVLQGRFGCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPA
AQITKQKWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSHQAP
GEKKKLKCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVVAVPP
QDTAPYSCHVQHSSLAQPLVVPWEASPVPSTPPTPSPSTPPTPSAS	  
L11	   GGZGZP	  
AGSGGSGGSGGSGGSGGSGGSGGSDGRYSLTYIYTGLSKHVEDVPAFQALGSLNDL
QFFRYNSKDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYND
SNGSHVLQGRFGCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQ
KWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSHQAPGEKKKL
KCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAP
YSCHVQHSSLAQPLVVPWEASGGSGGSGGSGGSDGRYSLTYIYTGLSKHVEDVPAF
QALGSLNDLQFFRYNSKDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMET
LKDIVEYYNDSNGSHVLQGRFGCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPF
DPAAQITKQKWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSH
QAPGEKKKLKCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVV
AVPPQDTAPYSCHVQHSSLAQPLVVPWEASPVPSTPPTPSPSTPPTPSPSAS	  
L12	   GcGcP	   AGSGNSSGSGGSGGSGNSSGSGGSPVPSTPPTPSPSTPPTPSPSAS	  
L13	   cTPR3	  
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAE
AWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIE
DYQKALELDPNNLQRSAGGGGSGGGGSGGGGAS	  
L14	   cTPR6	  
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAE
AWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIE
DYQKALELDPNNLQAEAWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNL
GNAYYKQGDYQKAIEYYQKALELDPNNAKAWYRRGNAYYKQGDYQKAIEDYQKAL
ELDPNNRSRSAGGGGSGGGGSGGGGAS	  
L15	   cTPR9	  
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAE
AWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIE
DYQKALELDPNNLQAEAWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNL
GNAYYKQGDYQKAIEYYQKALELDPNNAKAWYRRGNAYYKQGDYQKAIEDYQKAL
ELDPNNRSAEAWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYK
QGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNN
LQRSAGGGGSGGGGSGGGGAS	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L16	   cTPR12	  
KLSGGGGSGGGGSGGGGSAEAWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAE
AWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIE
DYQKALELDPNNLQAEAWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNL
GNAYYKQGDYQKAIEYYQKALELDPNNAKAWYRRGNAYYKQGDYQKAIEDYQKAL
ELDPNNRSAEAWYNLGNAYYKQGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYK
QGDYQKAIEYYQKALELDPNNAEAWYNLGNAYYKQGDYQKAIEDYQKALELDPNN
LQAEAWKNLGNAYYKQGDYQKAIEYYQKALELDPNNASAWYNLGNAYYKQGDYQ
KAIEYYQKALELDPNNAKAWYRRGNAYYKQGDYQKAIEDYQKALELDPNNRSAGG
GGSGGGGSGGGGAS	  
L17	   GS1	   GGGGSAS	  
L18	   GS2	   GGGGSGGGGSAS	  
L19	   GS3	   GGGGSGGGGSGGGGSAS	  
L20	   GS5	   GGGGSGGGGSGGGGSGGGGSGGGGSAS	  
L21	   GS6	   GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS	  
L22	   GS7	   AGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS	  
L23	   GS8	   AGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS	  
L24	   GS9	   AGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSAS	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Chapter Five 
The use of cancer therapeutic technology to inspire next generation HIV reagents. 
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This chapter describes the rationale and preliminary data for the use of two different 
classes of immunotherapies typically used as cancer treatments to inspire new anti-HIV 
reagents. This work was conceived by myself, and experiments were done in 
collaboration with post-doc Alok Joglekar, and Caltech undergrad Erin Isaza.  Technical 
support was provided by Devashish Joshi, Luke Klosterman, and  Priyanthi 
Gnanapragasam.    
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Introduction 
 
 The use of combination highly active antiretroviral therapy (HAART) has 
significantly reduced the morbidity and mortality associated with HIV-1 infection and 
AIDS. Consistent and prolonged use of HAART has enabled patients to have a longer life 
expectancy (ARTCC, 2008). Despite this, when patients fail to comply with their ART 
regimen, the virus is able to replicate and drug resistant mutant variants develop (Dybul 
et al., 2002). HIV-infected individuals must commit to lifelong anti-retroviral treatment 
in order to keep this from occurring. In order to develop a curative therapeutic, it is 
important to understand the harbors of the virus that lie while under ART treatment. One 
source of viral rebound is the CD4+ memory T cell (Churchill et al., 2016; Dahabieh et 
al., 2015).  
 Early on in an HIV infection, the  CCR5 tropic HIV virus targets the memory 
class of CD4+ T cells; these cells are long lived and can lie dormant while containing an 
integrated HIV provirus (Churchill et al., 2016; Dahabieh et al., 2015; Porter et al., 2011). 
Despite harboring the latent provirus, they do not express viral proteins or RNA to 
detectable levels, rendering them invisible to both ART therapy and the immune system 
(Marsden and Zack, 2015). Under incomplete compliance of ART therapy, this reservoir 
of HIV infected cells can become activated and produce new multidrug resistant virions. 
Thus, no HIV cure can be developed without complete eradication of the latent reservoir. 
Targeting the latent reservoir with the anti-cancer therapy anti-CTLA-4 was found to be 
promising, reducing the viral rebound frequency, but unfortunately it was unable to show 
complete eradication (Halper-Stromberg et al., 2014). Taking into account the current 
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efforts to purge the latent reservoir, the inability to control patient compliance and the 
insurmountable costs associated with HIV healthcare, it is necessary to explore non-
traditional approaches to attempt to cure HIV infection.  
 Within the past thirty years, there has been enormous advances in cancer 
immunotherapy (Topalian et al., 2011). Many cancer immunotherapeutic methods seek to 
block regulatory pathways found to inhibit clearance of the tumor, or boost the 
endogenous immune response. Many of these approaches have been found to lead to 
successful remission of the cancer (Topalian et al., 2011). Since many of the fundamental 
mechanisms of immune escape are shared by HIV and cancer, HIV immunotherapy 
attempts can take a cue from the recent advances in cancer therapy in hopes of seeing 
similar advancements in HIV+ treatment. As the two fields emerge, we hope to find more 
effective reagents towards a functional cure for HIV.  
 In the following chapter, we will discuss preliminary data for ongoing 
investigations of two different anti-HIV therapies utilizing both our knowledge of 
broadly neutralizing antibodies and the successes in current cancer immunotherapies.  
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Part One: Use of Chimeric Antigen Receptors against HIV  
 Adoptive cell transfer and gene therapy approaches to modify T-cell specificity 
have shown to be effective in modulating the immune response against both cancer and  
viruses (Barrett et al., 2014; Kalos et al., 2011; Leen et al., 2006; Maude et al., 2014; 
Porter et al., 2011). The use of chimeric antigen receptors (CARs) is one such approach 
where an antigen binding motif, an antigen binding site of an antibody for example, is 
linked to the intracellular domain of the CD3-ζ chain (Roberts et al., 1994). The utility of 
this design is that it allows for CD8+ t-cell recognition without the restriction of the 
MHC. Typically, CARs are signal chain constructs composed of the variable domains of 
an IgG fused (scFv) either to a TCR constant domain or a T-receptor domain (Kalos et 
al., 2011). These reagents are beneficial because they allow for the specificity of an 
antibody with the cytotoxic effects of a T-cell. In addition, there has been success in 
optimizing the activation potential of CARs, with second and third  generation CARs 
developed to include signaling molecules from costimulatory receptors such as CD28 or 
4-1BB (Zhong et al., 2010). 
 Particularly encouraging are recent clinical trials for patients suffering from B-cell 
chronic lymphocytic leukemia (B-CLL) using a CAR containing a scFv against CD19 
fused to TNF receptor, CD137 and CD3-ζ chain (Kalos et al., 2011). In this study, 
patients achieved complete remission of the leukemia (Kalos et al., 2011). However 
promising, the choice of antibody and target, as well as the addition of costimulatory 
modules, needs to be carefully chosen as it could lead to over activation and have adverse 
affects due to cytokine storms (Büning et al., 2010). 
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 The notion of employing chimeric antigen receptors against HIV is not a new one.  
Prior to the discovery of HAART therapy, early successes in chimeric antigen receptors 
with cancer led HIV researchers to explore this as a potential treatment. Preliminary 
studies testing the efficacy of gene therapy against HIV used primary CD8+ T-cells 
stably expressing a CD4 molecule fused to a CD3-ζ chain (CD4ζ) showed specific lysis 
of a cell line expressing HIV env trimer (Roberts et al., 1994). Following this result three 
clinical trials testing the efficacy of the CD4ζ CAR expressed in autologous CD4+ and 
CD8+ T-cells from acute viremia or late stage chronic HIV infected patients on ART 
therapy (Scholler et al., 2012).  In all three clinical trials, there was no significant 
difference in HIV viral load compared to the control placebo group (Deeks et al., 2002; 
Mitsuyasu et al., 2000). An additional concern with such CARs is whether the expression 
of CD4 on the surface of CD8+ T-cells would provide an additional target for HIV 
infection.  
 Despite disappointing effects on HIV clearance, these clinical trials provided data 
on the safety and expression of CD4ζ CARs in patients. In a longitudinal study following 
the patients from the CD4ζ CAR clinical trials determined that there were no significant 
adverse effects due to gene transfer with retroviral vectors over the ten years the patients 
have been monitored. Importantly, long term persistence of the functional CD4ζ CAR T-
cells were observed with a half-life over 16 years (Scholler et al., 2012). These data 
suggest that with a more promising HIV binding motif, safe long term expression of 
functional chimeric antigen receptors is attainable.   
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 CD4ζ CARs has resurfaced in two new studies showing greater success (Liu et 
al., 2015; Zhen et al., 2015). In the first study by Zhen et al., CD4ζ CAR was used in 
combination with two  small hairpin RNA molecule specific for CCR5 and the LTR 
sequence of HIV and shown to suppress HIV replication in a humanized mouse model 
(Zhen et al., 2015). These “Triple CARs” when transduced into CD8+ T-cells, resulted in 
cells expressing CD4 and reduced CCR5 expression (Zhen et al., 2015). As expected, 
however, these cells were more susceptible to HIV infection compared to un-transduced 
cells. Interestingly, in the same study, when the TRIPLE CAR was transduced into 
hematopoietic cells, expression of the CAR was found on all lymphocytes lineages as 
well as on myeloid cells. Within the T-cell population, the transduction of the triple CAR 
resulted in downregulation of the endogenous TCR (Zhen et al., 2015). However, unlike 
the Roberts et al. study, the TRIPLE CAR showed moderate suppression of HIV in vivo 
(Zhen et al., 2015). While promising, the use of CD4 in the TRIPLE CAR continues to be 
problematic, by providing CD8+ T-cells as an additional target for HIV. Not discussed 
however, is whether the NK cell population was also susceptible to infection, CCR5 and 
CXCR4 are both found on NK cells (Berahovich et al., 2006).  
 A second study by Liu and colleagues, designed a bispecific CD4 based CAR 
containing the domains 1-2 of CD4 linked to the scFv of a CD4i antibody, 17b fused to 
the CD28 transmembrane domain and CD3ζ. Similarly to the Richards and Zhen studies, 
the CD4-17b CAR can successfully be detected on CD8+ T-cells, and demonstrated 
specific lysis of cells with HIV Env surface expression, and suppression of HIV spread in 
an in-vitro PBMC assay. Surprisingly, Liu et al. report that unlike the previous two 
studies, the HIV-1 infection was not observed on CD8+ T-cells transduced with the CD4-
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17b CAR (Liu et al., 2015). However, careful examination of the flow cytometry results 
in the paper (Liu et al., 2015) show potential improper gating of the cell populations may 
have led to misreporting  of the result. While it appears to be reduced infectivity 
compared to the CD4 CAR, a population of infected cells are present in the CD4-17b 
CAR that is not seen in the un-transduced control cells.  
 While promising, all three studies show a need for a redesign of the current CARs 
against HIV. Here I will describe preliminary data of a chimeric antigen receptor utilizing 
broadly neutralizing antibodies (BnAb) instead of CD4 as the HIV target binding motif.  
 
Materials and Methods 
Construction of chimeric antigen receptor 
Genes encoding the hinge, transmembrane and cytoplasmic signaling domain of CD28 
followed by 41-BB domain and CD3 zeta chains were synthesized (Figure 1). Broadly 
neutralizing CD4bs J3 camelid VHH (McCoy et al., 2012) linked by a (gly4ser)7 linker 
to an IgG Fc (CH2-CH3) containing G236R D265A L328R mutation remove FcγR 
function (Bournazos et al., 2014; Horton et al., 2008).  The CAR gene was subcloned into 
both the mammalian expression plasmid PTT5 (NRC Biotechnology Research Institute), 
and a third generation lentiviral plasmid, pHAGE2 (Hao and Baltimore, 2009), 
previously described. The gene encoding the extracellular domain J3VHH-(gly4ser)7-Fc 
G236R D265A L328R was subcloned into PTT5 for initial characterization.  
 
Protein expression and purification. J3VHH-(Gly4Ser)7-Fc G236R L328R was 
expressed transiently in suspension HEK 293-6E cells (NRC Biotechnology Research 
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Institute) using 25 kDa linear polyethylenimine (PEI) (Polysciences) for transfection as 
described (8). The supernatants were passed over protein A resin (Thermo Fisher 
Scientific), eluted using pH 3.0 citrate buffer, and then immediately neutralized and 
subsequently purified by size exclusion chromatography using a Superdex 200 10/300 
GL column. 
In vitro neutralization assays  
A previously-described pseudovirus neutralization assay was used to evaluate the 
neutralization potencies of the reagents (Montefiori, 1996; Montefiori et al., 2001). 
Neutralization assays were performed in-house using the same protocol (Montefiori, 
1996; Montefiori et al., 2001). In brief, pseudoviruses were generated by cotransfection 
of HEK 293T cells with an HIV-1 Env expression plasmid and a replication-defective 
backbone plasmid. Neutralization was determined by measuring the decrease in 
luciferase reporter gene expression in the presence of a potential inhibitor following a 
single round of pseudovirus infection in TZM-bl cells. Nonlinear regression analysis was 
used to calculate the concentrations at which half-maximal inhibition was observed (IC50 
values).  
Detection of CAR on transfected 293T cells.  
 J3-Fc CAR in PTT5 was transfected into HEK293T cells (Invitrogen) using 
lipofectamine (Invitrogen) as recommended.  Three days’ post transfection, CAR cells 
and mock transfected cells were harvested and stained with FITC-labeled anti-Fc 
antibody and run on flow cytometry.   
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Results 
Design of BnAb chimeric antigen receptor 
 The VH domain of  J3 (J3VHH), a CD4 binding site camelid antibody isolated 
from llamas shown to be broadly neutralizing against a large panel of HIV-1 isolates  
(McCoy et al., 2012), was chosen as the antigen binding motif for our first CAR design. 
The unique structure of camelid antibodies (McCoy et al., 2012) (Figure 1) made J3 an 
ideal choice, and the lack of light chain allowed for simple design without the need to use 
a scFv format. Unlike the previous versions of anti-HIV CARs (Liu et al., 2015; Roberts 
et al., 1994; Zhen et al., 2015), J3VHH is linked to an IgG1 Fc domain (Figure 1) to 
allow for efficient dimerization of CD28 and CD3 zeta chains, thereby leading to 
enhanced activation of the CD8+ T-cell and lysis of target cell (Lazar-Molnar et al., 
2006; Rutledge et al., 1992).  
 Genes encoding the hinge, transmembrane, and cytoplasmic signaling domain of 
CD28 followed by 4-1BB domain and CD3 zeta chains were synthesized (Figure 1). 
Broadly neutralizing CD4bs J3 camelid VHH (McCoy et al., 2012) linked by a 
(Gly4Ser)7 linker to an IgG Fc (CH2-CH3) containing G236R L328R mutation remove 
FcγR function (Horton et al., 2008).  The CAR gene was subcloned into both the 
mammalian expression plasmid PTT5 (NRC Biotechnology Research Institute), and a 
third generation lentiviral plasmid, pHAGE2 (Hao and Baltimore, 2009) previously 
described.  
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Figure 1. Design of Chimeric Antigen Receptor reagents. Organization of gene 
construction is shown by linear figure. Schematic under gene represents imagined protein 
construct. TM: Transmembrane domain.    
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J3VHH-(G4S)7-Fc Neutralizes HIV-1 strain YU2 in vitro 
 The extracellular domain of a chimeric antigen receptor is important for effective 
recognition of the antigen (Topalian et al., 2011). As a surrogate for a traditional binding 
assay, the soluble version of our CAR, containing J3VHH-(Gly4Ser)7-Fc, was tested it in 
an in-vitro neutralization assay to assess binding ability to HIV-1 isolate YU2. As 
anticipated, J3VHH-(Gly4Ser)7-Fc neutralized YU2 with an IC50 of <0.05 ug/ml (Figure 
2).  We suspect that this will lead to a highly specific potent CAR T-cell.  
 
Detection of CAR on transfected 293T cells.  
 J3-Fc CAR in PTT5 was transfected into HEK293T cells (Invitrogen) using 
lipofectamine (Invitrogen) as recommended.  Three days post transfection, CAR cells and 
mock transfected cells were harvested and stained with FITC-labeled anti-Fc antibody 
and run on flow cytometry.  (Figure 2). Flow cytometry suggests efficient surface 
expression of the CAR in vitro; however, specificity of fully assembled CAR has yet to 
be tested. Current studies are underway to test CAR T-Cell binding to a fluorescently 
labelled soluble gp120.  
 
Discussion and Future Directions  
 Thus far, we designed, cloned, and expressed a chimeric antigen receptor 
containing a broadly neutralizing antibody J3, as the antigen binding motif. We have 
demonstrated that the extracellular portion of the CAR, J3VHH-(Gly4Ser)7-Fc, can 
effectively neutralize HIV-1, and the CAR can be expressed and detected as a surface 
receptor on transfected 293T cells (Figure 2). The use of a broadly neutralizing antibody  
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that can bind HIV instead of CD4 was a purposeful attempt to reduce potential HIV 
infection of the CAR T-Cell. Future experiments using lentivirus transduced CD8+ T-
cells will elucidate this further. Additional experiments include co-culturing experiments 
of HIV env expressing 293T cells with transduced J3-Fc CAR cells to assay CAR 
mediated lysis of infected cells. Future experiments could also include the transduction of 
hematopoietic stem cells and humanized mouse models.  
 Since most antigens expressed by human cancers are non-mutated surface 
receptors also found on normal cells (Houghton and Guevara-Patino, 2004), such as 
CD19 on B-cells (Porter et al., 2011), the consequence of an effective CAR therapy 
includes the elimination of all cells expressing the receptor. In the case of B-CLL, the 
CAR expressing anti-CD19 leads to the clearance of both leukemic and healthy B-cells in 
the patient (Barrett et al., 2014), leaving them with a reduced to no humoral immune 
system for the lifetime of the transduced cell. This makes chimeric antigen receptors an 
ideal candidate for HIV immunotherapy. Unlike in the case of B-CLL, HIV infected 
CD4+ T-cells express the HIV envelope trimer of its surface, making them easily 
decipherable from their uninfected counterparts (Ganser-Pornillos et al., 2008). Further, 
the use of BnAb CARs instead of previous CD4ζ iterations should avoid CAR mediated 
HIV infection (Liu et al., 2015; Zhen et al., 2015); however, this remains to be proven.
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Figure 2. J3-Fc CAR can neutralize HIV in-vitro and is presented on the surface of 
transfected cells. Neutralization assay against YU-2 HIV Isolate showed potent 
neutralization with an IC50 of 0.035 ug/ml. J3-Fc CAR can be detected on the surface of 
293T cells transfected with the CAR plasmid.  
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Part two: Elimination of latent reservoir using bispecific T-cell Engagers: BnAb 
BiTEremixes  
 Bi-specific antibody reagents have shown to be effective at redirecting T-cell 
targeting to tumor cells (Baeuerle and Reinhardt, 2009; Rossi et al., 2014; Wu et al., 
2015).  First described in 1985, hybrid antibodies were IgG based bispecific antibodies 
where one arm was targeted to the TCR of a CD8+ T-cell, while the other specific for an 
antigen located on the tumor cell but not the T-cell, was found to induce specific lysis of 
the target cell (Staerz et al., 1985). Currently, scFv bispecific reagents of a similar nature 
using anti-CD3 to stimulate the T-cell response has been used in clinical trials against 
various cancers at low effector cell: target ratios (Baeuerle and Reinhardt, 2009). These 
reagents, known as bispecific T-cell engagers (BiTEs) such as Blinatumomab (a BiTE 
specific for CD3 and CD19), have been assessed in  Phase II clinical trials with great 
success in B-cell lymphoma (Baeuerle and Reinhardt, 2009); however, due to the 
extremely short half-life of these reagents, the BiTE was delivered through continuous 
intravenous infusion over a six week period. In some cases up to five cycles were 
delivered to a given patient (Baeuerle and Reinhardt, 2009).  
   Recently, it was considered whether the bispecific T-cell engagers could 
potentially activate the latent reservoir of HIV infected cells. Nabel and colleagues 
designed a bispecific a potent broadly neutralizing antibody Fab against the CD4 binding 
site linked to a scFv version anti-CD3 antibody, OKT3 (Pegu et al., 2015). A clonal 
variant of NIH-45-46,  first discovered at Rockefeller University and later improved by 
introducing a G54W mutation within the heavy chain engineered in the Bjorkman Lab 
(Diskin et al., 2011b; Scheid et al., 2011a), was used in this study, and also contained the 
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G54W mutation known as VRC07 (Pegu et al., 2015). The reagent works two fold, first 
binding with the anti-CD3 arm, which allows activation of the latently infected memory 
T-cells. Next, a second BiTE binds to a nearby CD8+ T-cell, activating it, and then using 
the BnAb arm to tether it to newly activated memory cells. These reagents were also 
validated for safety in a non-human primate model.  
  While this reagent showed promise, with moderate capacity to activate latently 
infected T-cells and specificity to HIV env, it too has limitations based on its short half-
life in vivo. Here I describe preliminary data for a new brand of BiTE reagents known as 
BiTEremixes, based on the earliest hybrid antibodies, that has multiple specificities and 
can target CD8+ T-cells with CD3 activation to infected cells with the broadly 
neutralizing antibody arm. Through the addition of an Fc we expect increased half-life 
compared to the scFv and Fab Bispecific iterations. We hope to show in on-going 
experiments its ability to activate the latent reservoir through CD3 activation on memory 
CD4+ T-cells. Next generation BiTEremixes will include NK cell activation through 
CD16 stimulation (Murphy et al., 2012).  
 
Materials and Methods: 
Cloning of desired BiTEremix constructs  
Genes encoding the variable regions (VH and VL) of the murine OKT3 antibody were 
synthesized (Integrated DNA Technologies) based on sequences deposited to Genbank, 
accession numbers A22261 and A22259, respectively. Intact IgG genes were constructed 
by cloning the relevant variable domain on either human  heavy or light chain via Gibson 
cloning techniques, forming murine/human chimeric OKT3 antibody. Similar methods 
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were used to clone IgG1 variants of broadly neutralizing antibodies 3BNC117, 
PGDM1400, 10-1074, 8ANC195, and J3. Every F405L IgG was mutated further to 
include a StrepII Tag, and K409R mutated to include a 6x his tag.  The heavy chain of the 
chimera was mutated to include a single amino acid K409R mutation and a C-terminus 
6x His Tag or F405L mutation with C-terminus StrepII tag through site directed 
mutagenesis to allow for the ability to produce heterodimers mimicking natural IgG4 Fab 
arm swapping, through a previously described technique called controlled Fab Arm 
Exchange (FAE) (Labrijn et al., 2013; Labrijn et al., 2014). Similar to the CAR design, 
QuikChange mutagenesis was performed on both heavy chain constructs to introduce 
G236R D265A L328R mutations and remove the FcγR function (Bournazos et al., 2014; 
Horton et al., 2008).  
 
Protein expression and purification. Proteins were expressed transiently in suspension 
HEK 293-6E cells (NRC Biotechnology Research Institute) using 25 kDa linear 
polyethylenimine (PEI) (Polysciences) for transfection as described (8). When expressing 
heterodimeric constructs, the heavy chain (HC) and light chain (LC) plasmids were 
mixed at a 1:1 ratio by mass. Cell culture supernatants were collected six days post-
transfection. All constructs supernatants were passed over protein A resin (Thermo Fisher 
Scientific), eluted using pH 3.0 citrate buffer, and then immediately neutralized. All 
reagents were purified by size exclusion chromatography using a Superdex 200 10/300 
GL column.  
2-Mercaptoethylamine–Mediated Controlled Fab-arm Exchange in Vitro. Equimolar 
amounts of OKT3 IgG1-F405L StrepII and BnAb IgG1-K409R His antibodies were 
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mixed and incubated with 2-mercaptoethylamine (2-MEA; Sigma) at a final 
concentration of 1 mg/mL per antibody. The final concentration of 2-MEA was 25-75 
mM (the mixtures were typically incubated for 90 min at 37 °C or 5 h at 31 °C). 
Depending on the reaction volume, 2-MEA was removed by buffer-exchanging against 
PBS using Millipore 15ml 10-kDa MWCO conical concentrators, or Zebas desalting 
columns (1–5 mL; 7-kDa MWCO; Pierce). Samples were stored overnight at 4 °C to 
allow reoxidation of the disulfide bonds to occur. 
Protein expression and purification of FAE heterodimers  
Post reoxidation, FAE were purified via a dual tag purification technique to ensure 100% 
heterodimer in purified sample. His-Tagged proteins were purified using Ni-NTA 
chromatography and eluted using 300 mM imidazole. Post Ni-NTA purification proteins 
were purified over StrepII column (GE Healthcare) and eluted with 2.5mM desthiobiotin 
(sigma). Purified heterodimers are confirmed via size exclusion chromatography and 
SDS-PAGE analysis.  
In-vitro neutralization assays 
To ensure BnAb arm specificity in-vitro neutralization assays were  performed as 
discussed earlier in this chapter.  
Flow Cytometry 
To confirm specificity of the OKT3 arm, T-cells were stained using a primary of the 
heterodimer OKT3/BnAb at a concentration of 1ug/ml for 1 hr. at 25°C. Cells were 
washed with PBS five times and secondary APC-labelled anti-human IgG.  
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Cellular Cytotoxicity Assay 
 The capacity to induce effector cell-dependent lysis of HIV infected cells was 
evaluated by the assay depicted in Figure 5. In Brief, GXR cells, a CD4 T-lymphoblast 
stable cell line immortalized with a GFP under a HIV LTR inducible promoter, are 
infected with replication competent HIV strains NL4-3 or YU2. When an active infection 
can be measured of over 25% infected cells, infected cells are split into a 24-well plate 
and conditions containing various BiTEremix reagents are added  in the presence and 
absence of  PBMCs enriched for CD8+ T-cells. The cultures are monitored for the % 
GFP every 24 hours for 3-5 days (Figure 6).  
 Additional experiments using suspension 293 6E-cells expressing HIV envelope-
GFP instead of live HIV, as well as the use of a latenting infected cell line to see if the 
BiTEremix can activate the latent reservoir, are currently underway.   
 
Results and Conclusions 
 
Heterodimers containing Broadly Neutralizing Antibodies and OKT3 were 
efficiently produced through cFAE.  
Heterodimer BiTEremix reagents containing one arm of OKT3 chimeric IgG of either 
3BNC117, J3, 8ANC195, G52k5, PGDM1400, and 10-1074 IgG, See Schematic Fig 3.  
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Figure 3. First and Second Generation BiTEremix reagents  
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These reagents were capable of neutralizing HIV and also showed CD3 specificity 
through Flow cytometry (Figure 4). The Fc regions that were mutated have either a 
F405L or K409R mutation, which under reducing conditions allows IgG1 based reagents 
to undergo IgG4 like arm exchange (Labrijn et al., 2013; Labrijn et al., 2014; Rispens et 
al., 2013; Schuurman et al., 2012) in the BiTEremix reagents. All cFAE IgGs are first 
expressed as homodimers and purified.  Additional mutations in all of the cFAE 
BiTEremixes were made to introduce G236R L328R mutation remove FcγR 
function(Bournazos et al., 2014; Horton et al., 2008). We believe that this mutation 
would be necessary so as to not initiate Fc mediated antibody dependent cell cytotoxicity 
against the CD8+ T-cells.   
 Next generation BiTEremixes will include domains that can induce NK cell 
activation as well as other known latent reservoir activators such as the cancer 
immunotherapy, anti-CTLA-4, shown to block inhibitory signals on T-lymphocytes and 
activate the latent reservoir in an HIV humanized mouse model (Halper-Stromberg et al., 
2014) (Figure 3). However, over-activation of lymphocytes could cause adverse effects 
and should be thoroughly investigated prior to therapy (Topalian et al., 2011). 
OKT3/J3 was efficiently able to reduce HIV infection after 48 hours in culture 
 Due to a limitation of resources, thus far only one reagent, OKT3/J3 BiTEremix, 
has been tested in cytotoxicity assay. When compared to controls, OKT3/J3BiTEremix in 
the presence of CD8+ T-cells effectively showed a reduced HIV infection at 48-hour time 
point (Figures 5 and 6). Current efforts to repeat this experiment and test 293 expressing 
gp160 cell line are underway.  
	  	  
201	  
Put together, these preliminary data suggest that the OKT3/BnAb BiTEremix reagents are 
capable of recognizing both CD3 on the CD8+ T-cell as well as the HIV env on the 
surface of the infected cell.  
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Figure 4. a. Neutralization data shows BiTEremix reagent is capable of neutralizing HIV 
with only one arm specific for the virus. As expected, OKT3 antibody arm shows no 
protection against HIV in the absence of CD8+ T-cells. Panel b. shows BiTEremix 
staining of SupT1 –T-lymphoblast cell line. Unshaded trace shows unstained SupT1 
cells. Gray trace are cells stained with BiTEremix 
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Figure 5. Experimental Set up for in-vitro Co-culture assays to test BiTEremix reagents.  
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Figure 6. Co-culture experiments with HIV infected cells and OKT3/J3BiTEremix in the 
presence and absence of effect T-cells  
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Appendix A 
Modifications to AAV viral vector to enhance transgene expression and to adhere to FDA 
regulations 
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 This appendix describes the modification of Adeno-associated virus in order to 
address the difficulties of limited transgene size as well as potential oncogenic traits of 
the vehicle. The woodchuck post-transcriptional regulatory element (WPRE) in the viral 
vector has been implicated in oncogenesis. Modification of this element will aid in 
addressing both concerns. My contribution to this work was the design and 
characterization of the modified AAV vectors. This was done in the Baltimore Lab with 
helpful discussions with Alex Balazs.   
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Abstract: 
Adeno-associated virus has been employed as a vehicle to deliver the anti-HIV antibodies 
in a current and future clinical trials. As recombinant AAV (rAAV) viral vectors become 
increasingly applied to human clinical trials, it is critical to continually evaluate the risks 
and limitations for its use. The difficulty in developing viral vectors for treatment is in 
being able to achieve the expression level and safety required in the clinical realm. Here I 
show work I have done to  engineer novel rAAV serotype 8 viral vectors to address two 
major limitations that can affect the delivery of anti-HIV reagents in future clinical trials: 
the limited packaging capacity of the virus, and the potential immunogenicity of the 
virus. The woodchuck post-transcriptional regulatory element (WPRE) in the viral vector 
has been implicated in oncogenesis. Modification of this element will aid in addressing 
both concerns. Currently, this engineered improvements has been incorporated into an 
AAV viral vector being used for a clinical trial in 2016.   
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Introduction 
 In the past 10 years, the use of Adeno-Associated virus (AAV) vectors as a 
vehicle for gene therapy has rapidly increased (McLaughlin et al., 1988; Schnepp et al., 
2009; Schultz and Chamberlain, 2008). Lack of pathogenicity makes AAV an attractive 
candidate for gene therapy applications in humans (Schnepp et al., 2009) . To date there 
are over twelve human serotypes of AAV and over one hundred non-human primate 
serotypes identified (Schnepp et al., 2009). AAV is a small non-enveloped virus 
belonging to the genus Dependovirus and requires genes of a helper virus such as 
adenovirus or herpes virus in order to propagate (Schultz and Chamberlain, 2008). The 
4.7 kilobase DNA genome contains two open reading frames known as the cap region 
and the rep region (Schultz and Chamberlain, 2008). The cap region codes for three 
different proteins (VP1, VP2, and VP3), which comprise the icosahedral viral capsid and 
the rep region encodes for four proteins important to the replication of the virus (Schultz 
and Chamberlain, 2008). Flanking the genome are inverted terminal repeats or ITRs, 
which are required for the packaging of viral DNA into the capsid (McLaughlin et al., 
1988) (Figure 1).  
 
 Adeno-associated viruses can be engineered for gene therapy where four separate 
plasmids contain ITRs flanking the gene of interest cassette, the cap, and rep genes, and 
adenoviral helper genes are co-transfected together to produce a viral vector. One 
limitation to AAV viral vectors is the restricted genome capacity of approximately five 
kilobases, which must include the promoter, gene of interest, and any enhancer elements 
desired (Grimm and Kay, 2003). Another limitation to AAV viral vectors is its potential 
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to exhibit oncogenic or immunogenic properties. Host immune responses can be 
generated against rAAV vector and its encoded transgene; the magnitude of these 
responses is dependent upon the transgene and serotype administered (Grimm and Kay, 
2003) (Figure 1). 
 
 Previous research in the Baltimore lab revealed that recombinant adeno-
associated virus (rAAV) expressing known broadly neutralizing antibodies can protect 
against HIV infection in a humanized mouse model (Balazs et al., 2013; Balazs et al., 
2012; Balazs et al., 2014). As recombinant AAV viral vectors become increasingly 
applied to human clinical trials, it is critical to continually evaluate the risks and 
limitations for its use. Here I engineered rAAV serotype 8 viral vectors to address two 
major limitations for gene therapy applications: the limited packaging capacity of the 
virus, and the potential immunogenicity of the virus.  
 
Modification of AAV viral vector  
AAV has recently gained popularity as a viral vector for gene therapy because of its 
apparent lack of pathogenicity, ease in transducing various cell types, and the simplicity 
of its viral genome (Figure 1). The difficulty in developing viral vectors as vehicles for 
treatment is in being able to achieve the expectations required to bring the technology 
into clinical trials. An efficacious viral vector must be produced in high titers, exhibit 
long term expression of the transgene at high levels, cause little to no immune response, 
and results in minimal toxicity to the patient post transduction. As recombinant AAV 
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viral vectors are increasingly applied in human clinical trials, it is imperative to 
continually evaluate the risks of their use.    
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Figure 1.  Adeno-associated virus and AAV viral vectors.  
AAV is a small non-enveloped virus 20nm in diameter  belonging to the genus 
Dependovirus. In order to propagate the virus requires genes of a helper virus such as 
adenovirus or herpes virus. The 4.7 kb genome is composed of the Rep and Cap genes 
flanked by ITR on either end. AAV gene therapy system requires a three plasmid system 
to form functional virions, 1. Plasmid containing therapeutic gene of interest is flanked 
by the ITRs; 2. Plasmid containing the  Rep and Cap genes; 3. Replication defective 
adenovirus for helper genes. The therapeutic cassette is shown above. Image courtesy of 
Alex Balazs.  
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Results  
Modification of AAV to increase transgene cassette size 
 A significant limitation of AAV gene therapy lies in the small packaging capacity 
of the virus (Monahan and Samulski, 2000).  Until recently, the use of AAV viral vectors 
appeared unattainable because the wildtype viral genome of 4.7 kb can only withstand 
900 bp of inserted genetic material for genes (of interest) to be delivered (Hermonat et 
al., 1997). Current versions of recombinant AAV (rAAV) remove the rep and cap genes 
from the viral vector and are supplied on a separate plasmid. The removal of these genes 
allows for the insertion of transgenes up to 2kb in size into the viral genome (Monahan 
and Samulski, 2000). While this is a great advancement from the first generation AAV 
viral vectors, there is opportunity for improvement to increase the capacity of the insert.  
Additional insert capacity can provide the opportunity to insert multiple therapeutic 
reagents along with a suicide gene into a single vector in order to improve the safety of 
the vector. Eliminating superfluous sequences in the viral vector and modification of the 
promoters and enhancers will be necessary in order to accomplish this.  
 A potential area in which the transgene cassette size can be expanded is the use of 
a minimal synthetic polyadenylation site. The addition of a poly(A) tail to RNA 
molecules is necessary for termination of transcription. In eukaryotes, the poly(A) tail 
protects the mRNA from enzymatic degradation in the cytoplasm. Levitt et al. describe 
the use of a synthetic polyadenylation site that uses the minimum sequences required for 
efficient polyadenylation (Levitt et al., 1989). Replacement of the SV40 late 
polyadenylation site with this minimal synthetic sequence was performed to allow for a 
250 base pair cassette increase.   
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Modification of AAV to address FDA safety concerns for gene therapy 
While recombinant AAV efficacy has been demonstrated in numerous gene therapy 
studies, it is important to assess the potential risks before beginning a clinical trial. 
During wild type infections AAV integrates into human chromosome 19 in over 50% of 
latently infected cell lines (Hermonat et al., 1997). However, the mechanism of the site-
specific integration requires AAV rep proteins that are absent in the viral vector. Random 
integration of vector sequences has been demonstrated in recombinant AAV but at low 
frequency (~10%) in vivo (Hermonat et al., 1997). While this alludes to the low risk of 
activation of oncogenes and insertional mutagenesis through rAAV, one must not 
overlook the risks associated with engineering these viral vectors to become more 
effective. The use of stronger or less attenuated promoters such as Chicken Beta-Actin 
promoter (Xu et al., 2001) and inclusion of regulatory elements such as Woodchuck 
hepatitis posttranscriptional element (WPRE) (Loeb et al., 1999) can increase the 
potential oncogenic and immunogenic activity. Here I propose to increase the safety of 
the AAV viral vector through the elimination of the X-protein peptide within the WPRE 
element. 
 In an attempt to increase the cassette size of the AAV viral vector and reduce 
pathogenesis, I have designed, cloned, and tested AAV vectors containing truncated 
forms of the WPRE element. In particular, while it has been demonstrated that the WPRE 
gene has been greatly beneficial to the transgene expression in AAV (Loeb et al., 1999), 
the fragment also has the potential to express a 60 amino acid X-protein derived peptide 
known to be associated with liver pathogenesis (Loeb et al., 1999; Tu et al., 2001). The 
hepatitis B virus X protein is a transcriptional transactivator that has been implicated in 
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the development of HBV related hepatocellular carcinoma (Tu et al., 2001). Moreover, 
C-terminal truncations of the X protein have been shown to enhance the transforming 
ability of ras and myc oncogenes over the wildtype protein. This proves especially 
important in the modification of rAAV viruses.  Truncations to eliminate and reduce the 
size of the X-protein were cloned and transfected to produce intact AAV virions.  
 
AAV quantification and functional validation 
Virus titer was determined by qPCR in comparison with an AAV standard and shown 
below (Graph 1).  A vector containing no WPRE element was also included to provide a 
lower limit baseline of infectivity. Shortening the viral vectors did not appear to affect the 
overall ability to produce virions or infectivity when compared to the unmodified vector. 
The functional activity of the truncated mutant viruses was validated through an in 
vitro infection assays using 293T cells, and the concentration of the Luciferase 
expression in the cell supernatant measured. Genome copies (1011) of each virus were 
added to each well and allowed to infect for 6 days.  
 
AAV intramuscular injection and Imaging 
Mice were anaesthetized by isofluorane inhalation and a single injection containing 1011 
genome copies of each virus was administered into the gastrocnemius muscle. The mice 
were imaged for transgene expression at regular time points for x days following 
injection. To image, mice were anaesthetized by isofluorane inhalation and given D-
luciferin (Gold Biotechnology) by intraperitoneal injection. I found that all of the 
modified viral vectors expressed Luciferase at equal to or greater levels than the standard 
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vector. Surprisingly, the most truncated virus, containing the synthetic poly-adenylation 
and the WPRE element with the X-protein deletion had over a two-fold increase in 
expression of the transgene (Graph 2).  
 
Discussion 
Modifications of AAV vector  
I developed modifications of the WPRE element to remove the carcinogenic X-protein 
increased the safety of the viral vector, addressing the concerns of the Food and Drug 
Administration and researchers in the field. In addition, the removal increased the gene of 
interest cassette size by 200 base pairs and increased the expression of the transgene in 
vivo. Currently, in collaboration with Dr. David Baltimore, the NIH Vaccine Research 
Center led by Dr Gary Nabel is using this modification in the prototype AAV vector for 
an upcoming clinical trial.  
 
Possible other applications for the  AAV Technology  
In addition, the modifications made in the current AAV vector show promise for other 
potential gene therapy strategies. The development of viral vectors with the ability to 
express transgenes of various sizes with little host response is necessary for the progress 
of the gene therapy field.   
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 Figure 1. Viral titering of Luciferase expressing modified vector. Shortening the viral 
vectors did not appear to affect the overall ability to produce virions or infectivity when 
compared to the unmodified vector. 
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Figure 2. Transgene expression of Modified AAV.  
All the modified viral vectors expressed Luciferase at equal to or greater levels than the 
standard vector. Modified vector containing the synthetic poly Adenylation and removal 
of X protein produced 2-fold more overall expression of the transgene.  
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Potential and Limitations of Immunoadhesin Anti-HIV proteins 
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 This chapter describes the strengths and weaknesses of a class of antibody based 
reagents for the use in immunotherapies against HIV. This work was done in 
collaboration with Anthony West, and Priyanthi Gnanapragasam. My contribution to this 
work was in aiding Anthony in initial construct design, cloning of DNA, protein 
purification, and preliminary characterization of the reagents. This work has been 
published as West, A. P., Jr., Galimidi, R. P, et al. (2012). "Single-chain Fv-based anti-
HIV proteins: potential and limitations." J Virol 86(1): 195-202. 
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Abstract 
 The existence of very potent, broadly neutralizing antibodies against human 
immunodeficiency virus type 1 (HIV-1) offers the potential for prophylaxis against    
HIV-1 infection by passive immunization or gene therapy. Both routes permit the 
delivery of modified forms of IgGs. Smaller reagents are favored when considering ease 
of tissue penetration and the limited capacities of gene therapy vectors. Immunoadhesin 
(single-chain fragment variable [scFv]-Fc) forms of IgGs are one class of relatively small 
reagent that has been explored for delivery by adeno-associated virus. Here we 
investigated the neutralization potencies of immunoadhesins compared to those of their 
parent IgGs. For the antibodies VRC01, PG9, and PG16, the immunoadhesins showed 
modestly reduced potencies, likely reflecting reduced affinities compared to those of the 
parent IgG, and the VRC01 immunoadhesin formed dimers and multimers with reduced 
neutralization potencies. Although scFv forms of neutralizing antibodies may exhibit 
affinity reductions, they provide a means of building reagents with multiple activities. 
Attachment of the VRC01 scFv to PG16 IgG yielded a bispecific reagent whose 
neutralization activity combined activities from both parent antibodies. Although the 
neutralization activity due to each component was partially reduced, the combined 
reagent is attractive since fewer strains escaped neutralization. 
 
 
 
  
	  	  
230	  
Introduction  
 Developing an effective human immunodeficiency virus type 1 (HIV-1) vaccine has 
been a great challenge for over 25 years. Results from the RV144 vaccine trial in 
Thailand suggested that a partial degree of protection from infection was achieved  (32), 
but whether and how a more effective vaccine can be developed remain open questions 
(39, 40). Difficulties in making an effective vaccine result in part from the humoral 
immune response against HIV-1 in which the antibodies produced are generally strain-
specific and can be quickly evaded by the rapidly mutating virus (43). Highly potent 
cross-strain anti-HIV antibodies have been isolated (5, 35, 41, 46  42, 45), but the 
unresolved problem is how to elicit these rare antibodies.  
Although neutralizing antibodies have shown limited efficacy controlling an established 
HIV-1 infection (26, 31, 38), the observation that most new infections appear to be 
initiated by only one or a few viral particles (17, 33, 34) highlights the potential for 
antibodies to provide sterilizing immunity. Passive immunization studies with broadly 
neutralizing antibodies have demonstrated their ability to protect animals from an 
HIV/SIV chimera challenge (2, 11-13, 23, 24, 29, 30, 36). Hence, an alternative approach 
to prophylaxis is to deliver the genes for potent anti-HIV proteins to provide long lasting 
protection. A successful demonstration of this approach in rhesus macaques using adeno-
associated virus (AAV) as the gene delivery vehicle has been achieved (15). AAV is an 
attractive vector due to its long- term gene expression and low toxicity (10). However, 
the use of AAV vectors imposes a size restriction on the gene delivered – expression 
from AAV vectors with genomes larger than 4900 bases is greatly attenuated (7). This 
can make it difficult to use AAV for delivery of large proteins such as IgG antibodies, 
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which include a heavy chain with four domains (the Fab heavy (VH) and constant heavy 
1 (CH1) domains and the Fc CH2 and CH3 domains) and a light chain with two domains 
(the Fab variable light (VL) and constant light (CL) domains) (Fig. 1). Self-
complementary AAV vectors are one means of achieving high expression levels (25), 
however size restrictions for these vectors prevent simultaneous incorporation of 
conventional antibody heavy and light chain genes.  
To achieve high transduction levels, a smaller immunoglobulin architecture was used in 
the AAV-mediated gene therapy experiments in rhesus macaques (15): single-chain 
Fragment variable (scFv) units attached to a Fc domain (a scFv immunoadhesin 
comprising IgG VH, VL, CH2 and CH3 domains, hereafter referred to as an 
immunoadhesin or IA) (Fig. 1). A wide variety of Fc fusions have been developed over 
the last 20 years to take advantage of this architecture’s key benefits: avidity provided by 
the homodimeric Fc, serum persistence provided by the Fc region due to FcRn-mediated 
protection from catabolism, and a size large enough to avoid filtration by the kidneys 
(14). A scFv unit, in which VH is fused to VL with a short linking region usually 
composed of glycines and serines, generally retains the antigen binding functionality of 
its parent Fab, although the scFv is only about 1/2 the size of an intact Fab. Although 
scFv-based reagents have been under development for many years, their overall potential 
as drugs remains uncertain (28).  
Several broadly neutralizing and highly potent antibodies against HIV-1 have recently 
been isolated from infected individuals. Two such antibodies, PG9 and PG16, target a 
quaternary epitope involving the V1-V2 and V3 variables loops of gp120 (42). Another 
class of antibodies, typified by antibody VRC01, targets the CD4-binding site of gp120 
	  	  
232	  
(44). The efficacy of gene therapy reagents derived from these antibodies depends on a 
number of factors, including their potency, strain coverage, in vivo stability, effector 
function, and serum concentrations that can be achieved. To help inform decisions 
relating to the architecture of potential reagents, we systematically compared the 
potencies of IAs with their IgG and Fab counterparts. We also explored the potential to 
combine VCR01 and PG9/PG16 activities to produce a single reagent with two gp120 
specificities.  
MATERIALS AND METHODS  
Materials. Sequences for all constructs are in Fig. S1 in the supplemental material. 
VRC01 IgG was expressed using plasmids VRC8551 & VRC8552 provided by Gary 
Nabel (Vaccine Research Center, NIH). VRC01 Fab was expressed using a truncated 
VRC8552 heavy chain gene sequence encoding a 7x-His tag and stop codon after the 
CH1 domain. VRC01 IgG-2A was expressed using plasmid VRC9715 which contains a 
picornavirus 2A peptide sequence (37) between the heavy and light chain genes. VRC01 
IA was expressed using plasmid VRC9713 (provided by Gary Nabel), which encodes for 
an IA protein in which a VRC01 scFv (VH domain connected via a (Gly3Ser)4 linker to 
the VL domain) is fused to the Fc region from human IgG1. A VRC01 scFv gene was 
constructed by truncated the VRC01 IA gene by inserting a 6x- His tag and stop codon 
after the VL domain.  
Genes encoding the variable regions (VH and VL) or the intact light chain (VL -CL) of 
PG9 and PG16 Abs were synthesized (BlueHeron Biotechnologies or Integrated DNA 
Technologies) based on sequences provided by Dennis Burton (The Scripps Research 
	  	  
233	  
Institute). Intact IgG genes were constructed by subcloning the relevant variable 
sequences onto a human IgG1 sequence. The designs of the PG9 and PG16 IAs were 
patterned after the rhesus IAs described in (15); thus PG9 IA was constructed as VH-
(Gly4-Ser)3-VL-Fc, and PG16 IAs were constructed as VL-(Gly4-Ser)3-VH-Fc and VH-
(Gly4-Ser)3-VL-Fc; for these IAs, the Fc sequence was that of human IgG2. PG9 and 
PG16 Fabs were expressed using truncated heavy chains with additional 7x-His tags. The 
PG9 and PG16 constructs were subcloned into the mammalian expression vector pTT5 
(NRC Biotechnology Research Institute). The scFv genes for PG9 and PG16 were 
constructed by inserting a 6x-His tag and stop codon after the second variable domain.  
VRC01scFv–PG16, VRC01scFv–ZAGα3–Fc, and VRC01scFv–E51 were constructed 
by combining the scFv gene from VRC01 IA with IgG heavy chain or Fc fusion 
constructs by PCR and enzymatic ligation techniques. All gene constructs were verified 
by complete sequencing.  
Protein expression and purification. Proteins were expressed transiently in suspension 
HEK 293-6E cells (NRC Biotechnology Research Institute) using 25 kDa linear 
polyethylenimine (PEI) (Polysciences) for transfection as described (8). When expressing 
heterodimeric constructs, the heavy chain (HC) and light chain (LC) plasmids were 
mixed at a 1:1 ratio by mass. Cell culture supernatants were collected six days post-
transfection. For Fc-containing constructs, supernatants were passed over protein A resin 
(Thermo Fisher Scientific), eluted using pH 3.0 citrate buffer, and then immediately 
neutralized. 7x-His tagged Fabs and scFvs were purified using Ni-NTA chromatography 
and eluted using 300 mM imidazole. All reagents tested in neutralization assays were 
purified by size exclusion chromatography using a Superdex 200 10/300 GL column.  
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In vitro neutralization assays. A previously-described pseudovirus neutralization assay 
was used to evaluate the neutralization potencies of the reagents (21, 27). Neutralization 
assays were performed either by the Collaboration for AIDS Vaccine Discovery (CAVD) 
core neutralization facility (Table 1 and Tables S1 and S2 in the supplemental material) 
or by our laboratory (Table 2) using the same protocol (21, 27). Briefly, pseudoviruses 
were generated by cotransfection of HEK 293T cells with an Env expression plasmid and 
a replication-defective backbone plasmid. Neutralization was determined by measuring 
the reduction in luciferase reporter gene expression in the presence of a potential inhibitor 
following a single round of pseudovirus infection in TZM-bl cells. Nonlinear regression 
analysis was used to calculate the concentrations at which half-maximal inhibition was 
observed (IC50 values).  
Biosensor affinity measurements. A BIACORE 2000 biosensor system (GE 
Healthcare) was used to evaluate the interactions of VRC01 reagents with gp120. 
Approximately 750 response units (RUs) of Protein A was covalently immobilized on all 
flowcells of a CM5 biosensor chip using standard primary amine coupling chemistry 
(BIACORE manual). VRC01 IA, VRC01scFv –ZAGα3–Fc, and VRC01 IgG were then 
bound to three of the individual flow cells (~1400 RUs each), with the fourth flow cell 
serving as a blank. A concentration series of gp120 from strain Q259.d2.17 (expressed in 
baculovirus-infected insect cells as described (6)) was injected at room temperature in 10 
mM Hepes with 150 mM NaCl, 3 mM EDTA and 0.005% surfactant P20 at pH 7.4. 
Equilibrium dissociation constants (KDs) were determined from kinetic constants derived 
from sensorgram data using simultaneous fitting to the association and dissociation 
phases of the interaction.  
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RESULTS  
 In order to compare the neutralization potencies of various antibody forms, we 
produced IgG, IA, and Fab forms of the anti-HIV antibodies PG9, PG16, and VRC01 
(42, 44) (Fig. 1). We also produced the PG9 scFv, but were unable to express either the 
VRC01 or PG16 scFvs in isolation in sufficient quantities for testing. Proteins were 
expressed by transient transfection of mammalian cells, and purification was by Protein 
A or Ni-NTA chromatography followed by size exclusion chromatography. The size 
exclusion chromatography profiles of the PG9 and PG16 IAs revealed large peaks 
corresponding to the expected products (Fig. 2); i.e., a single Fc unit with two scFvs, 
which we will subsequently refer to as an IA monomer. During size exclusion 
chromatography of the VRC01 IA, however, both aggregated and apparently dimeric 
forms were observed in addition to the expected product (Fig. 2). These larger forms 
were a significant fraction of the material eluted from protein A chromatography, by 
contrast to the PG9 and PG16 IA purifications, in which only trace amounts of larger 
oligomers were observed.  
 The proteins were evaluated in an Env-pseudotyped HIV-1 neutralization assay 
against of panel of 30 strains (Table 1 and Table S1 in the supplemental material). As 
observed for other anti-HIV antibodies, the Fab forms were on average 5-10 fold less 
potent on a molar basis than the intact IgG (18). The 2A form of VRC01 IgG (translated 
from a single mRNA containing a picornavirus 2A peptide sequence (37) between the 
heavy and light chain genes) was equally as potent as VRC01 IgG. However, the IA 
forms of VRC01, PG9, and PG16 were less potent than the corresponding IgGs; the 
potencies were reduced overall by 5.9-fold (VRC01), 3.3-fold (PG9), and 15.5-fold 
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(PG16 IA, constructed as VL followed by VH). Two-tailed paired T-tests demonstrated 
that these differences were significant (P-values of 0.00045, 0.047, and 0.032). A PG16 
IA constructed with VH followed by VL was also expressed and tested on a more limited 
number of strains; this reagent was also less potent than PG16 IgG (Table S2 in the 
supplemental material). Although the dimeric fraction of the VRC01 IA was active in 
neutralization, it was 2.3-fold less potent on a mass basis (P-value of 0.00012) than 
monomeric VRC01 IA (Table 1).  
 Potential reasons for the IAs to be less potent than their parent IgGs include (i) a 
shorter span between the two antigen combining sites; (ii) reduced stability of  IAs versus 
IgGs in the assay media; and/or (iii) reduced affinity of the scFv antigen binding sites 
compared to Fab binding sites. To evaluate whether the shorter arm span of the IAs 
diminished their activity, we expressed a scFv-containing reagent with a combining site 
separation more similar to IgG by inserting an immunoglobulin constant region-like 
domain, the α3 domain from Zn-α2-glycoprotein (ZAG), between the scFv and Fc 
components to create VRC01scFv– ZAGα3–Fc (Fig. 1). The maximal separation 
between the VH-VL combining sites should be similar in VRC01scFv–ZAGα3–Fc and 
VRC01 IgG. To permit even greater separation, the VRC01 scFv was also attached to the 
N-terminus of the heavy chain of an unrelated IgG to create VRC01scFv–E51. The CD4-
induced (CD4i) antibody E51 was chosen for this construct because E51 IgG expresses 
well and is weakly or non-neutralizing in the absence of CD4 (22), as observed for other 
CD4i antibodies (19). Neutralization assays using these reagents (Table 1) demonstrated 
an average IC50 similar to VRC01 IA, indicating that the arm span of VRC01scFv–based 
reagents had  little impact on their neutralization potency.  
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 We next tested whether differences in reagent stability (i.e., survival) under our 
neutralization assay conditions contributed to the differences we observed between IAs 
and IgGs by conducting assays with a 12 or 24 hour pre-incubation in assay media prior 
to adding pseudovirus. No trend toward diminished neutralization potency over time was 
observed (Table 2), demonstrating that differential stability in the assay media did not 
account for differences in potency.  
  A weaker antigen-binding affinity of the scFv in an IA versus the Fab in an 
IgG was suggested by the less potent neutralization observed for PG9 scFv compared to 
PG9 Fab (Table 1). The possibility of reduced antigen-binding affinity was directly tested 
by comparing the binding of gp120 to VRC01 IgG versus scFv-containing forms of 
VRC01. Purified gp120 from strain Q259.d2.17 was injected over protein A-immobilized 
VRC01 IgG, VRC01 IA, or VRC01scFv–ZAGα3–Fc in a surface plasmon  resonance 
(SPR)-based binding assay (Fig. S2 in the supplemental material). The equilibrium 
dissociation constant (KD) derived for VRC01 IgG was 160 nM, compared with affinities 
of 590 nM and 570 nM for VRC01 IA and VRC01scFv– ZAGα3–Fc, respectively. The 
approximately 4-fold weaker affinity of the scFv-containing reagents was comparable to 
the 6-fold weaker neutralization IC50 of  VRC01 IA compared to VRC01 IgG.  
To explore the potential for combined reagents to provide greater neutralization breadth, 
we expressed a modified form of PG16 in which a VRC01 scFv was attached to the N-
terminus of the PG16 light chain with a (Gly3-Ser)6 linker. The neutralization properties 
of VRC01scFv–PG16 are shown in Table 1. Inspection of the measured IC50s for strains 
that were resistant to either VRC01 or PG16 confirmed that both components in the 
combined reagent were active.  
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We assessed the potencies of each of the components in the bispecific VRC01scFv–
PG16 reagent by a modeling procedure using the IC50 values for VRC01 IgG and PG16 
IgG as follows: Assume the IC50s of the parent IgGs VRC01 and PG16 are v and p, 
respectively, for a given HIV-1 strain. Consider an idealized combined reagent in which 
both components functioned independently with no synergy or interference. In a very 
simplified picture of virus neutralization, reagent binding is equivalent to neutralization 
and the IC50 can be approximated by a single binding event with the same equilibrium 
dissociation constant. Solving the equilibrium equations for 50% binding/neutralization, 
we found the modeled IC50 was .. In the actual 
bispecific reagent, we anticipated the individual components would have reduced 
activity, i.e., vreduced = veff × v, where veff is >1, and preduced = peff × p, where peff is >1. 
Assuming that veff and peff are constant across different strains, we solved for best-fit 
values of these parameters that minimized Σstrains(log IC50 observed − log IC50 modeled)2. A fit 
assuming only one active antibody did not fit the data as well as a fit assuming that both 
components were active (Fig. S3 in the supplemental material).  
 Using our neutralization data for VRC01scFv–PG16 (Table 1), we derived values 
of 3.16 and 3.22 for veff and peff, thus the VRC01 scFv component possessed about 1/3 
of the potency of VRC01 IgG, and the PG16 IgG portion possessed about 1/3 of the 
potency of unmodified PG16 IgG. On any given strain, the combined reagent was nearly 
always weaker than the stronger parent IgG. However, the combined reagent was 
superior on a mass basis to the weaker parent for 27 out of 30 strains (Fig. 3, bottom 
panel). In addition, the combined reagent neutralized more strains than either parent; e.g., 
using a IC50s < 5.0 µg/mL cutoff for neutralization, VRC01scFv–PG16 neutralized 90% 
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of the strains we tested, while VRC01 IgG neutralized 83%, and PG16 IgG neutralized 
70% (Table 1 and Fig. 3, top panel). However, this depends on the neutralization 
threshold chosen. For IC50s <1.0 µg/mL, the combined reagent neutralized 67% of 
strains, while VRC01 and PG16 neutralized 77% and 60%, respectively.  
DISCUSSION  
 Provision of prophylactic or therapeutic antibodies by direct injection or 
gene therapy permits consideration of a wide range of potential reagents building 
on initial discoveries of anti-HIV IgGs. Variations fall into three major categories: 
(i) those affecting the antigen binding site, (ii) choice of the overall architecture (e.g., 
IA versus IgG), and (iii) modulations of effector function. A thorough evaluation of the 
efficacies of the full range of potential reagents is a large task. A variety of 
selection strategies is available to screen variants in category (i), i.e., natural 
antibody repertoires and antigen binding site libraries. However, full exploration of the 
alternatives in categories (ii) and (iii) is limited by the need to produce purified, testable 
quantities of reagents and the screening limitations of evaluating effector function in 
complex cell- or animal-based assays. The present studies are intended to provide insight 
into the potential effects of architecture on reagent potency.  
 The size of a delivered reagent must be considered for gene therapy efforts 
involving AAV. In general, constructs approaching the size limit for packaging AAV 
suffer reduced expression level (7). Although the minimum serum or genital tract anti-
HIV IgG concentration necessary for protection is not known, a rough estimate of 100 
times the reagent’s IC50 has been suggested (30). For broad strain coverage with reagents 
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such as VRC01, PG9, or PG16, this implies desired concentrations in the tens to 
hundreds of µg/mL. Early efforts using an AAV vector with separate promoters for heavy 
and light chains directing expression of anti-HIV IgG b12 yielded serum concentrations 
of only ~5 µg/mL (20). Alternative AAV/IgG constructs have permitted high-level IgG 
expression in other cases. For example, use of a single promoter with 2A self-processing 
peptide inserted between the antibody heavy and light chains permitted ~1 mg/mL IgG 
levels to be achieved with AAV-transduced liver expression (9). Nevertheless, the 
smaller size of IA constructs versus conventional IgG is attractive for gene therapy 
approaches in which vector capacity is severely limited – in particular, for self-
complementary AAV vectors, which are more efficient at transduction than AAV vectors 
with a single stranded genome (25).  
  To more fully understand the potential trade-offs in vector and construct design, 
we compared the neutralization activities of IA versus IgG versions of three broadly 
neutralizing antibodies: PG9, PG16, and VRC01 (42, 44). We found that the PG9, PG16, 
and VRC01 IAs were several-fold less potent than their IgG forms. A reduced affinity of 
the scFv antigen-binding site is a likely contributing factor to this difference. Although 
some scFvs have affinities equivalent to the related Fab, it was noted in early studies that 
scFvs can exhibit up to 10-fold weaker binding (4). The weaker binding and 
neutralization by the VRC01 scFv-containing reagents is likely due to suboptimal 
geometry of the antigen binding site and/or steric interference by the Gly-Ser linker 
joining the VRC01 VH and VL domains. Steric interference from the scFv linker is 
consistent with the VRC01 Fab-gp120 crystal structure (45), in which the N-terminus of 
the Fab light chain is ~8 Å from the gp120 backbone. This relatively close distance 
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suggests that the Gly-Ser linker extending from the VL domain N-terminus could 
sterically interfere with antigen binding. It is possible that the scFvs in the reagents we 
tested were suboptimal – different designs might yield scFvs with affinities matching the 
corresponding Fabs. Thus, to achieve maximal efficacy it will be necessary to explore 
different architectures (VH–VL versus VL–VH) and different linker lengths for each 
scFv used in IAs.  
 A potential complication of scFv reagents is their tendency to dimerize or 
multimerize by 3-D domain swapping (3). The extent of dimerization of scFvs 
is variable, depending on linker length, antibody sequence, concentration, buffer 
conditions, and the presence or absence of antigen (1). The potential for IAs to form 
dimers or other oligomers as observed for VRC01 IA is a special concern for reagents 
that will be delivered by gene therapy, where it is not possible to remove higher order 
products once they are secreted from transduced cells. Multimeric forms of IAs may be 
less potent and potentially more immunogenic than the monomeric molecule; this may 
add to the immunogenicity of the artificial linker of IAs. AAV-mediated expression of 
IAs in rhesus macaques led to varying levels of IA- specific antibody response, which 
appeared correlated with reduced efficacy against viral challenge (15). The best means of 
addressing this possible complication is careful biophysical characterization of proposed 
gene therapy protein products.  
 In the recent rhesus macaque SIV challenge experiment, delivery of IAs 
was found to be superior to either scFv or whole IgG with respect to the serum 
concentrations that could be achieved (15). Although the IAs used in the challenge 
experiments exhibited neutralization IC50s well below 1.0 µg/mL, the Fabs from which 
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they were derived had IC50s that were 3-fold more potent on a mass basis (16). (The 
IC50s of the corresponding IgGs have not been reported). On a molar basis, the IAs were 
thus about 1.5-fold less potent than the Fab forms. This ratio is very similar to the 
average 1.2-fold and 1.5-fold weaker molar neutralization we observed for the VRC01 
and PG16 IAs versus the corresponding Fabs (Table 1). In the rhesus challenge study, the 
IA potencies (IC50s of 0.01-0.02 µg/mL against the SIVmac316 challenge strain) were 
sufficient to provide protection. However, since anti-HIV IgGs are generally 6-30 fold 
more potent than their corresponding Fabs on a molar basis (18), the IAs evaluated here 
represent a significant trade-off necessitated by the lower serum IgG concentrations 
achievable (15) with currently available AAV technology.  
 While VRC01, PG9, and PG16 have very broad activities, each of these 
antibodies fails to neutralize 9 to 27% of HIV-1 strains (using a cutoff IC50 of 50 µg/ml; 
at 1 µg/ml, 28 to 49% of strains are not neutralized) (42, 44). For passive immunization 
or gene therapy applications, addressing the incomplete strain coverage requires 
delivering either multiple antibodies or a single reagent combining two or more activities. 
Here we investigated the feasibility of one such bispecific reagent, in which a VRC01 
scFv was attached to PG16 IgG (VRC01scFv-PG16). In vitro neutralization assays against 
a panel of HIV-1 strains demonstrated both VRC01 and PG16 activities. Although both 
potencies were reduced compared to those of the parental IgGs, VRC01scFv-PG16 showed 
greater breadth, suggesting the potential for a bispecific reagent to provide complete or 
near-complete protection against HIV-1. Further development of such a reagent is 
possible, for example, given that the VRC01 scFv component of VRC01scFv-PG16 had a 
reduced activity similar to that observed for the VRC01 IA, improvement of the scFv 
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portion could be attempted. The weaker activity of the PG16 component may result from 
steric factors from the scFv attached to the N terminus of the PG16 light chain. Switching 
the VRC01 scFv to the N terminus of the PG16 heavy chain did not improve PG16 
activity (see Table S3 in the supplemental material). Changing the size or structure of the 
linker or switching to the C terminus of the heavy chain may permit greater PG16 
activity. Although the reduced potencies of the individual components of a bispecific 
reagent might increase the risk that resistance to these neutralizing activities could 
develop, this concern is arguably secondary to providing breadth of coverage in the 
context of infection prophylaxis (versus treatment) since the goal of infection prophylaxis 
is to neutralize a small viral inoculum rather than to control an established infection. 
 The design of gene therapy reagents for HIV-1 prophylaxis potentially involves a 
variety of trade-offs, including breadth of reagent, potency, expression level, and 
minimization of potential for immunogenicity and other side effects. The newly 
discovered anti-HIV antibodies (42, 44) demonstrate that breadth and great potency can 
be achieved simultaneously. Our results suggest that careful optimization of reagent 
architecture and full biophysical characterization of the oligomeric states of potential 
protein reagents are important for fully exploiting the potential offered by genetic 
approaches to providing HIV-1 immunity. Direct conversion of IgGs to IAs will often 
entail a loss of potency due to weaker binding of the scFv compared to the Fab binding 
site and/or domain swapping to create scFv multimers, which can perhaps be avoided by 
screening many scFv designs. Whether this loss of potency is acceptable depends on 
relative in vivo serum levels of AAV-expressed IAs and IgGs. For prophylaxis against a 
wide variety of circulating HIV-1 strains, a delivered reagent will face strains where its 
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activity is far from maximal. In this situation, optimization of the reagent will be critical 
to provide robust protection. 
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Figure 1. Schematic depiction of antibody reagent architectures. VH, variable 
domain of the IgG heavy chain (HC); VL, variable domain of the IgG light chain (LC); 
CH1, constant region 1 of the HC; CL, constant region of the LC; Fc, CH2 and CH3 
domains of dimerized HCs; scFv, single-chain fragment variable (VH and VL domains of 
an IgG). The scFv shown is VH followed by VL; scFvs can also be constructed as VL 
followed by VH. 
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Figure 2. Size exclusion chromatography profiles of PG16, PG9, and VRC01 IAs. 
Protein A-purified IAs were injected over a Superdex 200 10/300 GL column. IgGs 
normally elute at ∼13 ml (as indicated at the top of the figure), compared to the slightly 
smaller IA monomers, which elute at ∼14.5 ml. (Data are shown for the VL-VH version 
of the PG16 IA; similar results were obtained for the VH-VL version.) Although the PG9 
and PG16 IAs were predominantly monomeric, the VRC01 IA profile showed multimeric 
(presumably dimeric) and aggregate peaks in addition to the monomer. The tendency of 
scFv molecules to dimerize by 3-D domain swapping (shown schematically at the top in 
the box) may lead to the formation of dimeric and oligomeric forms of IAs (potential 
structures shown in the box). 
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Figure 3. Histograms displaying IC50s (µg/ml) of VRC01 IgG (red), PG16 IgG (blue), 
and VRC01scFv-PG16 (purple) (top; linear scale) or VRC01 IgG (red), PG16 IgG (blue), 
VRC01scFv-PG16 (purple), and the modeled IC50s of VRC01scFv-PG16 (light purple) 
(bottom; logarithmic scale). 
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Supplemental Table S1.  IC50 values ( g/mL) for IgG, Fab, IA, and scFv forms of 
VRC01, PG9, and PG16. IC50 values in nM are presented in Table 1. 
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Supplemental Table S2. IC50 values (nM) for PG16 IA (VH-VL) (opposite orientation to 
the PG16 IA (VL-VH) reagent in Table 1). †Due of the incomplete strain coverage of 
these data, a comparison of the mean potency with PG16 IgG is not given. ND = not 
determined. 
    PG16   
Virus Clade IgG Fab 
IA (VL-
VH) 
IA (VH-
VL) 
6535.3 B 285 1800 1.9 650 
QH0692.42 B >680* >2000 >930 >930 
SC422661.8 B 120 850 200 >930 
PVO.4 B 89.5 260 >930 >930 
TRO.11 B 19.4 390 >930 620 
AC10.0.29 B 0.22 1.2 3.7 ND 
REJO4541.67 B 0.11 26 45 ND 
TRJO4551.58 B 25.5 240 11 ND 
WITO4160.33 B 0.095 0.51 1.4 <0.46 
CAAN5342.A2 B 140 590 >930 200 
THRO4156.18 B 85.5 2000 >930 ND 
RHPA4259.7 B 3.4 53 >390 43 
      
Du156.12 C 0.16 0.67 4.9 <0.46 
Du172.17 C 0.41 2.6 12 0.65 
Du422.1 C 0.95 28 94 61 
ZM197M.PB7 C 8.1 73 33 ND 
ZM214M.PL15 C >680* >2000 >930 ND 
ZM233M.PB6 C 0.034 0.081 0.88 <0.46 
ZM249M.PL1 C 0.81 4.3 3.7 ND 
ZM53M.PB12 C 0.25 1.1 3.2 <0.46 
ZM109F.PB4 C 134 >2000 15 ND 
ZM135M.PL10a C >680* >2000 >930 ND 
CAP45.2.00.G3 C 0.027 0.061 9.0 ND 
CAP210.2.00.E8 C 0.47 14 51 <0.46 
      
Q23.17 A 0.014 0.20 0.45 <0.46 
Q842.d12 A 0.18 0.63 3.5 <0.46 
Q259.d2.17 A 0.068 19 3.4 ND 
3718.v3.c11 A 0.068 2.1 24 1.0 
0330.v4.c3 A 0.14 0.69 2.8 <0.46 
3415.v1.c1 A 0.14 2.3 22 2.0 
      
Geometric mean(*)  1.2 12.7 18.9 † 
MNR   10.5 15.5 † 
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Supplemental Table S3. IC50 values (nM) for VRC01scFv-PG16 reagents with the 
VRC01 scFv attached to the N-terminus of the PG16 light chain (the reagent shown in 
Table 1) or the N-terminus of the PG16 heavy chain. 
 
   
VRC01scFv-PG16 
     
   
scFv attached to: 
Virus Clade   LC HC 
6535.3 B 
 
48 7.1 
QH0692.42 B 
 
14 7.5 
SC422661.8 B 
 
2.1 3.4 
PVO.4 B 
 
15 13 
TRO.11 B 
 
5.4 3.9 
AC10.0.29 B 
 
0.34 1.1 
REJO4541.67 B 
 
0.15 0.10 
TRJO4551.58 B 
 
0.44 0.73 
WITO4160.33 B 
 
0.15 0.20 
CAAN5342.A2 B 
 
24 23 
THRO4156.18 B 
 
7.9 18 
RHPA4259.7 B 
 
1.0 0.73 
     Du156.12 C 
 
0.29 0.44 
Du172.17 C 
 
2.3 8.3 
Du422.1 C 
 
19 21 
ZM197M.PB7 C 
 
5.6 4.7 
ZM214M.PL15 C 
 
>49 31 
ZM233M.PB6 C 
 
0.05 0.15 
ZM249M.PL1 C 
 
0.34 0.24 
ZM53M.PB12 C 
 
0.34 0.63 
ZM109F.PB4 C 
 
3.1 1.4 
ZM135M.PL10a C 
 
37 8.6 
CAP45.2.00.G3 C 
 
0.05 0.05 
CAP210.2.00.E8 C 
 
2.8 16 
     Q23.17 A 
 
<0.024 <0.05 
Q842.d12 A 
 
0.15 0.15 
Q259.d2.17 A 
 
1.6 1.7 
3718.v3.c11 A 
 
1.4 1.4 
0330.v4.c3 A 
 
0.24 0.34 
3415.v1.c1 A 
 
0.59 1.02 
     Geometric mean 
  
1.40 1.56 
Model fit for veff 
  
3.16 1.80 
Model fit for peff 
  
3.22 9.24 
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Supplemental Figure. S1. DNA and amino acid sequences of constructs. In DNA 
sequences, surrounding non-coding sequences are shown in italics. For amino acid 
sequences, hydrophobic leader sequences are listed in the line above the sequence of the 
mature protein. 
 
The following sequences are listed: 
1) VRC01 IA (scFv(VH-VL)–Fc) – plasmid VRC9713 – from G. Nabel 
2) PG9 IA (scFv(VH-VL)–Fc) 
3) PG16 IA (scFv(VL-VH)–Fc) 
4) PG16 IA (scFv(VH-VL)–Fc) 
5) VRC01 HC–2A–LC plasmid VRC9715 – from G. Nabel 
6) PG9 scFv-His6 tagged 
7) VRC01scFv-E51 HC 
8) VRC01scFv-PG16 LC 
9) VRC01scFv-ZAG 3-Fc 
10) VRC01 Fab HC (Fd)- His7 tagged 
11) PG9 Fab HC (Fd)- His7 tagged 
12) PG16 Fab HC (Fd)- His7 tagged 
13) VRC01scFv–PG16 HC 
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1) VRC01 IA (VH-(G3S)4-VL-Fc (from hIgG1)) (plasmid VRC9713) 
DNA: 
TCTAGACCACCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAA
CCGGTGTACATTCCCAGGTGCAGCTGGTGCAGTCTGGAGGTCAGATGAAGAA
GCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTG
ATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGAT
GGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAG
GGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCT
GCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAA
AACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCGGTCA
TCGTCTCATCAGGAGGGGGAAGCGGAGGGGGAAGCGGAGGGGGAAGCGGAG
GGGGATCCGAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCA
GGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTG
GTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCT
ACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAG
ACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTAT
TGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTA
AAGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC
TGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGAC
ACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA
GCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGT
GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
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TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCA
TCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCC
ATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT
CCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT
CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAG
AGCCTCTCCCTGTCTCCGGGTAAATGATGA 
 
Protein: 
MGWSCIILFLVATATGVHSQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLN
WIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLT
VDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSGGGSGGGSGGGSGGGSEIV
LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRF
SGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKEPKSCDKTHTC
PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
SPGK 
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2) PG9 IA (VH-(G4S)3-VL-Fc(from hIgG2)) 
DNA: 
GAATTCGCCGCCACCATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTTTC
TTAAGAGGTGTCCAGTGTCAGCGATTAGTGGAGTCTGGGGGAGGCGTGGTCC
AGCCTGGGTCGTCCCTGAGACTCTCCTGTGCAGCGTCCGGATTCGACTTCAGT
AGACAAGGCATGCACTGGGTCCGCCAGGCTCCAGGCCAGGGGCTGGAGTGG
GTGGCATTTATTAAATATGATGGAAGTGAGAAATATCATGCTGACTCCGTAT
GGGGCCGACTCAGCATCTCCAGAGACAATTCCAAGGATACGCTTTATCTCCA
AATGAATAGCCTGAGAGTCGAGGACACGGCTACATATTTTTGTGTGAGAGAG
GCTGGTGGGCCCGACTACCGTAATGGGTACAACTATTACGATTTCTATGATGG
TTATTATAACTACCACTATATGGACGTCTGGGGCAAAGGGACCACCGTGACA
GTCTCGAGCGCCTCCGGTGGCGGTGGCTCCGGAGGTGGTGGGAGCGGTGGCG
GCGGATCTCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGA
CAGTCGATCACCATCTCCTGCAATGGAACCAGCAATGATGTTGGTGGCTATG
AATCTGTCTCCTGGTACCAACAACATCCCGGCAAAGCCCCCAAAGTCGTGAT
TTATGATGTCAGTAAACGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCA
AGTCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGA
GGGTGACTATTACTGCAAGTCTCTGACAAGCACGAGACGTCGGGTTTTCGGC
ACTGGGACCAAGCTGACCGTTCTAGAGCGCAAATGTTGTGTCGAGTGCCCAC
CGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGG
TGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGG
CGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAG
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CACGTTCCGTGTGGTCAGCGTCCTCACCGTTGTGCACCAGGACTGGCTGAAC
GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCG
AGAAAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACA
CCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTG
CCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACG
GCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA
GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
ACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGCGGCCGC 
 
Protein: 
MEFGLSWVFLVAFLRGVQCQRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMH
WVRQAPGQGLEWVAFIKYDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRV
EDTATYFCVREAGGPDYRNGYNYYDFYDGYYNYHYMDVWGKGTTVTVSSAS 
GGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCNGTSNDVGGYESVSWYQ
QHPGKAPKVVIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCKSLT
STRRRVFGTGTKLTVLERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV
TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD
WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK 
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3) PG16 IA (VL-(G4S)3-VH-Fc (from hIgG2)) 
DNA: 
ATGGCCTGGGCTCTGCTATTCCTCACCCTCTTCACTCAGGGCACAGGGTCCTG
GGGCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGA
CGATCACCATCTCCTGCAATGGAACCAGCAGTGACGTTGGTGGATTTGACTCT
GTCTCCTGGTACCAACAATCCCCAGGGAAAGCCCCCAAAGTCATGGTTTTTG
ATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAGTCC
GGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCG
ATTATTTCTGCTCTTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGG
ACCAAGGTGACCGTTCTAGGTGGCGGTGGCTCCGGAGGTGGTGGGAGCGGTG
GCGGCGGATCTCAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCC
GGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGATTCACGTTTCACAAAT
ATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGC
ACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGC
CGAGTCACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAG
CAGCCTGAAAGTCGAAGACACGGCTATGTTCTTCTGTGCGAGAGAGGCTGGT
GGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACT
ACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTC
GAGCGCCTCCGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCA
CCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCT
CATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAC
GAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATA
ATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGGT
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CAGCGTCCTCACCGTTGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAG
TGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAACCATCTCCA
AAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG
GGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTC
TACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC
AACTACAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTA
CAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTC
ATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTC
TCCCTGTCTCCGGGTAAA 
 
Protein: 
MAWALLFLTLFTQGTGSWGQSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVS
WYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCS
SLTDRSHRIFGGGTKVTVLGGGGSGGGGSGGGGSQEQLVESGGGVVQPGGSLRL
SCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISR
DNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYM
DVWGKGTTVTVSSASERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEV
TCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD
WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK 
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4) PG16 IA (VH-(G4S)3-VL-Fc (from hIgG2)) 
DNA: 
GAATTCGCCGCCACCATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTTTC
TTAAGAGGTGTCCAGTGTCAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGG
TCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTTTAGCGTCTGGATTCACGTTT
CACAAATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGT
GGGTGGCACTCATCTCAGATGACGGAATGAGGAAATATCATTCAGACTCCAT
GTGGGGCCGAGTCACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTG
CAATTCAGCAGCCTGAAAGTCGAAGACACGGCTATGTTCTTCTGTGCGAGAG
AGGCTGGTGGGCCAATCTGGCATGACGACGTCAAATATTACGATTTTAATGA
CGGCTACTACAACTACCACTACATGGACGTCTGGGGCAAGGGGACCACGGTC
ACCGTCTCGAGCGCCTCCGGTGGCGGTGGCTCCGGAGGTGGTGGGAGCGGTG
GCGGCGGATCTCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCT
GGACAGACGATCACCATCTCCTGCAATGGAACCAGCAGTGACGTTGGTGGAT
TTGACTCTGTCTCCTGGTACCAACAATCCCCAGGGAAAGCCCCCAAAGTCAT
GGTTTTTGATGTCAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTC
CAAGTCCGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGAC
GAGGGCGATTATTTCTGCTCTTCACTGACAGACAGAAGCCATCGCATATTCGG
CGGCGGGACCAAGGTGACCGTTCTAGAGCGCAAATGTTGTGTCGAGTGCCCA
CCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAA
ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTG
GTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACA
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GCACGTTCCGTGTGGTCAGCGTCCTCACCGTTGTGCACCAGGACTGGCTGAA
CGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATC
GAGAAAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTGTAC
ACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCT
GCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAA
TGGGCAGCCGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGAC
GGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGC
AGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA
CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGCGGCCGC 
 
Protein: 
MEFGLSWVFLVAFLRGVQCQEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGM
HWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLK
VEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSSA
SGGGGSGGGGSGGGGSQSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQ
QSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTD
RSHRIFGGGTKVTVLERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD
WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK 
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5) VRC01-HC-2A-LC plasmid (hIgG1) (Plasmid VRC9715) 
DNA: 
TCTAGACCACCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAA
CCGGTGTACATTCCCAGGTGCAGCTGGTGCAGTCTGGAGGTCAGATGAAGAA
GCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTG
ATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGAT
GGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAG
GGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCT
GCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAA
AACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCGGTCA
TCGTCTCATCACCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCC
TCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACT
ACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGG
CGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCA
GCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAA
CGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAA
ATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTG
GGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGA
TCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGA
CCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCC
AAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCA
AGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGC
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CAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAT
GAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATC
CCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACT
ACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGC
AAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCT
CCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCT
GTCTCCGGGTAAACGGCGGCGGCGGGCCCCCGTGAAGCAGACCCTGAACTTC
GACCTGCTGAAGCTGGCCGGCGACGTGGAGAGCAACCCCGGCCCCATGGGAT
GGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCAGAA
ATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAACAGC
CATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAGCCTGGTATCAACAGA
GGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGGCTCTACTCGGGCCGCT
GGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGGCCAGACTACAATCTCA
CCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTATTATTGCCAGCAGTAT
GAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGACATTAAACGTACGGTGG
CTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA
ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTACCCCAGAGAAGCCAAAGT
GCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGAAACAGCCAGGAAAGCGT
GACAGAGCAGGATTCCAAGGATTCCACATACAGCCTGAGCAGCACACTGACA
CTGTCCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACAC
ACCAGGGACTGTCCTCCCCTGTGACAAAGAGCTTCAACAGAGGAGAATGCTG
ATAGGATCC 
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Protein: 
MGWSCIILFLVATATGVHSQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLN
WIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLT
VDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSPSTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKRRRRAPVKQTLNFDL
LKLAGDVESNPGPMGWSCIILFLVATATGVHSEIVLTQSPGTLSLSPGETAIISCRT
SQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGD
FGVYYCQQYEFFGQGTKVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC 
 
  
	  	  
264	  
6) PG9 scFv-His6 tagged: 
DNA: 
GAATTCGCCGCCACCATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTTTC
TTAAGAGGTGTCCAGTGTCAGCGATTAGTGGAGTCTGGGGGAGGCGTGGTCC
AGCCTGGGTCGTCCCTGAGACTCTCCTGTGCAGCGTCCGGATTCGACTTCAGT
AGACAAGGCATGCACTGGGTCCGCCAGGCTCCAGGCCAGGGGCTGGAGTGG
GTGGCATTTATTAAATATGATGGAAGTGAGAAATATCATGCTGACTCCGTAT
GGGGCCGACTCAGCATCTCCAGAGACAATTCCAAGGATACGCTTTATCTCCA
AATGAATAGCCTGAGAGTCGAGGACACGGCTACATATTTTTGTGTGAGAGAG
GCTGGTGGGCCCGACTACCGTAATGGGTACAACTATTACGATTTCTATGATGG
TTATTATAACTACCACTATATGGACGTCTGGGGCAAAGGGACCACcGTgACaG
TCTCGAGCGGTGGCGGTGGCTCCGGAGGTGGTGGGAGCGGTGGCGGCGGATC
TCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGA
TCACCATCTCCTGCAATGGAACCAGCAATGATGTTGGTGGCTATGAATCTGTC
TCCTGGTACCAACAACATCCCGGCAAAGCCCCCAAAGTCGTGATTTATGATG
TCAGTAAACGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCCGGC
AACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGGTGACT
ATTACTGCAAGTCTCTGACAAGCACGAGACGTCGGGTTTTCGGCACTGGGAC
CAAGCTGACCGTTCTACATCATCACCATCACCACTGAGCGGCCGC 
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Protein: 
MEFGLSWVFLVAFLRGVQCQRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMH
WVRQAPGQGLEWVAFIKYDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRV
EDTATYFCVREAGGPDYRNGYNYYDFYDGYYNYHYMDVWGKGTTVTVSSGG
GGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCNGTSNDVGGYESVSWYQQH
PGKAPKVVIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTST
RRRVFGTGTKLTVLHHHHHH 
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7) VRC01scFv-E51 HC: 
DNA: 
AATTCGCCGCCACCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTG
CAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAGTCTGGAGGTCAGATGAA
GAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTA
TTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTG
GATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTT
CAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGG
AGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGG
AAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCG
GTCATCGTCTCATCAGGAGGGGGAAGCGGAGGGGGAAGCGGAGGGGGAAGC
GGAGGGGGATCCGAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTC
TCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAG
CCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGG
CTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGG
CCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTA
TTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC
ATTAAAGCCGGCGGCAGCGGAGGAGGATCTGGGGGAGGGTCCGGAGGCGGA
TCCGGGGGCGGTTCAGGTGGGGGTAGCGGAGGGGGCTCAGGCGGAGCTAGC
GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAACAAGCCTGGGTCCTCGG
TGAAGGTCTCCTGTCAGGCTTCTGGAGCCACCTTAAACAGTCATGCTTTCAGC
TGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGCAGGGATCATCC
CTATATTTGGTTCATCACACTACGCACAAAAGTTCCAGGGCAGAGTCACGATT
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ACCGCGGACGAGTCCACGCGCACAGTGTATTTGCATCTGAGAGGCCTGAGAT
CTGATGACACGGCCGTTTATTACTGTGCGAGTAATTCTATTGCCGGAGTAGCA
GCTGCCGGAGACTACGCTGACTACGATGGGGGCTACTACTACGATATGGATG
TCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCC
ATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCG
GCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGT
GGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA
GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCT
TGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAA
GGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACGTGCCCA
CCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCC
AAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTG
GTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
ACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCT
GAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGTCAGCCCCGAGAACCACAGGTG
TACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGA
CCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAG
CAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC
GACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGC
AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA
CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA 
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Protein: 
MGWSCIILFLVATATGVHSQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLN
WIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLT
VDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSGGGSGGGSGGGSGGGSEIV
LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRF
SGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKAGGSGGGSGG
GSGGGSGGGSGGGSGGGSGGASEVQLVQSGAEVNKPGSSVKVSCQASGATLNS
HAFSWVRQAPGQGLEWMAGIIPIFGSSHYAQKFQGRVTITADESTRTVYLHLRGL
RSDDTAVYYCASNSIAGVAAAGDYADYDGGYYYDMDVWGQGTTVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
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8) VRC01scFv–PG16 LC: 
DNA: 
AATTCGCCGCCACCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTG
CAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAGTCTGGAGGTCAGATGAA
GAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTA
TTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTG
GATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTT
CAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGG
AGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGG
AAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCG
GTCATCGTCTCATCAGGAGGGGGAAGCGGAGGGGGAAGCGGAGGGGGAAGC
GGAGGGGGATCCGAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTC
TCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAG
CCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGG
CTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGG
CCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTA
TTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC
ATTAAAGCCGGCGGCAGCGGAGGAGGATCTGGGGGAGGGTCCGGAGGCGGA
TCCGGGGGCGGTTCAGGTGGGGGTAGCGGAGGGGGCTCAGGCGGAGCTAGC
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGACGAT
CACCATCTCCTGCAATGGAACCAGCAGTGACGTTGGTGGATTTGACTCTGTCT
CCTGGTACCAACAATCCCCAGGGAAAGCCCCCAAAGTCATGGTTTTTGATGT
CAGTCATCGGCCCTCAGGTATCTCTAATCGCTTCTCTGGCTCCAAGTCCGGCA
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ACACGGCCTCCCTGACCATCTCTGGGCTCCACATTGAGGACGAGGGCGATTA
TTTCTGCTCTTCACTGACAGACAGAAGCCATCGCATATTCGGCGGCGGGACC
AAGGTGACCGTTCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCC
GCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATA
AGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCC
CCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACA
AGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCA
CAAAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGAC
AGTGGCCCCTACAGAATGTTCATAG 
 
Protein: 
MGWSCIILFLVATATGVHSQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLN
WIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLT
VDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSGGGSGGGSGGGSGGGSEIV
LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRF
SGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKAGGSGGGSGG
GSGGGSGGGSGGGSGGGSGGASQSALTQPASVSGSPGQTITISCNGTSSDVGGFD
SVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDY
FCSSLTDRSHRIFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFY
PGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSC
QVTHEGSTVEKTVAPTECS 
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9) VRC01scFv–ZAG 3–E51 HC: 
DNA: 
GAATTCCCTCTAGACCACCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGC
AACTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAGTCTGGAGGTCAG
ATGAAGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATG
AATTTATTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCT
GAGTGGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTC
CACTTCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTT
TTGGAGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAG
GGGAAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACC
CCGGTCATCGTCTCATCAGGAGGGGGAAGCGGAGGGGGAAGCGGAGGGGGA
AGCGGAGGGGGATCCGAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTT
TGTCTCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCC
TTAGCCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATT
CGGGCTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTG
GGGGCCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGT
GTTTATTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGT
CGACATTAAATCCGGAGGTGGCGGTAGTGGGGGAGGCGACCCGCCAAGCGT
GGTGGTCACATCCCATCAAGCCCCTGGTGAAAAGAAGAAGCTCAAATGTTTG
GCCTACGATTTCTATCCAGGGAAGATCGACGTGCACTGGACTAGAGCCGGAG
AAGTCCAGGAGCCGGAACTCAGGGGTGATGTCCTGCACAACGGCAACGGCA
CTTACCAGTCTTGGGTCGTCGTAGCCGTGCCACCTCAGGACACGGCGCCATA
CTCCTGCCATGTGCAACATTCTTCCCTCGCACAGCCCCTGGTCGTGCCTTGGG
AGGCCTCCGGTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTG
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CCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT
GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGC
GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC
ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG
GCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGA
GAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACAC
CCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATG
GGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGG
CTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAG
GGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACA
CGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGATGAGGATCC 
 
Protein: 
MGWSCIILFLVATATGVHS 
QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKP
RGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYN
WDFEHWGRGTPVIVSSGGGSGGGSGGGSGGGSEIVLTQSPGTLSLSPGETAIISCR
TSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESG
DFGVYYCQQYEFFGQGTKVQVDIKSGGGGSGGGDPPSVVVTSHQAPGEKKKLK
CLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAP
YSCHVQHSSLAQPLVVPWEASGEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK
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DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
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10) VRC01 Fab HC (Fd)- His7 tagged 
DNA: 
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACA
TTCCCAGGTGCAGCTGGTGCAGTCTGGAGGTCAGATGAAGAAGCCTGGCGAG
TCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTTATTGATTGTACGCT
AAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGTGGATGGGATGGCTG
AAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACTTCAGGGCAGAGTGA
CCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGGAGCTGCGCTCGTTG
ACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGGAAAAAACTGTGATT
ACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCGGTCATCGTCTCATC
ACCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC
ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACAC
CTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGA
CCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCA
CAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGA
CAAACATCATCACCATCACCACCAT 
 
Protein: 
MGWSCIILFLVATATGVHSQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLN
WIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLT
VDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSPSTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKKVEPKSCDKHHHHHHH
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11) PG9 Fab HC (Fd)- His7 tagged 
DNA: 
ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTTTCTTAAGAGGTGTCCA
GTGTCAGCGATTAGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGTCGTCC
CTGAGACTCTCCTGTGCAGCGTCCGGATTCGACTTCAGTAGACAAGGCATGC
ACTGGGTCCGCCAGGCTCCAGGCCAGGGGCTGGAGTGGGTGGCATTTATTAA
ATATGATGGAAGTGAGAAATATCATGCTGACTCCGTATGGGGCCGACTCAGC
ATCTCCAGAGACAATTCCAAGGATACGCTTTATCTCCAAATGAATAGCCTGA
GAGTCGAGGACACGGCTACATATTTTTGTGTGAGAGAGGCTGGTGGGCCCGA
CTACCGTAATGGGTACAACTATTACGATTTCTATGATGGTTATTATAACTACC
ACTATATGGACGTCTGGGGCAAAGGGACCACCGTGACAGTCTCGAGCGCCTC
CACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTG
GGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGT
GACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCC
CTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCC
AGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAACATC
ATCACCATCACCACCAT 
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Protein: 
MEFGLSWVFLVAFLRGVQCQRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMH
WVRQAPGQGLEWVAFIKYDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRV
EDTATYFCVREAGGPDYRNGYNYYDFYDGYYNYHYMDVWGKGTTVTVSSAS
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHHHHHHH 
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12) PG16 Fab HC (Fd)- His7 tagged 
DNA: 
ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGCAACTCTGTTAAGAGTTGTGAA
GTGTCAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGG
GTCCCTGAGACTCTCCTGTTTAGCGTCTGGATTCACGTTTCACAAATATGGCA
TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCACTCAT
CTCAGATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTC
ACCATCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCT
GAAAGTCGAAGACACGGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCA
ATCTGGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACTACAACTA
CCACTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCGAGCGCC
TCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTC
TGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCG
GTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCC
CGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC
CCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAC
ATCATCACCATCACCACCAT 
 
Protein: 
MEFGLSWVFLATLLRVVKCQEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGM
HWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLK
VEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSSA
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STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHHHHH
HH 
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13) VRC01scFv–PG16 HC: 
DNA: 
GAATTCGCCGCCACCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACT
GCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAGTCTGGAGGTCAGATGA
AGAAGCCTGGCGAGTCGATGAGAATTTCTTGTCGGGCTTCTGGATATGAATTT
ATTGATTGTACGCTAAATTGGATTCGTCTGGCCCCCGGAAAAAGGCCTGAGT
GGATGGGATGGCTGAAGCCTCGGGGGGGGGCCGTCAACTACGCACGTCCACT
TCAGGGCAGAGTGACCATGACTCGAGACGTTTATTCCGACACAGCCTTTTTGG
AGCTGCGCTCGTTGACAGTAGACGACACGGCCGTCTACTTTTGTACTAGGGG
AAAAAACTGTGATTACAATTGGGACTTCGAACACTGGGGCCGGGGCACCCCG
GTCATCGTCTCATCAGGAGGGGGAAGCGGAGGGGGAAGCGGAGGGGGAAGC
GGAGGGGGATCCGAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTC
TCCAGGGGAAACAGCCATCATCTCTTGTCGGACCAGTCAGTATGGTTCCTTAG
CCTGGTATCAACAGAGGCCCGGCCAGGCCCCCAGGCTCGTCATCTATTCGGG
CTCTACTCGGGCCGCTGGCATCCCAGACAGGTTCAGCGGCAGTCGGTGGGGG
CCAGACTACAATCTCACCATCAGCAACCTGGAGTCGGGAGATTTTGGTGTTTA
TTATTGCCAGCAGTATGAATTTTTTGGCCAGGGGACCAAGGTCCAGGTCGAC
ATTAAAGCCGGCGGCAGCGGAGGAGGATCTGGGGGAGGGTCCGGAGGCGGA
TCCGGGGGCGGTTCAGGTGGGGGTAGCGGAGGGGGCTCAGGCGGAGCTAGC
CAGGAACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCGGGGGGGTCC
CTGAGACTCTCCTGTTTAGCGTCTGGATTCACGTTTCACAAATATGGCATGCA
CTGGGTCCGCCAGGCTCCAGGCAAGGGCCTGGAGTGGGTGGCACTCATCTCA
GATGACGGAATGAGGAAATATCATTCAGACTCCATGTGGGGCCGAGTCACCA
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TCTCCAGAGACAATTCCAAGAACACTCTTTATCTGCAATTCAGCAGCCTGAAA
GTCGAAGACACGGCTATGTTCTTCTGTGCGAGAGAGGCTGGTGGGCCAATCT
GGCATGACGACGTCAAATATTACGATTTTAATGACGGCTACTACAACTACCA
CTACATGGACGTCTGGGGCAAGGGGACCACGGTCACCGTCTCGAGCGCCTCC
ACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG
ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG
CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCA
GCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCA
CACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTC
CTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT
CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACC
AGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCT
CCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGA
ACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGG
AGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCG
TGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAG
AGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTC
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TGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGC
GGCCGC 
 
Protein: 
MGWSCIILFLVATATGVHSQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLN
WIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLT
VDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSGGGSGGGSGGGSGGGSEIV
LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRF
SGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKAGGSGGGSGG
GSGGGSGGGSGGGSGGGSGGASQEQLVESGGGVVQPGGSLRLSCLASGFTFHKY
GMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFS
SLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
SLSPGK 
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Supplemental Figure S2. Biosensor analyses of gp120 binding to immobilized 
VRC01 reagents. Sensorgrams (colored curves) of injected gp120 binding to VRC01 IA 
(A), VRC01scFv-ZAG 3-Fc (B), and VRC01 IgG (C) immobilized using covalently 
attached protein A. Best fit binding curves (assuming a 1:1 binding model) are shown as 
thin black lines. 
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Supplemental Figure S3.  Measured versus modeled IC50 values of VRC01scFv–
PG16. One parameter (PG16 or VRC01) or two parameter (combined fit; PG16 and 
VRC01) best fits based on IC50s for PG16 IgG and VRC01 IgG. A 1:1 correlation 
between the modeled IC50 and the actual IC50 data is indicated by the y = x line. The 
parameters derived from the combined fit indicate that VRC01scFv–PG16 has ~1/3 of the 
activity of PG16 IgG plus ~1/3 the activity of VRC01 IgG. The values of the correlation 
coefficient R for the combined, PG16 only, and VRC01 only fits are 0.877, 0.825, and 
0.414, respectively. A reduced vs. full model F-test comparing the PG16 only fit with the 
2-parameter fit demonstrates that the 2-parameter model is superior (F-test analysis 
significance P<0.01).  
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